BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Ollier JC, EORTC Radiotherapy Group Trial 22921. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355:1114-1123. [PMID: 16971718 DOI: 10.1056/nejmoa060829] [Cited by in Crossref: 1797] [Cited by in F6Publishing: 614] [Article Influence: 112.3] [Reference Citation Analysis]
Number Citing Articles
1 Sermeus A, Leonard W, Engels B, De Ridder M. Advances in radiotherapy and targeted therapies for rectal cancer. World J Gastroenterol 2014; 20(1): 1-5 [PMID: 24415852 DOI: 10.3748/wjg.v20.i1.1] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
2 Osti MF, Agolli L, Bracci S, Masoni L, Valeriani M, Falco T, De Sanctis V, Maurizi Enrici R. Neoadjuvant chemoradiation with concomitant boost radiotherapy associated to capecitabine in rectal cancer patients. Int J Colorectal Dis. 2014;29:835-842. [PMID: 24825722 DOI: 10.1007/s00384-014-1879-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
3 De Felice F, Musio D, Izzo L, Pugliese F, Izzo P, Bolognese A, Tombolini V. Preoperative chemoradiotherapy in elderly patients with locally advanced rectal cancer. Biomed Res Int 2013;2013:610786. [PMID: 24392453 DOI: 10.1155/2013/610786] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
4 Tang J, Wu X, Gao Y, Jiang W, Kong L, Lin J, Wan D, Pan Z, Ding P. Long-Term Outcome of Oxaliplatin and Capecitabine (XELOX) Concomitant with Neoadjuvant Radiotherapy and Extended to the Resting Period in High Risk Locally Advanced Rectal Cancer. J Cancer. 2018;9:1365-1370. [PMID: 29721045 DOI: 10.7150/jca.23874] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
5 Callender GG, Das P, Rodriguez-Bigas MA, Skibber JM, Crane CH, Krishnan S, Delclos ME, Feig BW. Local excision after preoperative chemoradiation results in an equivalent outcome to total mesorectal excision in selected patients with T3 rectal cancer. Ann Surg Oncol 2010;17:441-7. [PMID: 19847569 DOI: 10.1245/s10434-009-0735-7] [Cited by in Crossref: 83] [Cited by in F6Publishing: 62] [Article Influence: 6.4] [Reference Citation Analysis]
6 Shamseddine A, Zeidan YH, Kreidieh M, Khalifeh I, Turfa R, Kattan J, Mukherji D, Temraz S, Alqasem K, Amarin R, Al Awabdeh T, Deeba S, Jamali F, Mohamad I, Elkhaldi M, Daoud F, Al Masri M, Dabous A, Hushki A, Jaber O, Khoury C, El Husseini Z, Charafeddine M, Al Darazi M, Geara F. Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced rectal adenocarcinoma. BMC Cancer 2020;20:831. [PMID: 32873251 DOI: 10.1186/s12885-020-07333-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Sanoff HK, Moon DH, Moore DT, Boles J, Bui C, Blackstock W, O'Neil BH, Subramaniam S, McRee AJ, Carlson C, Lee MS, Tepper JE, Wang AZ. Phase I/II trial of nano-camptothecin CRLX101 with capecitabine and radiotherapy as neoadjuvant treatment for locally advanced rectal cancer. Nanomedicine 2019;18:189-95. [PMID: 30858085 DOI: 10.1016/j.nano.2019.02.021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
8 Sheu MJ, Li CF, Lin CY, Lee SW, Lin LC, Chen TJ, Ma LJ. Overexpression of ANXA1 confers independent negative prognostic impact in rectal cancers receiving concurrent chemoradiotherapy. Tumour Biol 2014;35:7755-63. [PMID: 24810927 DOI: 10.1007/s13277-014-2032-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
9 Oki E, Ando K, Kasagi Y, Zaitsu Y, Sugiyama M, Nakashima Y, Sonoda H, Ohgaki K, Saeki H, Maehara Y. Recent advances in multidisciplinary approach for rectal cancer. Int J Clin Oncol 2015;20:641-9. [PMID: 26100273 DOI: 10.1007/s10147-015-0858-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
10 AlGizawy SM, Essa HH, Ahmed BM. Chemotherapy Alone for Patients With Stage II/III Rectal Cancer Undergoing Radical Surgery. Oncologist 2015;20:752-7. [PMID: 26040621 DOI: 10.1634/theoncologist.2015-0038] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
11 Hüttner FJ, Probst P, Kalkum E, Hackbusch M, Jensen K, Ulrich A, Debus J, Jäger D, Diener MK. Addition of Platinum Derivatives to Fluoropyrimidine-Based Neoadjuvant Chemoradiotherapy for Stage II/III Rectal Cancer: Systematic Review and Meta-Analysis. J Natl Cancer Inst 2019;111:887-902. [PMID: 31077329 DOI: 10.1093/jnci/djz081] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
12 Park IJ, Yu CS, Lim SB, Yoon YS, Kim CW, Kim TW, Kim JH, Kim JC. Ratio of metastatic lymph nodes is more important for rectal cancer patients treated with preoperative chemoradiotherapy. World J Gastroenterol 2015; 21(11): 3274-3281 [PMID: 25805934 DOI: 10.3748/wjg.v21.i11.3274] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
13 Chen Z, Li S, Wang Y, Fu Z, Liu N, Wang H, Liu X. Overall Survival Benefit in Rectal Cancer After Neoadjuvant Radiotherapy and Adjuvant Chemotherapy: A Propensity-Matched Population-Based Study. Front Oncol 2020;10:584835. [PMID: 33363014 DOI: 10.3389/fonc.2020.584835] [Reference Citation Analysis]
14 Grodsky MB, Sidani SM. Radiation proctopathy. Clin Colon Rectal Surg. 2015;28:103-111. [PMID: 26034407 DOI: 10.1055/s-0035-1547337] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
15 Tsukui H, Horie H, Koinuma K, Ohzawa H, Sakuma Y, Hosoya Y, Yamaguchi H, Yoshimura K, Lefor AK, Sata N, Kitayama J. CD73 blockade enhances the local and abscopal effects of radiotherapy in a murine rectal cancer model. BMC Cancer 2020;20:411. [PMID: 32397971 DOI: 10.1186/s12885-020-06893-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
16 Ye W, Shi L, Qian L, Sun Y, Sun X. Feasibility of relatively low neoadjuvant radiation doses for locally advanced rectal cancer: A propensity score-matched analysis. Cancer Rep (Hoboken) 2019;2:e1188. [PMID: 32721108 DOI: 10.1002/cnr2.1188] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Martin-Gonzalez P, de Mariscal EG, Martino ME, Gordaliza PM, Peligros I, Carreras JL, Calvo FA, Pascau J, Desco M, Muñoz-Barrutia A. Association of visual and quantitative heterogeneity of 18F-FDG PET images with treatment response in locally advanced rectal cancer: A feasibility study. PLoS One 2020;15:e0242597. [PMID: 33253194 DOI: 10.1371/journal.pone.0242597] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Ogura A, Konishi T, Cunningham C, Garcia-Aguilar J, Iversen H, Toda S, Lee IK, Lee HX, Uehara K, Lee P, Putter H, van de Velde CJH, Beets GL, Rutten HJT, Kusters M; Lateral Node Study Consortium. Neoadjuvant (Chemo)radiotherapy With Total Mesorectal Excision Only Is Not Sufficient to Prevent Lateral Local Recurrence in Enlarged Nodes: Results of the Multicenter Lateral Node Study of Patients With Low cT3/4 Rectal Cancer. J Clin Oncol. 2019;37:33-43. [PMID: 30403572 DOI: 10.1200/jco] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
19 Xiao J, Tan Y, Li W, Gong J, Zhou Z, Huang Y, Zheng J, Deng Y, Wang L, Peng J, Ren D, Lan P, Wang J. Tumor volume reduction rate is superior to RECIST for predicting the pathological response of rectal cancer treated with neoadjuvant chemoradiation: Results from a prospective study. Oncol Lett 2015;9:2680-6. [PMID: 26137128 DOI: 10.3892/ol.2015.3101] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
20 Cho H, Kim JE, Kim KP, Yu CS, Kim JC, Kim JH, Lee MA, Jang HS, Oh ST, Kim SY, Oh JH, Kim DY, Hong YS, Kim TW. Phase II Study of Preoperative Capecitabine and Oxaliplatin-based Intensified Chemoradiotherapy With or Without Induction Chemotherapy in Patients With Locally Advanced Rectal Cancer and Synchronous Liver-limited Resectable Metastases. Am J Clin Oncol 2016;39:623-9. [PMID: 27322695 DOI: 10.1097/COC.0000000000000315] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
21 Chen M, Song X, Chen LZ, Xu L, Lu YP, Zhang JS. Adjuvant Second-Dose Chemotherapy before Surgery for Patients with Locally Advanced Rectal Malignancy Is Not Beneficial: A Systematic Review and Meta-Analysis. Gastroenterol Res Pract 2017;2017:1373092. [PMID: 28835750 DOI: 10.1155/2017/1373092] [Reference Citation Analysis]
22 Jin T, Zhu Y, Luo JL, Zhou N, Li DC, Ju HX, Fan YT, Liu Y, Zhu YP, Feng HY, Liu LY. Prospective phase II trial of nimotuzumab in combination with radiotherapy and concurrent capecitabine in locally advanced rectal cancer. Int J Colorectal Dis 2015;30:337-45. [PMID: 25564344 DOI: 10.1007/s00384-014-2097-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
23 Galata C, Merx K, Mai S, Gaiser T, Wenz F, Post S, Kienle P, Hofheinz RD, Horisberger K. Impact of adjuvant chemotherapy on patients with ypT0-2 ypN0 rectal cancer after neoadjuvant chemoradiation: a cohort study from a tertiary referral hospital. World J Surg Oncol 2018;16:156. [PMID: 30071852 DOI: 10.1186/s12957-018-1455-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
24 Karoui M, Rullier A, Luciani A, Bonnetain F, Auriault ML, Sarran A, Monges G, Trillaud H, Le Malicot K, Leroy K, Sobhani I, Bardier A, Moreau M, Brindel I, Seitz JF, Taieb J. Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial--the PRODIGE 22--ECKINOXE trial. BMC Cancer 2015;15:511. [PMID: 26156156 DOI: 10.1186/s12885-015-1507-3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
25 Landi F, Espín E, Rodrigues V, Vallribera F, Martinez A, Charpy C, Brunetti F, Azoulay D, de'Angelis N. Pathologic response grade after long-course neoadjuvant chemoradiation does not influence morbidity in locally advanced mid-low rectal cancer resected by laparoscopy. Int J Colorectal Dis 2017;32:255-64. [PMID: 27757541 DOI: 10.1007/s00384-016-2685-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
26 Marks J, Nassif G, Schoonyoung H, DeNittis A, Zeger E, Mohiuddin M, Marks G. Sphincter-sparing surgery for adenocarcinoma of the distal 3 cm of the true rectum: results after neoadjuvant therapy and minimally invasive radical surgery or local excision. Surg Endosc. 2013;27:4469-4477. [PMID: 24057070 DOI: 10.1007/s00464-013-3092-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.2] [Reference Citation Analysis]
27 Roeder F, Meldolesi E, Gerum S, Valentini V, Rödel C. Recent advances in (chemo-)radiation therapy for rectal cancer: a comprehensive review. Radiat Oncol 2020;15:262. [PMID: 33172475 DOI: 10.1186/s13014-020-01695-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
28 Kawai K, Kitayama J, Tsuno NH, Sunami E, Watanabe T. Thrombocytosis before pre-operative chemoradiotherapy predicts poor response and shorter local recurrence-free survival in rectal cancer. Int J Colorectal Dis. 2013;28:527-535. [PMID: 23080345 DOI: 10.1007/s00384-012-1594-4] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
29 Watanabe J, Shoji H, Hamaguchi T, Miyamoto T, Hirano H, Iwasa S, Honma Y, Takashima A, Kato K, Ito Y, Itami J, Kanemitsu Y, Boku N. Chemoradiotherapy for Local Recurrence of Rectal Cancer: A Single Center Study of 18 Patients. In Vivo 2019;33:1363-8. [PMID: 31280231 DOI: 10.21873/invivo.11612] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
30 Jacobs L, Meek DB, van Heukelom J, Bollen TL, Siersema PD, Smits AB, Tromp E, Los M, Weusten BL, van Lelyveld N. Comparison of MRI and colonoscopy in determining tumor height in rectal cancer. United European Gastroenterol J 2018;6:131-7. [PMID: 29435323 DOI: 10.1177/2050640617707090] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
31 Ahmed S, Bathe O, Berry S, Buie D, Davies J, Doll C, Dowden S, Gill S, Gordon V, Hebbard P, Jones E, Kennecke H, Koski S, Krahn M, Le D, Lim H, Lund C, Luo Y, Mcffadden A, Mcghie J, Mulder K, Park J, Rashidi F, Sami A, Tan KT, Wong R. Consensus statement: the 16th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Saskatoon, Saskatchewan; September 5-6, 2014. Curr Oncol 2015;22:e113-23. [PMID: 25908916 DOI: 10.3747/co.22.2362] [Reference Citation Analysis]
32 Myerson RJ, Tan B, Hunt S, Olsen J, Birnbaum E, Fleshman J, Gao F, Hall L, Kodner I, Lockhart AC, Mutch M, Naughton M, Picus J, Rigden C, Safar B, Sorscher S, Suresh R, Wang-Gillam A, Parikh P. Five fractions of radiation therapy followed by 4 cycles of FOLFOX chemotherapy as preoperative treatment for rectal cancer. Int J Radiat Oncol Biol Phys. 2014;88:829-836. [PMID: 24606849 DOI: 10.1016/j.ijrobp.2013.12.028] [Cited by in Crossref: 55] [Cited by in F6Publishing: 39] [Article Influence: 6.9] [Reference Citation Analysis]
33 Slevin F, Hanna CR, Appelt A, Cunningham C, Marijnen CAM, Sebag-Montefiore D, Muirhead R. The Long and the Short of it: the Role of Short-course Radiotherapy in the Neoadjuvant Management of Rectal Cancer. Clin Oncol (R Coll Radiol) 2021:S0936-6555(21)00464-7. [PMID: 34955376 DOI: 10.1016/j.clon.2021.12.004] [Reference Citation Analysis]
34 Bijelic L, Kumar AS, Stuart OA, Sugarbaker PH. Systemic Chemotherapy prior to Cytoreductive Surgery and HIPEC for Carcinomatosis from Appendix Cancer: Impact on Perioperative Outcomes and Short-Term Survival. Gastroenterol Res Pract. 2012;2012:163284. [PMID: 22899903 DOI: 10.1155/2012/163284] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
35 Zhang J, Shen L, Deng Y, Sun X, Wang Y, Yao Y, Zhang H, Zou W, Zhang Z, Wan J, Yang L, Zhu J, Zhang Z. A novel LARCassigner3 classification predicts outcomes in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy: a retrospective training and validation analysis. Cancer Manag Res 2019;11:4153-70. [PMID: 31123421 DOI: 10.2147/CMAR.S196662] [Reference Citation Analysis]
36 Peng Y, Wang L, Du C, Gu J. Expression of vascular endothelial growth factor can predict distant metastasis and disease-free survival for clinical stage III rectal cancer following 30-Gy/10-f preoperative radiotherapy. Int J Colorectal Dis. 2012;27:1555-1560. [PMID: 22645074 DOI: 10.1007/s00384-012-1485-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
37 Nagasaki T, Akiyoshi T, Fujimoto Y, Konishi T, Nagayama S, Fukunaga Y, Ueno M. Preoperative Chemoradiotherapy Might Improve the Prognosis of Patients with Locally Advanced Low Rectal Cancer and Lateral Pelvic Lymph Node Metastases. World J Surg. 2017;41:876-883. [PMID: 27730348 DOI: 10.1007/s00268-016-3748-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
38 Hashiguchi Y, Muro K, Saito Y, Ito Y, Ajioka Y, Hamaguchi T, Hasegawa K, Hotta K, Ishida H, Ishiguro M, Ishihara S, Kanemitsu Y, Kinugasa Y, Murofushi K, Nakajima TE, Oka S, Tanaka T, Taniguchi H, Tsuji A, Uehara K, Ueno H, Yamanaka T, Yamazaki K, Yoshida M, Yoshino T, Itabashi M, Sakamaki K, Sano K, Shimada Y, Tanaka S, Uetake H, Yamaguchi S, Yamaguchi N, Kobayashi H, Matsuda K, Kotake K, Sugihara K;  Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25:1-42. [PMID: 31203527 DOI: 10.1007/s10147-019-01485-z] [Cited by in Crossref: 282] [Cited by in F6Publishing: 260] [Article Influence: 94.0] [Reference Citation Analysis]
39 Su M, Zhu LC, Wei HP, Luo WH, Lin RF, Zou CL. S-1-Based versus capecitabine-based preoperative chemoradiotherapy in the treatment of locally advanced rectal cancer: a matched-pair analysis. PLoS One 2014;9:e106162. [PMID: 25181318 DOI: 10.1371/journal.pone.0106162] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
40 Dijkstra EA, Mul VEM, Hemmer PHJ, Havenga K, Hospers GAP, Muijs CT, van Etten B. Re-Irradiation in Patients with Recurrent Rectal Cancer is Safe and Feasible. Ann Surg Oncol 2021;28:5194-204. [PMID: 34023946 DOI: 10.1245/s10434-021-10070-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Zhu J, Lian P, Liu F, Xu Y, Xu J, Guan Z, Liang L, Wang M, Cai S, Zhang Z. Phase II trial of first-line chemoradiotherapy with intensity-modulated radiation therapy followed by chemotherapy for synchronous unresectable distant metastases rectal adenocarcinoma. Radiat Oncol 2013;8:10. [PMID: 23295152 DOI: 10.1186/1748-717X-8-10] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
42 Hohenberger W, Lahmer G, Fietkau R, Croner RS, Merkel S, Göhl J, Sauer R. [Neoadjuvant radiochemotherapy for rectal cancer]. Chirurg 2009;80:294-302. [PMID: 19350306 DOI: 10.1007/s00104-009-1707-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
43 Smith JJ, Chow OS, Gollub MJ, Nash GM, Temple LK, Weiser MR, Guillem JG, Paty PB, Avila K, Garcia-Aguilar J; Rectal Cancer Consortium. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management. BMC Cancer 2015;15:767. [PMID: 26497495 DOI: 10.1186/s12885-015-1632-z] [Cited by in Crossref: 145] [Cited by in F6Publishing: 109] [Article Influence: 20.7] [Reference Citation Analysis]
44 Chen P, Yao Y, Gu J. Rectal cancer patients after neoadjuvant radiotherapy (30Gy/10f) with negative lymph node may not benefit from postoperative adjuvant chemotherapy: a retrospective study. Int J Colorectal Dis 2015;30:1695-704. [PMID: 26278877 DOI: 10.1007/s00384-015-2358-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
45 Wen Z, Chen Y, Yang X, Lu B, Liu Y, Shen B, Yu S. Application of magnetic resonance diffusion kurtosis imaging for distinguishing histopathologic subtypes and grades of rectal carcinoma. Cancer Imaging 2019;19:8. [PMID: 30744694 DOI: 10.1186/s40644-019-0192-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
46 Siani LM, Garulli G. Laparoscopic complete mesocolic excision with central vascular ligation in right colon cancer: A comprehensive review. World J Gastrointest Surg 2016; 8(2): 106-114 [PMID: 26981184 DOI: 10.4240/wjgs.v8.i2.106] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
47 Tham CK, Choo SP, Poon DYH, Toh HC, Ong SYK, Tan SH, Wang MLC, Foo KF. Capecitabine with radiation is an effective adjuvant therapy in gastric cancers. World J Gastroenterol 2010; 16(29): 3709-3715 [PMID: 20677345 DOI: 10.3748/wjg.v16.i29.3709] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
48 Bando H, Tsukada Y, Ito M, Yoshino T. Novel Immunological Approaches in the Treatment of Locally Advanced Rectal Cancer. Clin Colorectal Cancer 2021:S1533-0028(21)00099-2. [PMID: 34776358 DOI: 10.1016/j.clcc.2021.10.001] [Reference Citation Analysis]
49 Zheng R, Lian S, Huang X, Guan G, Li X, Chi P, Xu B. The survival benefit of intensified full-dose XELOX chemotherapy concomitant to radiotherapy and then resting-period consolidation chemotherapy in locally advanced rectal cancer. J Cancer 2019;10:730-6. [PMID: 30719172 DOI: 10.7150/jca.28265] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
50 Holm M, Joenväärä S, Saraswat M, Tohmola T, Ristimäki A, Renkonen R, Haglund C. Plasma protein expression differs between colorectal cancer patients depending on primary tumor location. Cancer Med 2020;9:5221-34. [PMID: 32452655 DOI: 10.1002/cam4.3178] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
51 Li FY, Zhu LC, Zhou L. Factors affecting acute myelosuppression induced by radiotherapy and chemotherapy for rectal cancer. Shijie Huaren Xiaohua Zazhi 2018; 26(8): 506-511 [DOI: 10.11569/wcjd.v26.i8.506] [Reference Citation Analysis]
52 Nakanishi R, Yamaguchi T, Akiyoshi T, Nagasaki T, Nagayama S, Mukai T, Ueno M, Fukunaga Y, Konishi T. Laparoscopic and robotic lateral lymph node dissection for rectal cancer. Surg Today 2020;50:209-16. [PMID: 31989237 DOI: 10.1007/s00595-020-01958-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
53 Mei SW, Liu Z, Wang Z, Pei W, Wei FZ, Chen JN, Wang ZJ, Shen HY, Li J, Zhao FQ, Wang XS, Liu Q. Impact factors of lymph node retrieval on survival in locally advanced rectal cancer with neoadjuvant therapy. World J Clin Cases 2020; 8(24): 6229-6242 [PMID: 33392304 DOI: 10.12998/wjcc.v8.i24.6229] [Reference Citation Analysis]
54 Swellengrebel HA, Peters EG, Cats A, Visser O, Blaauwgeers HG, Verwaal VJ, van Velthuysen ML, Cense HA, Bruin SC, Marijnen CA. Multidisciplinary discussion and management of rectal cancer: a population-based study. World J Surg 2011;35:2125-33. [PMID: 21720869 DOI: 10.1007/s00268-011-1181-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
55 Shoji H, Motegi M, Osawa K, Okonogi N, Okazaki A, Andou Y, Asao T, Kuwano H, Takahashi T, Ogoshi K. A novel strategy of radiofrequency hyperthermia (neothermia) in combination with preoperative chemoradiotherapy for the treatment of advanced rectal cancer: a pilot study. Cancer Med 2015;4:834-43. [PMID: 25664976 DOI: 10.1002/cam4.431] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
56 Merkel S, Weber K, Göhl J, Agaimy A, Fietkau R, Hohenberger W, Grützmann R, Hermanek P. Survival analysis in rectal carcinoma after neoadjuvant chemoradiation: various methods with different results. Int J Colorectal Dis 2017;32:1295-301. [PMID: 28730369 DOI: 10.1007/s00384-017-2861-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
57 Lee BH, Chang MY, Park SK, Eum T, Shin HJ, Ro NK, An CN, Lee HW, Kim LS, Park HC, Bae HS, Zang DY, Whelan RL. Laparoscopic assisted distal rectal cancer resection with preoperative concurrent chemoradiotherapy. Cancer Res Treat 2007;39:10-5. [PMID: 19746227 DOI: 10.4143/crt.2007.39.1.10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
58 Chung MJ, Chung SM, Kim JY, Ryu MR. Prognostic significance of serum carcinoembryonic antigen normalization on survival in rectal cancer treated with preoperative chemoradiation. Cancer Res Treat 2013;45:186-92. [PMID: 24155677 DOI: 10.4143/crt.2013.45.3.186] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
59 Peng JJ, Cai SJ, Lu HF, Cai GX, Lian P, Guan ZQ, Wang MH, Xu Y. Predicting prognosis of rectal cancer patients with total mesorectal excision using molecular markers. World J Gastroenterol 2007; 13(21): 3009-3015 [PMID: 17589956 DOI: 10.3748/wjg.v13.i21.3009] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
60 Sung S, Son SH, Park EY, Kay CS. Prognosis of locally advanced rectal cancer can be predicted more accurately using pre- and post-chemoradiotherapy neutrophil-lymphocyte ratios in patients who received preoperative chemoradiotherapy. PLoS One. 2017;12:e0173955. [PMID: 28291841 DOI: 10.1371/journal.pone.0173955] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
61 Santos MD, Silva C, Rocha A, Matos E, Nogueira C, Lopes C. Tumor regression grades: can they influence rectal cancer therapy decision tree? Int J Surg Oncol. 2013;2013:572149. [PMID: 24187617 DOI: 10.1155/2013/572149] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
62 Haanappel A, Kroon HM, Schaap DP, Bedrikovetski S, Dudi-Venkata NN, Lee HX, Thomas ML, Liu J, van der Valk MJM, Rutten HJT, Beets GL, Kusters M, Sammour T. Lateral Lymph Node Metastases in Locally Advanced Low Rectal Cancers May Not Be Treated Effectively With Neoadjuvant (Chemo)Radiotherapy Only.Front Oncol. 2019;9:1355. [PMID: 31850231 DOI: 10.3389/fonc.2019.01355] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
63 Chen TJ, He HL, Shiue YL, Yang CC, Lin LC, Tian YF, Chen SH. High chloride channel accessory 1 expression predicts poor prognoses in patients with rectal cancer receiving chemoradiotherapy. Int J Med Sci 2018;15:1171-8. [PMID: 30123054 DOI: 10.7150/ijms.26685] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
64 Panagiotopoulou IG, Parashar D, Qasem E, Mezher-Sikafi R, Parmar J, Wells AD, Bajwa FM, Menon M, Jephcott CR. Neoadjuvant Long-Course Chemoradiotherapy for Rectal Cancer: Does Time to Surgery Matter? Int Surg. 2015;100:968-973. [PMID: 26414816 DOI: 10.9738/intsurg-d-14-00192.1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
65 Liu H, Zhang C, Wang L, Luo R, Li J, Zheng H, Yin Q, Zhang Z, Duan S, Li X, Wang D. MRI radiomics analysis for predicting preoperative synchronous distant metastasis in patients with rectal cancer. Eur Radiol. 2019;29:4418-4426. [PMID: 30413955 DOI: 10.1007/s00330-018-5802-7] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 8.3] [Reference Citation Analysis]
66 Ofner D, Devries AF, Schaberl-Moser R, Greil R, Rabl H, Tschmelitsch J, Zitt M, Kapp KS, Fastner G, Keil F, Eisterer W, Jäger R, Offner F, Gnant M, Thaler J; TAKO 05/ABCSG R-02 Trial Investigators. Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary operable, cT₃NxM0, low rectal cancer: a phase II study. Strahlenther Onkol 2011;187:100-7. [PMID: 21267531 DOI: 10.1007/s00066-010-2182-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
67 Wong SJ, Winter K, Meropol NJ, Anne PR, Kachnic L, Rashid A, Watson JC, Mitchell E, Pollock J, Lee RJ, Haddock M, Erickson BA, Willett CG. Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2012;82:1367-1375. [PMID: 21775070 DOI: 10.1016/j.ijrobp.2011.05.027] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 4.0] [Reference Citation Analysis]
68 Abe S, Nozawa H, Kawai K, Sasaki K, Murono K, Emoto S, Kishikawa J, Ozawa T, Yokoyama Y, Nagai Y, Anzai H, Sonoda H, Ishihara S. Poor nutrition and sarcopenia are related to systemic inflammatory response in patients with rectal cancer undergoing preoperative chemoradiotherapy. Int J Colorectal Dis 2021. [PMID: 34633498 DOI: 10.1007/s00384-021-04039-w] [Reference Citation Analysis]
69 Wan JF, Yang LF, Zhu J, Li GC, Zhang Z. Adjuvant chemotherapy for patients with ypT0-2N0-category after neoadjuvant chemoradiotherapy for rectal cancer. Mol Clin Oncol 2017;7:864-8. [PMID: 29181181 DOI: 10.3892/mco.2017.1426] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
70 Shoji H, Motegi M, Osawa K, Okonogi N, Okazaki A, Andou Y, Asao T, Kuwano H, Takahashi T, Ogoshi K. Radiofrequency thermal treatment with chemoradiotherapy for advanced rectal cancer. Oncol Rep 2016;35:2569-75. [PMID: 26985914 DOI: 10.3892/or.2016.4659] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
71 Bosset JF, Nguyen F, Bosset M, Servagi-Vernat S, Schipman B. Recent advances in the treatment of localized rectal cancer. Curr Oncol Rep 2008;10:220-4. [PMID: 18765152 DOI: 10.1007/s11912-008-0034-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
72 Dellas K, Höhler T, Reese T, Würschmidt F, Engel E, Rödel C, Wagner W, Richter M, Arnold D, Dunst J. Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer. Radiat Oncol 2013;8:90. [PMID: 23587311 DOI: 10.1186/1748-717X-8-90] [Cited by in Crossref: 29] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
73 Pinto C, Di Bisceglie M, Di Fabio F, Bochicchio A, Latiano T, Cordio S, Rosati G, Aschele C, Marino A, Bergamo F, Bustreo S, Frassineti L, Ciardiello F, Damato A, Giaquinta S, Baldari D, Boni L. Phase II Study of Preoperative Treatment with External Radiotherapy Plus Panitumumab in Low-Risk, Locally Advanced Rectal Cancer (RaP Study/STAR-03). Oncologist 2018;23:912-8. [PMID: 29523646 DOI: 10.1634/theoncologist.2017-0484] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
74 Toiyama Y, Kusunoki M. Changes in surgical therapies for rectal cancer over the past 100 years: A review. Ann Gastroenterol Surg 2020;4:331-42. [PMID: 32724876 DOI: 10.1002/ags3.12342] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
75 Gustavsson B, Carlsson G, Swartling T, Kurlberg G, Derwinger K, Björkqvist H, Odin E, Gibson F. Phase 1 dose de-escalation trial of the endogenous folate [6R]-5,10-methylene tetrahydrofolate in combination with fixed-dose pemetrexed as neoadjuvant therapy in patients with resectable rectal cancer. Invest New Drugs 2015;33:1078-85. [PMID: 26189513 DOI: 10.1007/s10637-015-0272-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
76 Lescut N, Lepinoy A, Schipman B, Cerda T, Guimas V, Bednarek C, Bosset JF. [Preoperative chemoradiotherapy for rectal cancer: experience from one centre]. Cancer Radiother 2015;19:98-105. [PMID: 25769650 DOI: 10.1016/j.canrad.2014.11.011] [Reference Citation Analysis]
77 Viganò L, Karoui M, Ferrero A, Tayar C, Cherqui D, Capussotti L. Locally advanced mid/low rectal cancer with synchronous liver metastases. World J Surg. 2011;35:2788-2795. [PMID: 21947493 DOI: 10.1007/s00268-011-1272-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
78 Lee JH, Jeong JU, Kim SH, Nam TK, Lee JH, Jeong S, Yu M, Jang HS. Nadir/pre-chemoradiotherapy ratio of white blood-cell count can predict tumor response and recurrence-free survival in locally advanced rectal cancer: a multi-institutional analysis. Int J Colorectal Dis 2019;34:105-12. [PMID: 30350135 DOI: 10.1007/s00384-018-3174-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
79 Zitt M, DeVries A, Thaler J, Kafka-Ritsch R, Eisterer W, Lukas P, Öfner D. Long-term surveillance of locally advanced rectal cancer patients with neoadjuvant chemoradiation and aggressive surgical treatment of recurrent disease: a consecutive single-centre experience. Int J Colorectal Dis. 2015;30:1705-1714. [PMID: 26293791 DOI: 10.1007/s00384-015-2366-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
80 Zhu J, Liu F, Gu W, Lian P, Sheng W, Xu J, Cai G, Shi D, Cai S, Zhang Z. Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase II study. Radiat Oncol 2014;9:70. [PMID: 24606870 DOI: 10.1186/1748-717X-9-70] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
81 van Gijn W, van de Velde CJ. 2010 SSO John Wayne clinical research lecture: rectal cancer outcome improvements in Europe: population-based outcome registrations will conquer the world. Ann Surg Oncol. 2011;18:691-696. [PMID: 20844966 DOI: 10.1245/s10434-010-1326-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
82 Hsieh CH, Hou ML, Wang LY, Tai HC, Tsai TH, Chen YJ. Local pelvic irradiation modulates Pharmacokinetics of 5-Fluorouracil in the plasma but not in the Lymphatic System. BMC Cancer 2015;15:316. [PMID: 25928348 DOI: 10.1186/s12885-015-1344-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
83 Kim HJ, Choi GS, Park JS, Park SY, Lee HJ, Woo IT, Park IK. Selective lateral pelvic lymph node dissection: a comparative study of the robotic versus laparoscopic approach. Surg Endosc 2018;32:2466-73. [PMID: 29124406 DOI: 10.1007/s00464-017-5948-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 4.2] [Reference Citation Analysis]
84 Wei IH, Garcia-Aguilar J. Non-operative management of rectal cancer: understanding tumor biology. Minerva Chir 2018;73:601-18. [PMID: 29795066 DOI: 10.23736/S0026-4733.18.07743-X] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
85 Ozaki K, Kawai K, Nozawa H, Sasaki K, Murono K, Emoto S, Iida Y, Ishii H, Yokoyama Y, Anzai H, Sonoda H, Sugihara K, Ishihara S. Therapeutic effects and limitations of chemoradiotherapy in advanced lower rectal cancer focusing on T4b. Int J Colorectal Dis 2021;36:1525-34. [PMID: 33937942 DOI: 10.1007/s00384-021-03936-4] [Reference Citation Analysis]
86 Cristóbal I, Rubio J, Santos A, Torrejón B, Caramés C, Imedio L, Mariblanca S, Luque M, Sanz-Alvarez M, Zazo S, Madoz-Gúrpide J, Rojo F, García-Foncillas J. MicroRNA-199b Downregulation Confers Resistance to 5-Fluorouracil Treatment and Predicts Poor Outcome and Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Patients. Cancers (Basel) 2020;12:E1655. [PMID: 32580513 DOI: 10.3390/cancers12061655] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
87 Yamashita H, Ishihara S, Nozawa H, Kawai K, Kiyomatsu T, Okuma K, Abe O, Watanabe T, Nakagawa K. Comparison of volumetric-modulated arc therapy using simultaneous integrated boosts (SIB-VMAT) of 45 Gy/55 Gy in 25 fractions with conventional radiotherapy in preoperative chemoradiation for rectal cancers: a propensity score case-matched analysis. Radiat Oncol 2017;12:156. [PMID: 28934968 DOI: 10.1186/s13014-017-0894-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
88 Wirsdörfer F, Jendrossek V. The Role of Lymphocytes in Radiotherapy-Induced Adverse Late Effects in the Lung. Front Immunol 2016;7:591. [PMID: 28018357 DOI: 10.3389/fimmu.2016.00591] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 7.5] [Reference Citation Analysis]
89 Pavlík T, Májek O, Mužík J, Koptíková J, Slavíček L, Fínek J, Feltl D, Vyzula R, Dušek L. Estimating the number of colorectal cancer patients treated with anti-tumour therapy in 2015: the analysis of the Czech National Cancer Registry. BMC Public Health 2012;12:117. [PMID: 22325812 DOI: 10.1186/1471-2458-12-117] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
90 Yang KL, Yang SH, Liang WY, Kuo YJ, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, Chang SC. Carcinoembryonic antigen (CEA) level, CEA ratio, and treatment outcome of rectal cancer patients receiving pre-operative chemoradiation and surgery. Radiat Oncol. 2013;8:43. [PMID: 23452434 DOI: 10.1186/1748-717x-8-43] [Cited by in Crossref: 41] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
91 Kim YJ, Kim JH, Yu CS, Kim TW, Jang SJ, Choi EK, Kim JC, Choi W. Effect of time interval between capecitabine intake and radiotherapy on local recurrence-free survival in preoperative chemoradiation for locally advanced rectal cancer. Radiat Oncol J 2017;35:129-36. [PMID: 28712273 DOI: 10.3857/roj.2017.00010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
92 Methy N, Bedenne L, Bonnetain F. Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists. BMC Cancer 2010;10:277. [PMID: 20537166 DOI: 10.1186/1471-2407-10-277] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
93 Dudani S, Marginean H, Gotfrit J, Tang PA, Monzon JG, Dennis K, Kennecke HF, Powell ED, Babak S, Cheung WY, Vickers MM. The Impact of Chronic Kidney Disease in Patients With Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiation. Dis Colon Rectum 2021;64:1471-8. [PMID: 34657078 DOI: 10.1097/DCR.0000000000002116] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
94 George TJ, Allegra CJ, Yothers G. Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical Trials. Curr Colorectal Cancer Rep. 2015;11:275-280. [PMID: 26321890 DOI: 10.1007/s11888-015-0285-2] [Cited by in Crossref: 61] [Cited by in F6Publishing: 59] [Article Influence: 8.7] [Reference Citation Analysis]
95 Hiratsuka T, Etoh T, Hara T, Akagi T, Tahara K, Matsumoto T, Ogawa T, Fujii K, Shiromizu A, Shiroshita H, Inomata M. Long-term outcomes of neoadjuvant-synchronous S-1 plus radiotherapy for locally advanced rectal cancer: a multi-institutional prospective phase II study. J Anus Rectum Colon 2018;2:168-75. [PMID: 31559360 DOI: 10.23922/jarc.2018-011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
96 Antelo G, Hierro C, Fernández JP, Baena E, Bugés C, Layos L, Manzano JL, Caro M, Mesia R. Rectal neuroendocrine carcinoma: case report of a rare entity and perspective review of promising agents. Drugs Context 2020;9:2020-2-4. [PMID: 32477420 DOI: 10.7573/dic.2020-2-4] [Reference Citation Analysis]
97 Lund JL, Sturmer T, Sanoff HK. Comparative effectiveness of postoperative chemotherapy among older patients with non-metastatic rectal cancer treated with preoperative chemoradiotherapy. J Geriatr Oncol 2016;7:176-86. [PMID: 26926829 DOI: 10.1016/j.jgo.2016.01.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
98 Jones WE 3rd, Thomas CR Jr, Herman JM, Abdel-Wahab M, Azad N, Blackstock W, Das P, Goodman KA, Hong TS, Jabbour SK, Konski AA, Koong AC, Rodriguez-Bigas M, Small W Jr, Zook J, Suh WW. ACR appropriateness criteria®  resectable rectal cancer. Radiat Oncol 2012;7:161. [PMID: 23006527 DOI: 10.1186/1748-717X-7-161] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
99 Gallamini A, Zwarthoed C, Borra A. Positron Emission Tomography (PET) in Oncology. Cancers (Basel). 2014;6:1821-1889. [PMID: 25268160 DOI: 10.3390/cancers6041821] [Cited by in Crossref: 146] [Cited by in F6Publishing: 126] [Article Influence: 18.3] [Reference Citation Analysis]
100 Huang CM, Huang MY, Tsai HL, Huang CW, Ma CJ, Lin CH, Huang CJ, Wang JY. A retrospective comparison of outcome and toxicity of preoperative image-guided intensity-modulated radiotherapy versus conventional pelvic radiotherapy for locally advanced rectal carcinoma. J Radiat Res 2017;58:247-59. [PMID: 27738080 DOI: 10.1093/jrr/rrw098] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
101 Thompson MK, Poortmans P, Chalmers AJ, Faivre-Finn C, Hall E, Huddart RA, Lievens Y, Sebag-Montefiore D, Coles CE. Practice-changing radiation therapy trials for the treatment of cancer: where are we 150 years after the birth of Marie Curie? Br J Cancer 2018;119:389-407. [PMID: 30061587 DOI: 10.1038/s41416-018-0201-z] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 12.3] [Reference Citation Analysis]
102 Maffione AM, Ferretti A, Grassetto G, Bellan E, Capirci C, Chondrogiannis S, Gava M, Marzola MC, Rampin L, Bondesan C. Fifteen different 18F-FDG PET/CT qualitative and quantitative parameters investigated as pathological response predictors of locally advanced rectal cancer treated by neoadjuvant chemoradiation therapy. Eur J Nucl Med Mol Imaging. 2013;40:853-864. [PMID: 23417501 DOI: 10.1007/s00259-013-2357-3] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 5.6] [Reference Citation Analysis]
103 Wong AC, Stock S, Schrag D, Kahn KL, Salz T, Charlton ME, Rogers SO Jr, Goodman KA, Keating NL. Physicians' beliefs about the benefits and risks of adjuvant therapies for stage II and stage III colorectal cancer. J Oncol Pract 2014;10:e360-7. [PMID: 24986112 DOI: 10.1200/JOP.2013.001309] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
104 Moureau-Zabotto L, Gal J, Resbeut M, Mineur L, Teissier É, Hébuterne X, Muyldermans P, Francois É, Chamorey E, Gérard JP. [Management and clinical outcome in patients over 80 years with rectal cancer treated between 2006 and 2008 in Southern France (PACA region)]. Cancer Radiother 2015;19:725-32. [PMID: 26548601 DOI: 10.1016/j.canrad.2015.05.029] [Reference Citation Analysis]
105 Kondo K, Shimbo T, Tanaka K, Yamamoto M, Narumi Y, Okuda J, Uchiyama K. Clinical implications of preoperative chemoradiotherapy prior to laparoscopic surgery for locally advanced low rectal cancer. Mol Clin Oncol 2017;6:23-8. [PMID: 28123724 DOI: 10.3892/mco.2016.1098] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
106 Yang SY, Han YD, Cho MS, Hur H, Min BS, Lee KY, Kim NK. Late anastomotic leakage after anal sphincter saving surgery for rectal cancer: is it different from early anastomotic leakage? Int J Colorectal Dis 2020;35:1321-30. [PMID: 32372379 DOI: 10.1007/s00384-020-03608-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
107 Agostini M, Janssen KP, Kim IJ, D'Angelo E, Pizzini S, Zangrando A, Zanon C, Pastrello C, Maretto I, Digito M, Bedin C, Jurisica I, Rizzolio F, Giordano A, Bortoluzzi S, Nitti D, Pucciarelli S. An integrative approach for the identification of prognostic and predictive biomarkers in rectal cancer. Oncotarget. 2015;6:32561-32574. [PMID: 26359356 DOI: 10.18632/oncotarget.4935] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
108 Miwa K, Oki E, Enomoto M, Ihara K, Ando K, Fujita F, Tominaga M, Mori S, Nakayama G, Shimokawa M, Saeki H, Baba H, Mori M, Akagi Y. Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301). BMC Cancer 2021;21:23. [PMID: 33402130 DOI: 10.1186/s12885-020-07766-5] [Reference Citation Analysis]
109 Cha YJ, Park EJ, Baik SH, Lee KY, Kang J. Prognostic impact of persistent lower neutrophil-to-lymphocyte ratio during preoperative chemoradiotherapy in locally advanced rectal cancer patients: A propensity score matching analysis. PLoS One. 2019;14:e0214415. [PMID: 30901357 DOI: 10.1371/journal.pone.0214415] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
110 Morais M, Fonseca T, Machado-Neves R, Honavar M, Coelho AR, Lopes J, Barbosa E, Guerreiro E, Carneiro S. Can pretreatment blood biomarkers predict pathological response to neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer? Future Oncol 2021;17:4947-57. [PMID: 34734533 DOI: 10.2217/fon-2021-0707] [Reference Citation Analysis]
111 Zhao Y, Zhu J, Yang B, Gao Q, Xu Y, Wei X, Kong D, Ji S, Fei B. Retrospective study of total neoadjuvant therapy for locally advanced rectal cancer. Future Oncol 2021. [PMID: 34878307 DOI: 10.2217/fon-2021-0644] [Reference Citation Analysis]
112 Guo Y, Guo Y, Luo Y, Song X, Zhao H, Li L. Comparison of pathologic outcomes of robotic and open resections for rectal cancer: A systematic review and meta-analysis. PLoS One 2021;16:e0245154. [PMID: 33439912 DOI: 10.1371/journal.pone.0245154] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
113 Lee KH, Song MS, Park JB, Kim JS, Kang DY, Kim JY. A Phase II Study of Additional Four-Week Chemotherapy With Capecitabine During the Resting Periods After Six-Week Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer. Ann Coloproctol 2013;29:192-7. [PMID: 24278857 DOI: 10.3393/ac.2013.29.5.192] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
114 Saigusa S, Toiyama Y, Tanaka K, Inoue Y, Mori K, Ide S, Imaoka H, Kawamura M, Mohri Y, Kusunoki M. Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy. Int J Clin Oncol 2016;21:946-52. [PMID: 26919982 DOI: 10.1007/s10147-016-0962-4] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
115 Zhao M, Zhao L, Yang H, Duan Y, Li G. Apparent diffusion coefficient for the prediction of tumor response to neoadjuvant chemo-radiotherapy in locally advanced rectal cancer. Radiat Oncol 2021;16:17. [PMID: 33472660 DOI: 10.1186/s13014-020-01738-6] [Reference Citation Analysis]
116 Smith CA, Mont S, Traver G, Sekhar KR, Crooks PA, Freeman ML. Targeting Enox1 in tumor stroma increases the efficacy of fractionated radiotherapy. Oncotarget 2016;7:77926-36. [PMID: 27788492 DOI: 10.18632/oncotarget.12845] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
117 Alberda WJ, Haberkorn BC, Morshuis WG, Oudendijk JF, Nuyttens JJ, Burger JW, Verhoef C, van Meerten E. Response to chemotherapy in patients with recurrent rectal cancer in previously irradiated area. Int J Colorectal Dis 2015;30:1075-80. [PMID: 26077667 DOI: 10.1007/s00384-015-2270-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
118 Zhu S, Brodin NP, English K, Ohri N, Chuy JW, Rajdev LN, Narang R, Kalnicki S, Guha C, Garg MK, Kabarriti R. Comparing outcomes following total neoadjuvant therapy and following neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer. EClinicalMedicine 2019;16:23-9. [PMID: 31832617 DOI: 10.1016/j.eclinm.2019.09.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
119 García-Flórez LJ, Gómez-Álvarez G, Frunza AM, Barneo-Serra L, Fresno-Forcelledo MF. Response to chemoradiotherapy and lymph node involvement in locally advanced rectal cancer. World Journal of Gastrointestinal Surgery 2015; 7(9): 196-202 [PMID: 26425268 DOI: 10.4240/wjgs.v7.i9.196] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
120 Lin N, Yu C, Yang J, Wang Y. Nano-carbon and titanium clip combined labeling assisted surgery before neoadjuvant radiotherapy and chemotherapy for rectal cancer. Asian J Surg 2020;43:383-4. [PMID: 31607418 DOI: 10.1016/j.asjsur.2019.09.003] [Reference Citation Analysis]
121 Gao XH, Yu GY, Gong HF, Liu LJ, Xu Y, Hao LQ, Liu P, Liu ZH, Bai CG, Zhang W. Differences of protein expression profiles, KRAS and BRAF mutation, and prognosis in right-sided colon, left-sided colon and rectal cancer. Sci Rep 2017;7:7882. [PMID: 28801584 DOI: 10.1038/s41598-017-08413-z] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 7.2] [Reference Citation Analysis]
122 Guimas V, Boustani J, Schipman B, Lescut N, Puyraveau M, Bosset JF, Servagi-Vernat S. Preoperative Chemoradiotherapy for Rectal Cancer in Patients Aged 75 Years and Older: Acute Toxicity, Compliance with Treatment, and Early Results. Drugs Aging 2016;33:419-25. [PMID: 27138958 DOI: 10.1007/s40266-016-0367-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
123 Yeo SG, Kim DY. An update on preoperative radiotherapy for locally advanced rectal cancer. J Korean Soc Coloproctol 2012;28:179-87. [PMID: 22993703 DOI: 10.3393/jksc.2012.28.4.179] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
124 Caramés C, Cristóbal I, Moreno V, del Puerto L, Moreno I, Rodriguez M, Marín JP, Correa AV, Hernández R, Zenzola V, Hernández T, León A, Martín JI, Sánchez-Fayos P, García-Olmo D, Rojo F, Goel A, Fernandez-Aceñero MJ, García-Foncillas J. MicroRNA-21 predicts response to preoperative chemoradiotherapy in locally advanced rectal cancer. Int J Colorectal Dis 2015;30:899-906. [PMID: 25953218 DOI: 10.1007/s00384-015-2231-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
125 Fung-Kee-Fung SD. Therapeutic approaches in the management of locally advanced rectal cancer. J Gastrointest Oncol 2014;5:353-61. [PMID: 25276408 DOI: 10.3978/j.issn.2078-6891.2014.067] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
126 Zhong X, Zhou Y, Cui W, Su X, Guo Z, Hidasa I, Li Q, Wang Z, Song Y. The Addition of EGFR Inhibitors in Neoadjuvant Therapy for KRAS-Wild Type Locally Advanced Rectal Cancer Patients: A Systematic Review and Meta-Analysis. Front Pharmacol 2020;11:706. [PMID: 32499700 DOI: 10.3389/fphar.2020.00706] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
127 Kim MJ, Kim SJ, Park SC, Kim DY, Park JW, Ryoo SB, Jeong SY, Park KJ, Oh HK, Kim DW, Kang SB, Joo JN, Oh JH; SEoul COlorectal Group (SECOG). Adjuvant radiotherapy for the treatment of stage IV rectal cancer after curative resection: A propensity score-matched analysis and meta-analysis. Medicine (Baltimore) 2016;95:e4925. [PMID: 27893653 DOI: 10.1097/MD.0000000000004925] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
128 Jalil O, Claydon L, Arulampalam T. Review of Neoadjuvant Chemotherapy Alone in Locally Advanced Rectal Cancer. J Gastrointest Cancer 2015;46:219-36. [PMID: 26133151 DOI: 10.1007/s12029-015-9739-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
129 Spanos CP, Mamopoulos A, Tsapas A, Syrakos T, Kiskinis D. Female fertility and colorectal cancer. Int J Colorectal Dis 2008;23:735-43. [PMID: 18458919 DOI: 10.1007/s00384-008-0483-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
130 Artus A, Tabchouri N, Iskander O, Michot N, Muller O, Giger-Pabst U, Bourlier P, Bourbao-Tournois C, Kraemer-Bucur A, Lecomte T, Salamé E, Ouaissi M. Long term outcome of anastomotic leakage in patients undergoing low anterior resection for rectal cancer. BMC Cancer 2020;20:780. [PMID: 32819329 DOI: 10.1186/s12885-020-07109-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
131 Scher N, Bonvalot S, Le Tourneau C, Chajon E, Verry C, Thariat J, Calugaru V. Review of clinical applications of radiation-enhancing nanoparticles. Biotechnol Rep (Amst) 2020;28:e00548. [PMID: 33204660 DOI: 10.1016/j.btre.2020.e00548] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
132 Bohlok A, Hendlisz A, Bouazza F, Galdon MG, Van de Stadt J, Moretti L, El Nakadi I, Liberale G. The potential benefit of adjuvant chemotherapy in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy is not predicted by tumor regression grade. Int J Colorectal Dis 2018;33:1383-91. [PMID: 29984385 DOI: 10.1007/s00384-018-3115-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
133 Kennedy A, Brown DB, Feilchenfeldt J, Marshall J, Wasan H, Fakih M, Gibbs P, Knuth A, Sangro B, Soulen MC, Pittari G, Sharma RA. Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: expert consensus. J Gastrointest Oncol 2017;8:1079-99. [PMID: 29299370 DOI: 10.21037/jgo.2017.09.10] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
134 Yasuda K, Nirei T, Sunami E, Nagawa H, Kitayama J. Density of CD4(+) and CD8(+) T lymphocytes in biopsy samples can be a predictor of pathological response to chemoradiotherapy (CRT) for rectal cancer. Radiat Oncol 2011;6:49. [PMID: 21575175 DOI: 10.1186/1748-717X-6-49] [Cited by in Crossref: 62] [Cited by in F6Publishing: 39] [Article Influence: 5.6] [Reference Citation Analysis]
135 Sekizawa K, Nakagawa K, Ichikawa Y, Suwa H, Ozawa M, Momiyama M, Ishibe A, Watanabe J, Ota M, Kato I, Endo I. Relationship between stromal regulatory T cells and the response to neoadjuvant chemotherapy for locally advanced rectal cancer. Surg Today 2021. [PMID: 34081199 DOI: 10.1007/s00595-021-02311-8] [Reference Citation Analysis]
136 Nelson VM, Benson AB 3rd. Pathological complete response after neoadjuvant therapy for rectal cancer and the role of adjuvant therapy. Curr Oncol Rep 2013;15:152-61. [PMID: 23381584 DOI: 10.1007/s11912-013-0297-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
137 Peponi E, Skloupiotis V, Tsironis D, Tasiou I, Capizzello A, Tsironis C, Tsimoyiannis KE, Pitouli E, Tsimoyiannis E, Tsekeris P. Preoperative Chemoradiation in Locally Advanced Rectal Cancer: Efficacy and Safety. Gastroenterology Res 2015;8:303-8. [PMID: 27785313 DOI: 10.14740/gr681w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
138 Cercek A, Goodman KA, Hajj C, Weisberger E, Segal NH, Reidy-Lagunes DL, Stadler ZK, Wu AJ, Weiser MR, Paty PB, Guillem JG, Nash GM, Temple LK, Garcia-Aguilar J, Saltz LB. Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer. J Natl Compr Canc Netw. 2014;12:513-519. [PMID: 24717570 DOI: 10.6004/jnccn.2014.0056] [Cited by in Crossref: 121] [Cited by in F6Publishing: 97] [Article Influence: 15.1] [Reference Citation Analysis]
139 Reis T, Khazzaka E, Welzel G, Wenz F, Hofheinz RD, Mai S. Acute small-bowel toxicity during neoadjuvant combined radiochemotherapy in locally advanced rectal cancer: determination of optimal dose-volume cut-off value predicting grade 2-3 diarrhoea. Radiat Oncol 2015;10:30. [PMID: 25636703 DOI: 10.1186/s13014-015-0336-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
140 Lee SJ, Kang BW, Chae YS, Cho SH, Kim HJ, Park SY, Park JS, Choi GS, Kim JG. Pilot study of modified FOLFOX6 adjuvant chemotherapy for high-risk rectal cancer treated with neoadjuvant chemoradiotherapy. Cancer Chemother Pharmacol 2015;76:29-34. [PMID: 25956708 DOI: 10.1007/s00280-015-2764-1] [Reference Citation Analysis]
141 Díaz Beveridge R, Aparicio J, Tormo A, Estevan R, Artes J, Giménez A, Segura Á, Roldán S, Palasí R, Ramos D. Long-term results with oral fluoropyrimidines and oxaliplatin-based preoperative chemoradiotherapy in patients with resectable rectal cancer. A single-institution experience. Clin Transl Oncol 2012;14:471-80. [PMID: 22634537 DOI: 10.1007/s12094-012-0826-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
142 Koukourakis GV, Kouloulias V, Koukourakis MJ, Zacharias GA, Zabatis H, Kouvaris J. Efficacy of the oral fluorouracil pro-drug capecitabine in cancer treatment: a review. Molecules 2008;13:1897-922. [PMID: 18794792 DOI: 10.3390/molecules13081897] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 3.3] [Reference Citation Analysis]
143 Gollins SW, Myint S, Susnerwala S, Haylock B, Wise M, Topham C, Samuel L, Swindell R, Morris J, Mason L, Levine E. Preoperative downstaging chemoradiation with concurrent irinotecan and capecitabine in MRI-defined locally advanced rectal cancer: a phase I trial (NWCOG-2). Br J Cancer 2009;101:924-34. [PMID: 19690550 DOI: 10.1038/sj.bjc.6605258] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
144 Fujita S, Yamamoto S, Akasu T, Moriya Y. Outcome of patients with clinical stage II or III rectal cancer treated without adjuvant radiotherapy. Int J Colorectal Dis 2008;23:1073-9. [PMID: 18594841 DOI: 10.1007/s00384-008-0513-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
145 Hays E, Bonavida B. Nitric Oxide-Mediated Enhancement and Reversal of Resistance of Anticancer Therapies. Antioxidants (Basel) 2019;8:E407. [PMID: 31533363 DOI: 10.3390/antiox8090407] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
146 Arrington AK, Heinrich EL, Lee W, Duldulao M, Patel S, Sanchez J, Garcia-Aguilar J, Kim J. Prognostic and predictive roles of KRAS mutation in colorectal cancer. Int J Mol Sci 2012;13:12153-68. [PMID: 23202889 DOI: 10.3390/ijms131012153] [Cited by in Crossref: 107] [Cited by in F6Publishing: 96] [Article Influence: 10.7] [Reference Citation Analysis]
147 Zhou S, Jiang Y, Pei W, Liang J, Zhou Z. Risk factors and prognostic significance of lateral pelvic lymph node dissection after neoadjuvant chemoradiotherapy for rectal patients with clinically suspected lateral lymph node metastasis. BMC Surg 2021;21:441. [PMID: 34961494 DOI: 10.1186/s12893-021-01443-5] [Reference Citation Analysis]
148 Kawai K, Ishihara S, Nozawa H, Hata K, Kiyomatsu T, Tanaka T, Nishikawa T, Otani K, Yasuda K, Murono K, Sasaki K, Watanabe T. Recent advances in neoadjuvant chemoradiotherapy in locally advanced rectal cancer. J Anus Rectum Colon 2017;1:39-44. [PMID: 31583299 DOI: 10.23922/jarc.2017-005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
149 Peacock O, Chang GJ. "Watch and Wait" for complete clinical response after neoadjuvant chemoradiotherapy for rectal cancer. Minerva Chir 2019;74:481-95. [PMID: 31580047 DOI: 10.23736/S0026-4733.19.08184-7] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
150 García-Albéniz X, Gallego R, Hofheinz RD, Fernández-Esparrach G, Ayuso-Colella JR, Bombí JA, Conill C, Cuatrecasas M, Delgado S, Ginés A, Miquel R, Pagés M, Pineda E, Pereira V, Sosa A, Reig O, Victoria I, Feliz L, María de Lacy A, Castells A, Burkholder I, Hochhaus A, Maurel J. Adjuvant therapy sparing in rectal cancer achieving complete response after chemoradiation. World J Gastroenterol 2014; 20(42): 15820-15829 [PMID: 25400468 DOI: 10.3748/wjg.v20.i42.15820] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
151 Honma S, Hisamori S, Nishiuchi A, Itatani Y, Obama K, Shimono Y, Sakai Y. F-Box/WD Repeat Domain-Containing 7 Induces Chemotherapy Resistance in Colorectal Cancer Stem Cells. Cancers (Basel) 2019;11:E635. [PMID: 31067777 DOI: 10.3390/cancers11050635] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
152 Tan BR, Thomas F, Myerson RJ, Zehnbauer B, Trinkaus K, Malyapa RS, Mutch MG, Abbey EE, Alyasiry A, Fleshman JW, McLeod HL. Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma. J Clin Oncol 2011;29:875-83. [PMID: 21205745 DOI: 10.1200/JCO.2010.32.3212] [Cited by in Crossref: 48] [Cited by in F6Publishing: 17] [Article Influence: 4.4] [Reference Citation Analysis]
153 Santos MD, Silva C, Rocha A, Matos E, Nogueira C, Lopes C. Prognostic value of mandard and dworak tumor regression grading in rectal cancer: study of a single tertiary center. ISRN Surg. 2014;2014:310542. [PMID: 24729903 DOI: 10.1155/2014/310542] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
154 Nicosia L, Gentile G, Reverberi C, Minniti G, Valeriani M, de Sanctis V, Marinelli L, Cipolla F, de Luca O, Simmaco M, Osti MF. Single nucleotide polymorphism of <italic>GSTP1</italic> and pathological complete response in locally advanced rectal cancer patients treated with neoadjuvant concomitant radiochemotherapy. Radiat Oncol J 2018;36:218-26. [PMID: 30309213 DOI: 10.3857/roj.2018.00094] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
155 Watanabe T, Muro K, Ajioka Y, Hashiguchi Y, Ito Y, Saito Y, Hamaguchi T, Ishida H, Ishiguro M, Ishihara S, Kanemitsu Y, Kawano H, Kinugasa Y, Kokudo N, Murofushi K, Nakajima T, Oka S, Sakai Y, Tsuji A, Uehara K, Ueno H, Yamazaki K, Yoshida M, Yoshino T, Boku N, Fujimori T, Itabashi M, Koinuma N, Morita T, Nishimura G, Sakata Y, Shimada Y, Takahashi K, Tanaka S, Tsuruta O, Yamaguchi T, Yamaguchi N, Tanaka T, Kotake K, Sugihara K;  Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol. 2018;23:1-34. [PMID: 28349281 DOI: 10.1007/s10147-017-1101-6] [Cited by in Crossref: 400] [Cited by in F6Publishing: 364] [Article Influence: 80.0] [Reference Citation Analysis]
156 Klink CD, Binnebösel M, Holy R, Neumann UP, Junge K. Influence of intraoperative radiotherapy (IORT) on perioperative outcome after surgical resection of rectal cancer. World J Surg 2014;38:992-6. [PMID: 24178183 DOI: 10.1007/s00268-013-2313-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
157 Grupa VEM, Kroon HM, Ozmen I, Bedrikovetski S, Dudi-Venkata NN, Hunter RA, Sammour T. Current practice in Australia and New Zealand for defunctioning ileostomy after rectal cancer surgery with anastomosis: Analysis of the Binational Colorectal Cancer Audit. Colorectal Dis 2021;23:1421-33. [PMID: 33650280 DOI: 10.1111/codi.15607] [Reference Citation Analysis]
158 Kye BH, Cho HM. Overview of radiation therapy for treating rectal cancer. Ann Coloproctol 2014;30:165-74. [PMID: 25210685 DOI: 10.3393/ac.2014.30.4.165] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
159 Lee SJ, Ha S, Pahk K, Choi YY, Choi JY, Kim S, Kwon HW. Changes in treatment intent and target definition for preoperative radiotherapy after 18F-Fluorodeoxyglucose positron emission tomography in rectal cancer: A Meta-analysis. Eur J Radiol 2021;145:110061. [PMID: 34839213 DOI: 10.1016/j.ejrad.2021.110061] [Reference Citation Analysis]
160 Citrin D, Camphausen K, Wood BJ, Quezado M, Denobile J, Pingpank JF, Royal RE, Alexander HR, Seidel G, Steinberg SM, Shuttack Y, Libutti SK. A pilot feasibility study of TNFerade™ biologic with capecitabine and radiation therapy followed by surgical resection for the treatment of rectal cancer. Oncology 2010;79:382-8. [PMID: 21447969 DOI: 10.1159/000323488] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
161 Appelt AL, Vogelius IR, Pløen J, Rafaelsen SR, Lindebjerg J, Havelund BM, Bentzen SM, Jakobsen A. Long-term results of a randomized trial in locally advanced rectal cancer: no benefit from adding a brachytherapy boost. Int J Radiat Oncol Biol Phys 2014;90:110-8. [PMID: 25015203 DOI: 10.1016/j.ijrobp.2014.05.023] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
162 Tchelebi LT, Romesser PB, Feuerlein S, Hoffe S, Latifi K, Felder S, Chuong MD. Magnetic Resonance Guided Radiotherapy for Rectal Cancer: Expanding Opportunities for Non-Operative Management. Cancer Control 2020;27:1073274820969449. [PMID: 33118384 DOI: 10.1177/1073274820969449] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
163 Eschrich SA, Pramana J, Zhang H, Zhao H, Boulware D, Lee JH, Bloom G, Rocha-Lima C, Kelley S, Calvin DP, Yeatman TJ, Begg AC, Torres-Roca JF. A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation. Int J Radiat Oncol Biol Phys 2009;75:489-96. [PMID: 19735873 DOI: 10.1016/j.ijrobp.2009.06.014] [Cited by in Crossref: 172] [Cited by in F6Publishing: 144] [Article Influence: 13.2] [Reference Citation Analysis]
164 Yamashita K, Matsuda T, Hasegawa H, Mukohyama J, Arimoto A, Tanaka T, Yamamoto M, Matsuda Y, Kanaji S, Nakamura T, Sumi Y, Suzuki S, Kakeji Y. Recent advances of neoadjuvant chemoradiotherapy in rectal cancer: Future treatment perspectives. Ann Gastroenterol Surg 2019;3:24-33. [PMID: 30697607 DOI: 10.1002/ags3.12213] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
165 Li Q, Peng Y, Wang LA, Wei X, Li MX, Qing Y, Xia W, Cheng M, Zi D, Li CX, Wang D. The influence of neoadjuvant therapy for the prognosis in patients with rectal carcinoma: a retrospective study. Tumour Biol 2016;37:3441-9. [PMID: 26449827 DOI: 10.1007/s13277-015-4153-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
166 Tsai CJ, Crane CH, Skibber JM, Rodriguez-Bigas MA, Chang GJ, Feig BW, Eng C, Krishnan S, Maru DM, Das P. Number of lymph nodes examined and prognosis among pathologically lymph node-negative patients after preoperative chemoradiation therapy for rectal adenocarcinoma. Cancer. 2011;117:3713-3722. [PMID: 21328329 DOI: 10.1002/cncr.25973] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 3.9] [Reference Citation Analysis]
167 Hata T, Takahashi H, Sakai D, Haraguchi N, Nishimura J, Kudo T, Chu M, Takemasa I, Taroh S, Mizushima T, Doki Y, Mori M. Neoadjuvant CapeOx therapy followed by sphincter-preserving surgery for lower rectal cancer. Surg Today 2017;47:1372-7. [PMID: 28474202 DOI: 10.1007/s00595-017-1527-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
168 Charlton ME, Lin C, Jiang D, Stitzenberg KB, Halfdanarson TR, Pendergast JF, Chrischilles EA, Wallace RB. Factors associated with use of preoperative chemoradiation therapy for rectal cancer in the Cancer Care Outcomes Research and Surveillance Consortium. Am J Clin Oncol 2013;36:572-9. [PMID: 22992624 DOI: 10.1097/COC.0b013e318261082b] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
169 Mammano E, Galdi F, Pierobon M, Tessari E, Deng J, Pucciarelli S, Agostini M, De Marchi F, Canzonieri V, De Paoli A. Multiplexed protein signal pathway mapping identifies patients with rectal cancer that responds to neoadjuvant treatment. Clin Colorectal Cancer. 2012;11:268-274. [PMID: 22658458 DOI: 10.1016/j.clcc.2012.05.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
170 Hattori N, Nakayama G, Uehara K, Aiba T, Ishigure K, Sakamoto E, Tojima Y, Kanda M, Kobayashi D, Tanaka C, Yamada S, Koike M, Fujiwara M, Nagino M, Kodera Y. Phase II study of capecitabine plus oxaliplatin (CapOX) as adjuvant chemotherapy for locally advanced rectal cancer (CORONA II). Int J Clin Oncol 2020;25:118-25. [PMID: 31542847 DOI: 10.1007/s10147-019-01546-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
171 Matsunaga M, Miwa K, Oka Y, Nagasu S, Sakaue T, Fukahori M, Ushijima T, Akagi Y. mFOLFOX6 Chemotherapy after Resection of Anal Canal Mucinous Adenocarcinoma. Case Rep Oncol 2016;9:280-4. [PMID: 27239184 DOI: 10.1159/000446066] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
172 Lakkis Z, Panis Y. Is There Any Reason Not to Perform Standard Laparoscopic Total Mesorectal Excision? Clin Colon Rectal Surg 2017;30:333-8. [PMID: 29184468 DOI: 10.1055/s-0037-1606110] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
173 Liu H, Cui Y, Shen W, Fan X, Cui L, Zhang C, Ren G, Fu J, Wang D. Pretreatment magnetic resonance imaging of regional lymph nodes with carcinoembryonic antigen in prediction of synchronous distant metastasis in patients with rectal cancer. Oncotarget 2016;7:27199-207. [PMID: 27070083 DOI: 10.18632/oncotarget.7979] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
174 Cui J, Fang H, Zhang L, Wu YL, Zhang HZ. Advances for achieving a pathological complete response for rectal cancer after neoadjuvant therapy. Chronic Dis Transl Med 2016;2:10-6. [PMID: 29063019 DOI: 10.1016/j.cdtm.2016.06.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
175 Bloy N, Pol J, Manic G, Vitale I, Eggermont A, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Radioimmunotherapy for oncological indications. Oncoimmunology 2014;3:e954929. [PMID: 25941606 DOI: 10.4161/21624011.2014.954929] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 4.0] [Reference Citation Analysis]
176 Choi E, Kim JH, Kim OB, Kim MY, Oh YK, Baek SG. Predictors of pathologic complete response after preoperative concurrent chemoradiotherapy of rectal cancer: a single center experience. Radiat Oncol J 2016;34:106-12. [PMID: 27306776 DOI: 10.3857/roj.2015.01585] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
177 Brouquet A, Bachet JB, Huguet F, Karoui M, Artru P, Sabbagh C, Lefèvre JH, Vernerey D, Mariette C, Vicaut E, Benoist S; on behalf the FRENCH , GRECCAR, PRODIGE study groups. NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial). BMC Cancer 2020;20:485. [PMID: 32471382 DOI: 10.1186/s12885-020-06968-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
178 Zengel B, Uslu A, Adıbelli Z, Yetiş H, Cengiz F, Aykas A, Şimşek C, Akpınar G, Eliyatkın N, Duran A. Adjuvant versus neoadjuvant chemoradiotherapy in distal rectal cancer: Comparison of two decades in a single center. Ulus Cerrahi Derg 2015;31:218-23. [PMID: 26668530 DOI: 10.5152/UCD.2015.3015] [Reference Citation Analysis]
179 Ling Y, Yang L, Huang H, Hu X, Zhao C, Huang H, Ying Y. Prognostic Significance of Statin Use in Colorectal Cancer: A Systematic Review and Meta-Analysis. Medicine (Baltimore). 2015;94:e908. [PMID: 26107680 DOI: 10.1097/md.0000000000000908] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 3.4] [Reference Citation Analysis]
180 Mihmanlı M, Kabul Gürbulak E, Akgün İE, Celayir MF, Yazıcı P, Tunçel D, Bek TT, Öz A, Ömeroğlu S. Delaying surgery after neoadjuvant chemoradiotherapy improves prognosis of rectal cancer. World J Gastrointest Oncol 2016; 8(9): 695-706 [PMID: 27672428 DOI: 10.4251/wjgo.v8.i9.695] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
181 Inoue Y, Okigami M, Kawamoto A, Okugawa Y, Hiro J, Saigusa S, Toiyama Y, Tanaka K, Mohri Y, Kusunoki M. Phase I study of 5-fluorouracil, leucovorin and bevacizumab in combination with radiation therapy in patients with locally advanced rectal cancer. Mol Clin Oncol 2013;1:511-6. [PMID: 24649202 DOI: 10.3892/mco.2013.78] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
182 Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, Hamaguchi T, Hyodo I, Igarashi M, Ishida H, Ishiguro M, Kanemitsu Y, Kokudo N, Muro K, Ochiai A, Oguchi M, Ohkura Y, Saito Y, Sakai Y, Ueno H, Yoshino T, Fujimori T, Koinuma N, Morita T, Nishimura G, Sakata Y, Takahashi K, Takiuchi H, Tsuruta O, Yamaguchi T, Yoshida M, Yamaguchi N, Kotake K, Sugihara K; Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol 2012;17:1-29. [PMID: 22002491 DOI: 10.1007/s10147-011-0315-2] [Cited by in Crossref: 491] [Cited by in F6Publishing: 477] [Article Influence: 44.6] [Reference Citation Analysis]
183 Bostel T, Dreher C, Wollschläger D, Mayer A, König F, Bickelhaupt S, Schlemmer HP, Huber PE, Sterzing F, Bäumer P, Debus J, Nicolay NH. Exploring MR regression patterns in rectal cancer during neoadjuvant radiochemotherapy with daily T2- and diffusion-weighted MRI. Radiat Oncol 2020;15:171. [PMID: 32653003 DOI: 10.1186/s13014-020-01613-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
184 Duldulao MP, Lee W, Nelson RA, Ho J, Le M, Chen Z, Li W, Kim J, Garcia-Aguilar J. Gene polymorphisms predict toxicity to neoadjuvant therapy in patients with rectal cancer. Cancer 2013;119:1106-12. [PMID: 23096768 DOI: 10.1002/cncr.27862] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
185 Lin CY, Lee YE, Tian YF, Sun DP, Sheu MJ, Lin CY, Li CF, Lee SW, Lin LC, Chang IW, Wang CT, He HL. High Expression of EphA4 Predicted Lesser Degree of Tumor Regression after Neoadjuvant Chemoradiotherapy in Rectal Cancer. J Cancer 2017;8:1089-96. [PMID: 28529623 DOI: 10.7150/jca.17471] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
186 Glimelius B. Multidisciplinary treatment of patients with rectal cancer: Development during the past decades and plans for the future. Ups J Med Sci 2012;117:225-36. [PMID: 22512246 DOI: 10.3109/03009734.2012.658974] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
187 Liu Y, Zhang FJ, Zhao XX, Yang Y, Liang CY, Feng LL, Wan XB, Ding Y, Zhang YW. Development of a Joint Prediction Model Based on Both the Radiomics and Clinical Factors for Predicting the Tumor Response to Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer. Cancer Manag Res 2021;13:3235-46. [PMID: 33880066 DOI: 10.2147/CMAR.S295317] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
188 Rana N, Chakravarthy AB, Kachnic LA. Neoadjuvant Treatment for Locally Advanced Rectal Cancer: New Concepts in Clinical Trial Design. Curr Treat Options Oncol. 2017;18:13. [PMID: 28281215 DOI: 10.1007/s11864-017-0454-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
189 Peng B, Lu J, Wu Z, Li G, Wei F, Cao J, Li W. Intersphincteric Resection Versus Abdominoperineal Resection for Low Rectal Cancer: A Meta-Analysis. Surg Innov 2020;27:392-401. [PMID: 32390544 DOI: 10.1177/1553350620918414] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
190 Wu KC, Chen SW, Hsieh TC, Yen KY, Law KM, Kuo YC, Chang RF, Kao CH. Prediction of Neoadjuvant Chemoradiotherapy Response in Rectal Cancer with Metric Learning Using Pretreatment 18F-Fluorodeoxyglucose Positron Emission Tomography. Cancers (Basel) 2021;13:6350. [PMID: 34944970 DOI: 10.3390/cancers13246350] [Reference Citation Analysis]
191 Potemin S, Kübler J, Uvarov I, Wenz F, Giordano F. Intraoperative radiotherapy as an immediate adjuvant treatment of rectal cancer due to limited access to external-beam radiotherapy. Radiat Oncol 2020;15:11. [PMID: 31924250 DOI: 10.1186/s13014-020-1458-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
192 Rodon J, Perez J, Kurzrock R. Combining targeted therapies: practical issues to consider at the bench and bedside. Oncologist 2010;15:37-50. [PMID: 20080862 DOI: 10.1634/theoncologist.2009-0117] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 3.1] [Reference Citation Analysis]
193 Shiraishi T, Sasaki T, Tsukada Y, Ikeda K, Nishizawa Y, Ito M. Radiologic Factors and Areas of Local Recurrence in Locally Advanced Lower Rectal Cancer After Lateral Pelvic Lymph Node Dissection. Dis Colon Rectum 2021;64:1479-87. [PMID: 34657076 DOI: 10.1097/DCR.0000000000001921] [Reference Citation Analysis]
194 AlSaeed EF, Tunio M, Zubaidi A, Al-Obaid O, Ahmed AK, Al-Omar OA, Abid EA, Alsiwat MJ. Five-year outcomes of preoperative chemoradiation for rectal carcinoma in Saudi population: single-institutional experience. Ann Saudi Med. 2015;35:23-30. [PMID: 26142934 DOI: 10.5144/0256-4947.2015.23] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
195 de Nes LCF, van der Heijden JAG, Verstegen MG, Drager L, Tanis PJ, Verhoeven RHA, de Wilt JHW. Predictors of undergoing multivisceral resection, margin status and survival in Dutch patients with locally advanced colorectal cancer. Eur J Surg Oncol 2021:S0748-7983(21)00789-7. [PMID: 34810058 DOI: 10.1016/j.ejso.2021.11.004] [Reference Citation Analysis]
196 Baek JH, Jeon Y, Han KW, Jung DH, Kim KO. Effect of mistletoe extract on tumor response in neoadjuvant chemoradiotherapy for rectal cancer: a cohort study. World J Surg Oncol 2021;19:178. [PMID: 34130688 DOI: 10.1186/s12957-021-02293-4] [Reference Citation Analysis]
197 Dayde D, Tanaka I, Jain R, Tai MC, Taguchi A. Predictive and Prognostic Molecular Biomarkers for Response to Neoadjuvant Chemoradiation in Rectal Cancer. Int J Mol Sci. 2017;18. [PMID: 28272347 DOI: 10.3390/ijms18030573] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 10.2] [Reference Citation Analysis]
198 Das P, Eng C, Rodriguez-Bigas MA, Chang GJ, Skibber JM, You YN, Maru DM, Munsell MF, Clemons MV, Kopetz SE, Garrett CR, Shureiqi I, Delclos ME, Krishnan S, Crane CH. Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial. Int J Radiat Oncol Biol Phys 2014;88:301-5. [PMID: 24315563 DOI: 10.1016/j.ijrobp.2013.10.034] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
199 Cheong C, Shin JS, Suh KW. Prognostic value of changes in serum carcinoembryonic antigen levels for preoperative chemoradiotherapy response in locally advanced rectal cancer. World J Gastroenterol 2020; 26(44): 7022-7035 [PMID: 33311947 DOI: 10.3748/wjg.v26.i44.7022] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
200 Hsu CY, Wang CW, Kuo CC, Chen YH, Lan KH, Cheng AL, Kuo SH. Tumor compactness improves the preoperative volumetry-based prediction of the pathological complete response of rectal cancer after preoperative concurrent chemoradiotherapy. Oncotarget 2017;8:7921-34. [PMID: 27974702 DOI: 10.18632/oncotarget.13855] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
201 Smith JJ, Garcia-Aguilar J. Advances and challenges in treatment of locally advanced rectal cancer. J Clin Oncol. 2015;33:1797-1808. [PMID: 25918296 DOI: 10.1200/jco.2014.60.1054] [Cited by in Crossref: 98] [Cited by in F6Publishing: 47] [Article Influence: 14.0] [Reference Citation Analysis]
202 Hur H, Cho MS, Koom WS, Lim JS, Kim TI, Ahn JB, Kim H, Kim NK. Nomogram for prediction of pathologic complete remission using biomarker expression and endoscopic finding after preoperative chemoradiotherapy in rectal cancer. Chin J Cancer Res 2020;32:228-41. [PMID: 32410800 DOI: 10.21147/j.issn.1000-9604.2020.02.10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
203 Bisceglia G, Mastrodonato N, Tardio B, Mazzoccoli G, Corsa P, Troiano M, Parisi S. Intermediate neoadjuvant radiotherapy for T3 low/middle rectal cancer: postoperative outcomes of a non-controlled clinical trial. Oncotarget 2014;5:11143-53. [PMID: 25373926 DOI: 10.18632/oncotarget.2603] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
204 Elshazly WG, Farouk M, Samy M. Preoperative concomitant radiotherapy with oral capecitabine in advanced rectal cancer within 6 cm from anal verge. Int J Colorectal Dis. 2009;24:401-407. [PMID: 19084971 DOI: 10.1007/s00384-008-0623-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
205 Yang X, Yang S, Hu T, Gu C, Wei M, Deng X, Wang Z, Zhou Z. What is the role of lateral lymph node dissection in rectal cancer patients with clinically suspected lateral lymph node metastasis after preoperative chemoradiotherapy? A meta-analysis and systematic review. Cancer Med 2020;9:4477-89. [PMID: 32352659 DOI: 10.1002/cam4.2643] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
206 Lin CC, Bruinooge SS, Kirkwood MK, Hershman DL, Jemal A, Guadagnolo BA, Yu JB, Hopkins S, Goldstein M, Bajorin D, Giordano SH, Kosty M, Arnone A, Hanley A, Stevens S, Olsen C. Association Between Geographic Access to Cancer Care and Receipt of Radiation Therapy for Rectal Cancer. Int J Radiat Oncol Biol Phys 2016;94:719-28. [PMID: 26972644 DOI: 10.1016/j.ijrobp.2015.12.012] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 5.3] [Reference Citation Analysis]
207 Hamabe A, Ishii M, Onodera K, Okita K, Nishidate T, Okuya K, Akizuki E, Miura R, Korai T, Hatakenaka M, Takemasa I. MRI-detected extramural vascular invasion potentiates the risk for pathological metastasis to the lateral lymph nodes in rectal cancer. Surg Today 2021. [PMID: 33665727 DOI: 10.1007/s00595-021-02250-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
208 Murphy CC, Harlan LC, Lund JL, Lynch CF, Geiger AM. Patterns of Colorectal Cancer Care in the United States: 1990-2010. J Natl Cancer Inst 2015;107:djv198. [PMID: 26206950 DOI: 10.1093/jnci/djv198] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 5.4] [Reference Citation Analysis]
209 Ogura A, van Oostendorp S, Kusters M. Neoadjuvant (chemo)radiotherapy and Lateral Node Dissection: Is It Mutually Exclusive? Clin Colon Rectal Surg 2020;33:355-60. [PMID: 33162839 DOI: 10.1055/s-0040-1714239] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
210 Schrag D, Weiser MR, Goodman KA, Gonen M, Hollywood E, Cercek A, Reidy-Lagunes DL, Gollub MJ, Shia J, Guillem JG, Temple LK, Paty PB, Saltz LB. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol 2014;32:513-8. [PMID: 24419115 DOI: 10.1200/JCO.2013.51.7904] [Cited by in Crossref: 272] [Cited by in F6Publishing: 102] [Article Influence: 34.0] [Reference Citation Analysis]
211 Glimelius B. Optimal Time Intervals between Pre-Operative Radiotherapy or Chemoradiotherapy and Surgery in Rectal Cancer? Front Oncol. 2014;4:50. [PMID: 24778990 DOI: 10.3389/fonc.2014.00050] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
212 Ricardi U, Racca P, Franco P, Munoz F, Fanchini L, Rondi N, Dongiovanni V, Gabriele P, Cassoni P, Ciuffreda L, Morino M, Filippi AR, Aglietta M, Bertetto O. Prospective phase II trial of neoadjuvant chemo-radiotherapy with Oxaliplatin and Capecitabine in locally advanced rectal cancer (XELOXART). Med Oncol 2013;30:581. [PMID: 23606239 DOI: 10.1007/s12032-013-0581-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
213 Michel P, Di Fiore F. [Chemotherapy and rectal cancer]. Cancer Radiother 2011;15:436-9. [PMID: 21885319 DOI: 10.1016/j.canrad.2011.06.002] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
214 Sole CV, Calvo FA, Alvarez E, Peligros I, Garcia-Alfonso P, Ferrer C, Ochoa E, Herranz R, Carreras JL. Clinical significance of VEGFR-2 and ¹⁸F-FDG PET/CT SUVmax pretreatment score in predicting the long-term outcome of patients with locally advanced rectal cancer treated with neoadjuvant therapy. Eur J Nucl Med Mol Imaging 2013;40:1635-44. [PMID: 23801169 DOI: 10.1007/s00259-013-2479-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
215 Chang YJ, Chen LJ, Chang YJ, Chung KP, Lai MS. Risk groups defined by Recursive Partitioning Analysis of patients with colorectal adenocarcinoma treated with colorectal resection. BMC Med Res Methodol. 2012;12:2. [PMID: 22214198 DOI: 10.1186/1471-2288-12-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
216 Ding M, Zhang J, Hu H, Cai Y, Ling J, Wu Z, Xie X, Li J, Li W, Deng Y. mFOLFOXIRI versus mFOLFOX6 as neoadjuvant chemotherapy in locally advanced rectal cancer: A Propensity Score Matching Analysis. Clin Colorectal Cancer 2021:S1533-0028(21)00125-0. [PMID: 34963563 DOI: 10.1016/j.clcc.2021.11.009] [Reference Citation Analysis]
217 Dossa F, Acuna SA, Rickles AS, Berho M, Wexner SD, Quereshy FA, Baxter NN, Chadi SA. Association Between Adjuvant Chemotherapy and Overall Survival in Patients With Rectal Cancer and Pathological Complete Response After Neoadjuvant Chemotherapy and Resection. JAMA Oncol 2018;4:930-7. [PMID: 29710274 DOI: 10.1001/jamaoncol.2017.5597] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 15.7] [Reference Citation Analysis]
218 Shigeta K, Okabayashi K, Baba H, Hasegawa H, Tsuruta M, Yamafuji K, Kubochi K, Kitagawa Y. A meta-analysis of the use of a transanal drainage tube to prevent anastomotic leakage after anterior resection by double-stapling technique for rectal cancer. Surg Endosc. 2016;30:543-550. [PMID: 26091985 DOI: 10.1007/s00464-015-4237-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
219 Jung F, Lee M, Doshi S, Zhao G, Cheung KLT, Chesney T, Guidolin K, Englesakis M, Lukovic J, O'Kane G, Quereshy FA, Chadi SA. Neoadjuvant therapy versus direct to surgery for T4 colon cancer: meta-analysis. Br J Surg 2021;109:30-6. [PMID: 34921604 DOI: 10.1093/bjs/znab382] [Reference Citation Analysis]
220 Lee KH, Kim JS, Kim JY. Long-term oncologic outcomes of neoadjuvant concurrent chemoradiotherapy with capecitabine and radical surgery in locally advanced rectal cancer: 10-year experiences at a single institution. Ann Surg Treat Res 2016;91:178-86. [PMID: 27757395 DOI: 10.4174/astr.2016.91.4.178] [Reference Citation Analysis]
221 Ladeira KM, Martins SFF. Prognostic impact of the number of resected lymph node on survival in Colorectal Cancer. Journal of Coloproctology 2021;36:130-8. [DOI: 10.1016/j.jcol.2016.04.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
222 Watanabe T, Hata K. Robotic surgery for rectal cancer with lateral lymph node dissection. Br J Surg 2016;103:1755-7. [PMID: 27901281 DOI: 10.1002/bjs.10412] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
223 Peng J, Ding Y, Tu S, Shi D, Sun L, Li X, Wu H, Cai S. Prognostic nomograms for predicting survival and distant metastases in locally advanced rectal cancers. PLoS One 2014;9:e106344. [PMID: 25171093 DOI: 10.1371/journal.pone.0106344] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
224 Kilsdonk MJ, van Dijk BA, Otter R, Siesling S, van Harten WH. The impact of organisational external peer review on colorectal cancer treatment and survival in the Netherlands. Br J Cancer 2014;110:850-8. [PMID: 24423922 DOI: 10.1038/bjc.2013.814] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
225 Meng Y, Zhang C, Zou S, Zhao X, Xu K, Zhang H, Zhou C. MRI texture analysis in predicting treatment response to neoadjuvant chemoradiotherapy in rectal cancer. Oncotarget. 2018;9:11999-12008. [PMID: 29552288 DOI: 10.18632/oncotarget.23813] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
226 Fusco R, Petrillo M, Granata V, Filice S, Sansone M, Catalano O, Petrillo A. Magnetic Resonance Imaging Evaluation in Neoadjuvant Therapy of Locally Advanced Rectal Cancer: A Systematic Review. Radiol Oncol 2017;51:252-62. [PMID: 28959161 DOI: 10.1515/raon-2017-0032] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
227 Glynne-Jones R, Hava N, Goh V, Bosompem S, Bridgewater J, Chau I, Gaya A, Wasan H, Moran B, Melcher L, MacDonald A, Osborne M, Beare S, Jitlal M, Lopes A, Hall M, West N, Quirke P, Wong WL, Harrison M;  Bacchus investigators. Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): a phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum. BMC Cancer. 2015;15:764. [PMID: 26493588 DOI: 10.1186/s12885-015-1764-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
228 Kim MB, Hong TS, Wo JY. Treatment of stage II-III rectal cancer patients. Curr Oncol Rep 2014;16:362. [PMID: 24323626 DOI: 10.1007/s11912-013-0362-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
229 Dean CJ, Sykes JR, Cooper RA, Hatfield P, Carey B, Swift S, Bacon SE, Thwaites D, Sebag-Montefiore D, Morgan AM. An evaluation of four CT-MRI co-registration techniques for radiotherapy treatment planning of prone rectal cancer patients. Br J Radiol 2012;85:61-8. [PMID: 22190750 DOI: 10.1259/bjr/11855927] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 4.2] [Reference Citation Analysis]
230 van Rees JM, Hartman W, Nuyttens JJME, Oomen-de Hoop E, van Vugt JLA, Rothbarth J, Verhoef C, van Meerten E. Relation between body composition and severe diarrhea in patients treated with preoperative chemoradiation with capecitabine for rectal cancer: a single-centre cohort study. BMC Gastroenterol 2021;21:313. [PMID: 34348673 DOI: 10.1186/s12876-021-01886-3] [Reference Citation Analysis]
231 Liu JH, Tsai TH, Chen YJ, Wang LY, Liu HY, Hsieh CH. Local Irradiation Modulates the Pharmacokinetics of Metabolites in 5-Fluorouracil-Radiotherapy-Pharmacokinetics Phenomenon. Front Pharmacol 2020;11:141. [PMID: 32174836 DOI: 10.3389/fphar.2020.00141] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
232 Deng S, Iscaro A, Zambito G, Mijiti Y, Minicucci M, Essand M, Lowik C, Muthana M, Censi R, Mezzanotte L, Di Martino P. Development of a New Hyaluronic Acid Based Redox-Responsive Nanohydrogel for the Encapsulation of Oncolytic Viruses for Cancer Immunotherapy. Nanomaterials (Basel) 2021;11:E144. [PMID: 33435600 DOI: 10.3390/nano11010144] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
233 Müller-Stich BP, Linke GR, Wagner M, Steinemann DC. [Laparoscopic versus open rectal cancer resection: oncologically equal?]. Chirurg 2016;87:552-9. [PMID: 27364141 DOI: 10.1007/s00104-016-0222-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
234 Alickikus ZA, Kuru A, Aydin B, Akcay D, Gorken IB. The importance of mesorectum motion in determining PTV margins in rectal cancer patients treated with neoadjuvant radiotherapy. J Radiat Res 2020;61:335-42. [PMID: 31867610 DOI: 10.1093/jrr/rrz092] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
235 Nishimura J, Hasegawa J, Noura S, Ikeda K, Yasui M, Komori T, Tsujie M, Yasumasa K, Shingai T, Uemura M, Hata T, Matsuda C, Mizushima T, Ikeda M, Doki Y, Mori M. Adjuvant Chemotherapy after Neoadjuvant Chemotherapy and Long-term Outcomes of CAPOX Plus Bevacizumab Followed by TME for High-risk Localized Rectal Cancer. J Anus Rectum Colon 2020;4:108-13. [PMID: 32743112 DOI: 10.23922/jarc.2019-042] [Reference Citation Analysis]
236 Abdelsattar ZM, Reames BN, Regenbogen SE, Hendren S, Wong SL. Critical evaluation of the scientific content in clinical practice guidelines. Cancer 2015;121:783-9. [PMID: 25376967 DOI: 10.1002/cncr.29124] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
237 Lee SH. How to Achieve a Higher Pathologic Complete Response in Patients With Locally Advanced Rectal Cancer Who Receive Preoperative Chemoradiation Therapy. Ann Coloproctol 2019;35:3-8. [PMID: 30879278 DOI: 10.3393/ac.2019.02.17] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
238 Ollivier L, Guilloit JM, Dos Santos M, Guillemette L, Florescu C, M'vondo CM, Meyer E, Galais MP, Corbinais S, Parzy A, Varatharajah S, Lesueur P. Implantation of tissue expander prior to irradiation in the era of intensity modulated radiotherapy: impact on the management of patients with pelvic digestive cancers. Int J Colorectal Dis 2020;35:559-64. [PMID: 31853620 DOI: 10.1007/s00384-019-03475-z] [Reference Citation Analysis]
239 Baek SK. From Total Mesorectal Excision to Organ Preservation for the Treatment of Rectal Cancer. Ann Coloproctol 2019;35:51-2. [PMID: 31113169 DOI: 10.3393/ac.2019.04.15] [Reference Citation Analysis]
240 Tian YF, Chen TJ, Lin CY, Chen LT, Lin LC, Hsing CH, Lee SW, Sheu MJ, Lee HH, Shiue YL. SKP2 overexpression is associated with a poor prognosis of rectal cancer treated with chemoradiotherapy and represents a therapeutic target with high potential. Tumour Biol. 2013;34:1107-1117. [PMID: 23328995 DOI: 10.1007/s13277-013-0652-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
241 Huang MY, Huang JJ, Huang CM, Lin CH, Tsai HL, Huang CW, Chai CY, Lin CY, Wang JY. Relationship Between Expression of Proteins ERCC1, ERCC2, and XRCC1 and Clinical Outcomes in Patients with Rectal Cancer Treated with FOLFOX-Based Preoperative Chemoradiotherapy. World J Surg 2017;41:2884-97. [PMID: 28608017 DOI: 10.1007/s00268-017-4070-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
242 Binefa G, Rodríguez-Moranta F, Teule &, Medina-Hayas M. Colorectal cancer: From prevention to personalized medicine. World J Gastroenterol 2014; 20(22): 6786-6808 [PMID: 24944469 DOI: 10.3748/wjg.v20.i22.6786] [Cited by in CrossRef: 155] [Cited by in F6Publishing: 145] [Article Influence: 19.4] [Reference Citation Analysis]
243 Marchegiani F, Palatucci V, Capelli G, Guerrieri M, Belluco C, Rega D, Morpurgo E, Coco C, Restivo A, De Franciscis S, Aschele C, Perin A, Bonomo M, Muratore A, Spinelli A, Ramuscello S, Bergamo F, Montesi G, Spolverato G, Del Bianco P, Gambacorta MA, Delrio P, Pucciarelli S. Rectal Sparing Approach After Neoadjuvant Therapy in Patients with Rectal Cancer: The Preliminary Results of the ReSARCh Trial. Ann Surg Oncol 2021. [PMID: 34855063 DOI: 10.1245/s10434-021-11121-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
244 Rühlmann F, Nietert M, Sprenger T, Wolff HA, Homayounfar K, Middel P, Bohnenberger H, Beissbarth T, Ghadimi BM, Liersch T, Conradi LC. The Prognostic Value of Tyrosine Kinase SRC Expression in Locally Advanced Rectal Cancer. J Cancer 2017;8:1229-37. [PMID: 28607598 DOI: 10.7150/jca.16980] [Reference Citation Analysis]
245 Fischer MA, Vrugt B, Alkadhi H, Hahnloser D, Hany TF, Veit-Haibach P. Integrated ¹⁸F-FDG PET/perfusion CT for the monitoring of neoadjuvant chemoradiotherapy in rectal carcinoma: correlation with histopathology. Eur J Nucl Med Mol Imaging 2014;41:1563-73. [PMID: 24760269 DOI: 10.1007/s00259-014-2752-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
246 Rampazzo E, Del Bianco P, Bertorelle R, Boso C, Perin A, Spiro G, Bergamo F, Belluco C, Buonadonna A, Palazzari E, Lonardi S, De Paoli A, Pucciarelli S, De Rossi A. The predictive and prognostic potential of plasma telomerase reverse transcriptase (TERT) RNA in rectal cancer patients. Br J Cancer 2018;118:878-86. [PMID: 29449673 DOI: 10.1038/bjc.2017.492] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
247 Koukourakis GV, Zacharias G, Tsalafoutas J, Theodoridis D, Kouloulias V. Capecitabine for locally advanced and metastatic colorectal cancer: A review. World J Gastrointest Oncol 2010; 2(8): 311-321 [PMID: 21160892 DOI: 10.4251/wjgo.v2.i8.311] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
248 Gural Z, Saglam S, Yucel S, Kaytan-Saglam E, Asoglu O, Ordu C, Acun H, Sharifov R, Onder S, Kizir A, Oral EN. Neoadjuvant hyperfractionated accelerated radiotherapy plus concomitant 5-fluorouracil infusion in locally advanced rectal cancer: A phase II study. World J Gastrointest Oncol 2018; 10(1): 40-47 [PMID: 29375747 DOI: 10.4251/wjgo.v10.i1.40] [Reference Citation Analysis]
249 Wang QX, Li SH, Zhang X, Xie L, Cai PQ, An X, Pan ZZ, Ding PR. Identification of locally advanced rectal cancer with low risk of local recurrence. PLoS One 2015;10:e0117141. [PMID: 25629521 DOI: 10.1371/journal.pone.0117141] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
250 Goldberg N, Kundel Y, Purim O, Bernstine H, Gordon N, Morgenstern S, Idelevich E, Wasserberg N, Sulkes A, Groshar D. Early prediction of histopathological response of rectal tumors after one week of preoperative radiochemotherapy using 18 F-FDG PET-CT imaging. A prospective clinical study. Radiat Oncol. 2012;7:124. [PMID: 22853868 DOI: 10.1186/1748-717X-7-124] [Cited by in Crossref: 25] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
251 Jang S, Lee JM, Yoon JH, Bae JS. Reduced field-of-view versus full field-of-view diffusion-weighted imaging for the evaluation of complete response to neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer. Abdom Radiol (NY) 2021;46:1468-77. [PMID: 32986174 DOI: 10.1007/s00261-020-02763-5] [Reference Citation Analysis]
252 Hernando-Requejo O, López M, Cubillo A, Rodriguez A, Ciervide R, Valero J, Sánchez E, Garcia-Aranda M, Rodriguez J, Potdevin G, Rubio C. Complete pathological responses in locally advanced rectal cancer after preoperative IMRT and integrated-boost chemoradiation. Strahlenther Onkol 2014;190:515-20. [PMID: 24715243 DOI: 10.1007/s00066-014-0650-0] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 5.3] [Reference Citation Analysis]
253 Zhao J, Liu X, Wang W, Hu K, Zhang F, Hou X, Meng Q. Concomitant dose escalation with image-guided Tomotherapy in locally advanced mid-low rectal cancer: a single-center study. Cancer Manag Res 2019;11:1579-86. [PMID: 30863168 DOI: 10.2147/CMAR.S193657] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
254 Harada Y, Kazama S, Morikawa T, Murono K, Yasuda K, Otani K, Nishikawa T, Tanaka T, Kiyomatsu T, Kawai K, Hata K, Nozawa H, Yamaguchi H, Ishihara S, Watanabe T. Leucine-rich repeat-containing G protein-coupled receptor 5 and CD133 expression is associated with tumor progression and resistance to preoperative chemoradiotherapy in low rectal cancer. Oncol Lett 2017;14:7791-8. [PMID: 29250176 DOI: 10.3892/ol.2017.7207] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
255 Park SW, Kim JS, Kim JY, Lee KH. Additional 4-week capecitabine during the resting periods after 6-week neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: long-term oncologic outcomes. Ann Surg Treat Res 2018;94:306-11. [PMID: 29854708 DOI: 10.4174/astr.2018.94.6.306] [Reference Citation Analysis]
256 Rega D, Pecori B, Scala D, Avallone A, Pace U, Petrillo A, Aloj L, Tatangelo F, Delrio P. Evaluation of Tumor Response after Short-Course Radiotherapy and Delayed Surgery for Rectal Cancer. PLoS One 2016;11:e0160732. [PMID: 27548058 DOI: 10.1371/journal.pone.0160732] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
257 Mathis KL, Nelson H. Randomized Controlled Trials in Surgical Oncology:. Surgical Oncology Clinics of North America 2012;21:449-66. [DOI: 10.1016/j.soc.2012.03.002] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
258 Shen L, Wang L, Li G, Zhang H, Liang L, Fan M, Wu Y, Deng W, Sheng W, Zhu J, Zhang Z. Can tumor regression grade influence survival outcome in ypT3 rectal cancer? Clin Transl Oncol 2016;18:693-9. [PMID: 26527031 DOI: 10.1007/s12094-015-1419-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
259 Ohira G, Miyauchi H, Hayano K, Imanishi S, Tochigi T, Maruyama T, Hanaoka T, Okada K, Kobayashi H, Uno T, Matsubara H. Preoperative chemoradiotherapy using S-1 combined with celecoxib for advanced lower rectal cancer: Phase I/II study. J Anus Rectum Colon 2019;3:43-8. [PMID: 31559366 DOI: 10.23922/jarc.2018-026] [Reference Citation Analysis]
260 Wang L, Zhong X, Lin H, Shao L, Chen G, Wu J. The Correlation Between Survival Benefit of Preoperative Radiotherapy and Pretreatment Carcinoembryonic Antigen Level in Locally Advanced Rectal Cancer. Front Oncol 2021;11:735882. [PMID: 34692510 DOI: 10.3389/fonc.2021.735882] [Reference Citation Analysis]
261 Kripp M, Merx K, Wirtz RM, Gaiser T, Eidt S, Schwaab J, Post S, Wenz F, Hochhaus A, Hofheinz RD, Erben P. Prognostic Impact of mRNA Expression Levels of HER1-4 (ERBB1-4) in Patients with Locally Advanced Rectal Cancer. Gastroenterol Res Pract 2016;2016:3481578. [PMID: 27610130 DOI: 10.1155/2016/3481578] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
262 Koeberle D, Burkhard R, von Moos R, Winterhalder R, Hess V, Heitzmann F, Ruhstaller T, Terraciano L, Neuweiler J, Bieri G, Rust C, Toepfer M. Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer. Br J Cancer. 2008;98:1204-1209. [PMID: 18349837 DOI: 10.1038/sj.bjc.6604297] [Cited by in Crossref: 60] [Cited by in F6Publishing: 60] [Article Influence: 4.3] [Reference Citation Analysis]
263 Liu Z, Wang S, Dong D, Wei J, Fang C, Zhou X, Sun K, Li L, Li B, Wang M, Tian J. The Applications of Radiomics in Precision Diagnosis and Treatment of Oncology: Opportunities and Challenges. Theranostics. 2019;9:1303-1322. [PMID: 30867832 DOI: 10.7150/thno.30309] [Cited by in Crossref: 149] [Cited by in F6Publishing: 146] [Article Influence: 49.7] [Reference Citation Analysis]
264 Debucquoy A, Goethals L, Libbrecht L, Perneel C, Geboes K, Ectors N, McBride WH, Haustermans K. Molecular and clinico-pathological markers in rectal cancer: a tissue micro-array study. Int J Colorectal Dis. 2009;24:129-138. [PMID: 19050903 DOI: 10.1007/s00384-008-0608-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
265 Das P, Crane CH. Staging, prognostic factors, and therapy of localized rectal cancer. Curr Oncol Rep 2009;11:167-74. [PMID: 19336008 DOI: 10.1007/s11912-009-0025-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
266 Lim JW, Chew MH, Lim KH, Tang CL. Close distal margins do not increase rectal cancer recurrence after sphincter-saving surgery without neoadjuvant therapy. Int J Colorectal Dis. 2012;27:1285-1294. [PMID: 22918660 DOI: 10.1007/s00384-012-1467-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
267 Bazarbashi S, Aljubran A, Alzahrani A. Adjuvant chemotherapy for rectal cancer: time to change the guidelines. Future Oncol 2016;12:1009-13. [PMID: 26863297 DOI: 10.2217/fon-2015-0042] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
268 Ogilvie JW, Ricciardi R. Complications of perineal surgery. Clin Colon Rectal Surg. 2009;22:51-59. [PMID: 20119557 DOI: 10.1055/s-0029-1202887] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
269 Morielli AR, Boulé NG, Usmani N, Tankel K, Joseph K, Severin D, Fairchild A, Nijjar T, Courneya KS. Effects of exercise during and after neoadjuvant chemoradiation on symptom burden and quality of life in rectal cancer patients: a phase II randomized controlled trial. J Cancer Surviv 2021. [PMID: 34841461 DOI: 10.1007/s11764-021-01149-w] [Reference Citation Analysis]
270 Shim BY, Sun S, Won HS, Lee MA, Hong SU, Jung JH, Cho HM, Ko YH. Role of autophagy-related protein expression in patients with rectal cancer treated with neoadjuvant chemoradiotherapy. BMC Cancer 2016;16:207. [PMID: 26965179 DOI: 10.1186/s12885-016-2250-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
271 Kitayama J, Yasuda K, Kawai K, Sunami E, Nagawa H. Circulating lymphocyte number has a positive association with tumor response in neoadjuvant chemoradiotherapy for advanced rectal cancer. Radiat Oncol. 2010;5:47. [PMID: 20525293 DOI: 10.1186/1748-717x-5-47] [Cited by in Crossref: 78] [Cited by in F6Publishing: 52] [Article Influence: 6.5] [Reference Citation Analysis]
272 de Wilt JH, Vermaas M, Ferenschild FT, Verhoef C. Management of locally advanced primary and recurrent rectal cancer. Clin Colon Rectal Surg 2007;20:255-63. [PMID: 20011207 DOI: 10.1055/s-2007-984870] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
273 Ha RK, Park B, Park SC, Chang HJ, Oh JH. Effect of lateral lymph node dissection on the quality of life and genitourinary function after neoadjuvant chemoradiotherapy for rectal cancer. Ann Surg Treat Res 2021;100:109-18. [PMID: 33585355 DOI: 10.4174/astr.2021.100.2.109] [Reference Citation Analysis]
274 Peng J, Lin J, Qiu M, Wu X, Lu Z, Chen G, Li L, Ding P, Gao Y, Zeng Z, Zhang H, Wan D, Pan Z. Clinical factors of post-chemoradiotherapy as valuable indicators for pathological complete response in locally advanced rectal cancer. Clinics (Sao Paulo) 2016;71:449-54. [PMID: 27626475 DOI: 10.6061/clinics/2016(08)07] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
275 Jia Y, Dai G, Wang J, Gao X, Zhao Z, Duan Z, Gu B, Yang W, Wu J, Ju Y, Wang M, Li Z. c-MET inhibition enhances the response of the colorectal cancer cells to irradiation in vitro and in vivo. Oncol Lett 2016;11:2879-85. [PMID: 27073569 DOI: 10.3892/ol.2016.4303] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
276 Li W, Peng J, Li C, Yuan L, Fan W, Pan Z, Wu X, Lin J. Prognosis and risk factors for the development of pulmonary metastases after preoperative chemoradiotherapy and radical resection in patients with locally advanced rectal cancer. Ann Transl Med 2020;8:117. [PMID: 32175410 DOI: 10.21037/atm.2019.12.108] [Reference Citation Analysis]
277 Perrakis A, Weber K, Merkel S, Matzel K, Agaimy A, Gebbert C, Hohenberger W. Lymph node metastasis of carcinomas of transverse colon including flexures. Consideration of the extramesocolic lymph node stations. Int J Colorectal Dis. 2014;29:1223-1229. [PMID: 25060216 DOI: 10.1007/s00384-014-1971-2] [Cited by in Crossref: 52] [Cited by in F6Publishing: 34] [Article Influence: 6.5] [Reference Citation Analysis]
278 Kong M, Hong SE, Choi WS, Kim SY, Choi J. Preoperative concurrent chemoradiotherapy for locally advanced rectal cancer: treatment outcomes and analysis of prognostic factors. Cancer Res Treat 2012;44:104-12. [PMID: 22802748 DOI: 10.4143/crt.2012.44.2.104] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
279 Khrizman P, Niland JC, ter Veer A, Milne D, Bullard Dunn K, Carson WE 3rd, Engstrom PF, Shibata S, Skibber JM, Weiser MR, Schrag D, Benson AB 3rd. Postoperative adjuvant chemotherapy use in patients with stage II/III rectal cancer treated with neoadjuvant therapy: a national comprehensive cancer network analysis. J Clin Oncol 2013;31:30-8. [PMID: 23169502 DOI: 10.1200/JCO.2011.40.3188] [Cited by in Crossref: 74] [Cited by in F6Publishing: 38] [Article Influence: 7.4] [Reference Citation Analysis]
280 Fu J, Wang CY, Wang CG, Li HL, Yang XJ, Sun Y, Shao YH, Zhang LH, Yang XM, Zhang XL. Efficacy and Side Effects of Combined Capecitabine Plus Intensity Modulated Radiotherapy as an Effective Adjuvant Therapy for Gastric Cancers. Iran J Pharm Res 2020;19:365-71. [PMID: 33841549 DOI: 10.22037/ijpr.2019.14622.12542] [Reference Citation Analysis]
281 Ali F, Keshinro A, Weiser MR. Advances in the treatment of locally advanced rectal cancer. Ann Gastroenterol Surg 2021;5:32-8. [PMID: 33532678 DOI: 10.1002/ags3.12389] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
282 Yorio JT, Bhadkamkar NA, Kee BK, Garrett CR. A Primer on the Current State-of-the-Science Neoadjuvant and Adjuvant Therapy for Patients with Locally Advanced Rectal Adenocarcinomas. Int J Surg Oncol 2012;2012:863034. [PMID: 22666572 DOI: 10.1155/2012/863034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
283 Liu T, Duo L, Duan P. Ginsenoside Rg3 Sensitizes Colorectal Cancer to Radiotherapy through Downregulation of Proliferative and Angiogenic Biomarkers. Evid Based Complement Alternat Med 2018;2018:1580427. [PMID: 29743919 DOI: 10.1155/2018/1580427] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
284 Lin XL, Xiao XY. Progress in neoadjuvant drug therapy of rectal cancer. Shijie Huaren Xiaohua Zazhi 2018; 26(22): 1340-1347 [DOI: 10.11569/wcjd.v26.i22.1340] [Reference Citation Analysis]
285 Wu F, Zhou C, Wu B, Zhang X, Wang K, Wang J, Xiao L, Wang G. Adding Adjuvants to Fluoropyrimidine-based Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: An Option Worthy of Serious Consideration. J Cancer 2021;12:417-27. [PMID: 33391438 DOI: 10.7150/jca.48337] [Reference Citation Analysis]
286 Shin SJ, Yoon HI, Kim NK, Lee KY, Min BS, Ahn JB, Keum KC, Koom WS. Upfront systemic chemotherapy and preoperative short-course radiotherapy with delayed surgery for locally advanced rectal cancer with distant metastases. Radiat Oncol 2011;6:99. [PMID: 21864368 DOI: 10.1186/1748-717X-6-99] [Cited by in Crossref: 28] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
287 Thomas F, Motsinger-Reif AA, Hoskins JM, Dvorak A, Roy S, Alyasiri A, Myerson RJ, Fleshman JW, Tan BR, McLeod HL. Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer. Br J Cancer 2011;105:1654-62. [PMID: 22045187 DOI: 10.1038/bjc.2011.442] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
288 Sun L, Zhao F, Zeng Y, Yi C. Risks and Benefits of Multimodal Esophageal Cancer Treatments: A Meta-Analysis. Med Sci Monit 2017;23:889-910. [PMID: 28214903 DOI: 10.12659/msm.903328] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
289 Sirohi B, Shrikhande SV, Perakath B, Raghunandharao D, Julka PK, Lele V, Chaturvedi A, Nandakumar A, Ramadwar M, Bhatia V, Mittal R, Kaur T, Shukla DK, Rath GK. Indian Council of Medical Research consensus document for the management of colorectal cancer. Indian J Med Paediatr Oncol 2014;35:192-6. [PMID: 25336788 DOI: 10.4103/0971-5851.142031] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
290 Bökkerink GM, de Graaf EJ, Punt CJ, Nagtegaal ID, Rütten H, Nuyttens JJ, van Meerten E, Doornebosch PG, Tanis PJ, Derksen EJ. The CARTS study: Chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery. BMC Surg. 2011;11:34. [PMID: 22171697 DOI: 10.1186/1471-2482-11-34] [Cited by in Crossref: 63] [Cited by in F6Publishing: 44] [Article Influence: 5.7] [Reference Citation Analysis]
291 Zhong W, Xue X, Dai L, Li R, Nie K, Zhou S. Neoadjuvant treatments for resectable rectal cancer: A network meta-analysis. Exp Ther Med 2020;19:2604-14. [PMID: 32256740 DOI: 10.3892/etm.2020.8494] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
292 Nakagawa R, Inoue Y, Ohki T, Kaneko Y, Maeda F, Yamamoto M. Efficacy and short-term outcomes of preoperative chemoradiotherapy with intermittent oral tegafur-uracil plus leucovorin in Japanese rectal cancer patients: a single center experience retrospective analysis. World J Surg Oncol 2017;15:112. [PMID: 28566093 DOI: 10.1186/s12957-017-1177-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
293 Siegel R, Burock S, Wernecke KD, Kretzschmar A, Dietel M, Loy V, Koswig S, Budach V, Schlag PM. Preoperative short-course radiotherapy versus combined radiochemotherapy in locally advanced rectal cancer: a multi-centre prospectively randomised study of the Berlin Cancer Society. BMC Cancer. 2009;9:50. [PMID: 19200365 DOI: 10.1186/1471-2407-9-501471-2407-9-50] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
294 Peng J, Shi D, Goodman KA, Goldstein D, Xiao C, Guan Z, Cai S. Early results of quality of life for curatively treated rectal cancers in Chinese patients with EORTC QLQ-CR29. Radiat Oncol. 2011;6:93. [PMID: 21835046 DOI: 10.1186/1748-717x-6-93] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
295 Fields EC, Kaplan BJ, Karlin J, Myers JL, Mukhopadhyay N, Deng X, Sankala H, Grossman SR, Matin K. Phase 1 Study of Neoadjuvant Short-Course Radiation Therapy Concurrent With Infusional 5-Fluorouracil for the Treatment of Locally Advanced Rectal Cancer. Adv Radiat Oncol 2019;4:605-12. [PMID: 31673654 DOI: 10.1016/j.adro.2019.04.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
296 Chung MJ, Kim DW, Chung WK, Lee SH, Jeong SK, Hwang JK, Jeong CS. Preoperative short- vs. long-course chemoradiotherapy with delayed surgery for locally advanced rectal cancer. Oncotarget 2017;8:60479-86. [PMID: 28947986 DOI: 10.18632/oncotarget.10280] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
297 Beppu N, Yanagi H, Tomita N. A review of preoperative chemoradiotherapy for lower rectal cancer. J Anus Rectum Colon 2017;1:65-73. [PMID: 31583303 DOI: 10.23922/jarc.2017-013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
298 Nussbaum DP, Speicher PJ, Ganapathi AM, Englum BR, Keenan JE, Mantyh CR, Migaly J. Laparoscopic versus open low anterior resection for rectal cancer: results from the national cancer data base. J Gastrointest Surg 2015;19:124-31; discussion 131-2. [PMID: 25091847 DOI: 10.1007/s11605-014-2614-1] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
299 Du CZ, Li J, Cai Y, Sun YS, Xue WC, Gu J. Effect of multidisciplinary team treatment on outcomes of patients with gastrointestinal malignancy. World J Gastroenterol 2011; 17(15): 2013-2018 [PMID: 21528081 DOI: 10.3748/wjg.v17.i15.2013] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 38] [Article Influence: 4.1] [Reference Citation Analysis]
300 Ostenfeld EB, Erichsen R, Iversen LH, Gandrup P, Nørgaard M, Jacobsen J. Survival of patients with colon and rectal cancer in central and northern Denmark, 1998-2009. Clin Epidemiol 2011;3 Suppl 1:27-34. [PMID: 21814467 DOI: 10.2147/CLEP.S20617] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
301 West MA, Loughney L, Lythgoe D, Barben CP, Adams VL, Bimson WE, Grocott MP, Jack S, Kemp GJ. The effect of neoadjuvant chemoradiotherapy on whole-body physical fitness and skeletal muscle mitochondrial oxidative phosphorylation in vivo in locally advanced rectal cancer patients--an observational pilot study. PLoS One 2014;9:e111526. [PMID: 25478898 DOI: 10.1371/journal.pone.0111526] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
302 Kassahun WT. Unresolved issues and controversies surrounding the management of colorectal cancer liver metastasis. World J Surg Oncol 2015;13:61. [PMID: 25890279 DOI: 10.1186/s12957-014-0420-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
303 González-Flores E, Losa F, Pericay C, Polo E, Roselló S, Safont MJ, Vera R, Aparicio J, Cano MT, Fernández-Martos C. SEOM Clinical Guideline of localized rectal cancer (2016). Clin Transl Oncol 2016;18:1163-71. [PMID: 27905053 DOI: 10.1007/s12094-016-1591-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
304 Sole CV, Calvo FA, Ferrer C, Alvarez E, Carreras JL, Ochoa E. Human cytomegalovirus and Epstein-Barr virus infection impact on (18)F-FDG PET/CT SUVmax, CT volumetric and KRAS-based parameters of patients with locally advanced rectal cancer treated with neoadjuvant therapy. Eur J Nucl Med Mol Imaging. 2015;42:186-196. [PMID: 25269837 DOI: 10.1007/s00259-014-2910-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
305 Du CZ, Chen YC, Cai Y, Xue WC, Gu J. Oncologic outcomes of primary and post-irradiated early stage rectal cancer: A retrospective cohort study. World J Gastroenterol 2011; 17(27): 3229-3234 [PMID: 21912472 DOI: 10.3748/wjg.v17.i27.3229] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
306 Hu-Lieskovan S, Vallbohmer D, Zhang W, Yang D, Pohl A, Labonte MJ, Grimminger PP, Hölscher AH, Semrau R, Arnold D, Dellas K, Debucquoy A, Haustermans K, Machiels JP, Sempoux C, Rödel C, Bracko M, Velenik V, Lenz HJ. EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients. Clin Cancer Res 2011;17:5161-9. [PMID: 21673069 DOI: 10.1158/1078-0432.CCR-10-2666] [Cited by in Crossref: 34] [Cited by in F6Publishing: 13] [Article Influence: 3.1] [Reference Citation Analysis]
307 Taira T, Nozawa H, Kawai K, Sasaki K, Murono K, Kaneko M, Emoto S, Iida Y, Ishii H, Yokoyama Y, Anzai H, Sonoda H, Ishihara S. Oncological Outcomes of Pathological T1 Lower Rectal Cancer Patients With or Without Preoperative Chemoradiotherapy. In Vivo 2020;34:3559-64. [PMID: 33144468 DOI: 10.21873/invivo.12199] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
308 Koizumi M, Yamada T, Shinji S, Yokoyama Y, Takahashi G, Iwai T, Takeda K, Hara K, Ohta K, Uchida E, Yoshida H. Feasibility of Neoadjuvant FOLFOX Therapy Without Radiotherapy for Baseline Resectable Rectal Cancer. In Vivo. 2018;32:937-943. [PMID: 29936483 DOI: 10.21873/invivo.11332] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
309 Bae JH, Koh W, Kim HH, Lee YS. Standardized Step-by-step Technique Using Surgical Landmarks in Robotic Lateral Pelvic Lymph Node Dissection. Ann Coloproctol 2021;37:58-60. [PMID: 32972093 DOI: 10.3393/ac.2020.08.05] [Reference Citation Analysis]
310 Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, Barni S. Pathologic complete response and disease-free survival are not surrogate endpoints for 5-year survival in rectal cancer: an analysis of 22 randomized trials. J Gastrointest Oncol 2017;8:39-48. [PMID: 28280607 DOI: 10.21037/jgo.2016.11.03] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
311 Dionisi F, Musio D, Raffetto N, Codacci-Pisanelli G, Iannacone E, Caiazzo R, Banelli E. Preoperative intensified radiochemotherapy for rectal cancer: experience of a single institution. Int J Colorectal Dis. 2011;26:153-164. [PMID: 21107849 DOI: 10.1007/s00384-010-1064-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
312 Hong TS, Moughan J, Garofalo MC, Bendell J, Berger AC, Oldenburg NB, Anne PR, Perera F, Lee RJ, Jabbour SK, Nowlan A, DeNittis A, Crane C. NRG Oncology Radiation Therapy Oncology Group 0822: A Phase 2 Study of Preoperative Chemoradiation Therapy Using Intensity Modulated Radiation Therapy in Combination With Capecitabine and Oxaliplatin for Patients With Locally Advanced Rectal Cancer. Int J Radiat Oncol Biol Phys 2015;93:29-36. [PMID: 26163334 DOI: 10.1016/j.ijrobp.2015.05.005] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 6.4] [Reference Citation Analysis]
313 Velenik V, Ocvirk J, Music M, Bracko M, Anderluh F, Oblak I, Edhemovic I, Brecelj E, Kropivnik M, Omejc M. Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study. Radiat Oncol. 2011;6:105. [PMID: 21880132 DOI: 10.1186/1748-717x-6-105] [Cited by in Crossref: 61] [Cited by in F6Publishing: 26] [Article Influence: 5.5] [Reference Citation Analysis]
314 Haynes AB, You YN, Hu CY, Eng C, Kopetz ES, Rodriguez-Bigas MA, Skibber JM, Cantor SB, Chang GJ. Postoperative chemotherapy use after neoadjuvant chemoradiotherapy for rectal cancer: Analysis of Surveillance, Epidemiology, and End Results-Medicare data, 1998-2007. Cancer 2014;120:1162-70. [PMID: 24474245 DOI: 10.1002/cncr.28545] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
315 Engin G, Sharifov R. Magnetic resonance imaging for diagnosis and neoadjuvant treatment evaluation in locally advanced rectal cancer: A pictorial review. World J Clin Oncol 2017; 8(3): 214-229 [PMID: 28638791 DOI: 10.5306/wjco.v8.i3.214] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
316 Cai W, Ge W, Hu H, Mao J. Rectal NETs and rectosigmoid junction NETs may need to be treated differently. Cancer Med 2020;9:971-9. [PMID: 31840409 DOI: 10.1002/cam4.2779] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
317 Wada Y, Shimada M, Morine Y, Ikemoto T, Saito Y, Zhu Z, Wang X, Etxart A, Park Y, Bujanda L, Park IJ, Goel A. Circulating miRNA Signature Predicts Response to Preoperative Chemoradiotherapy in Locally Advanced Rectal Cancer. JCO Precis Oncol 2021;5:PO. [PMID: 34913022 DOI: 10.1200/PO.21.00015] [Reference Citation Analysis]
318 Muñoz-Galván S, Rivero M, Peinado-Serrano J, Martinez-Pérez J, Fernández-Fernández MC, Ortiz MJ, García-Heredia JM, Carnero A. PAI1 is a Marker of Bad Prognosis in Rectal Cancer but Predicts a Better Response to Treatment with PIM Inhibitor AZD1208. Cells 2020;9:E1071. [PMID: 32344898 DOI: 10.3390/cells9051071] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
319 Brouwer NPM, Bos ACRK, Lemmens VEPP, Tanis PJ, Hugen N, Nagtegaal ID, de Wilt JHW, Verhoeven RHA. An overview of 25 years of incidence, treatment and outcome of colorectal cancer patients. Int J Cancer. 2018;143:2758-2766. [PMID: 30095162 DOI: 10.1002/ijc.31785] [Cited by in Crossref: 80] [Cited by in F6Publishing: 79] [Article Influence: 20.0] [Reference Citation Analysis]
320 Abraha I, Aristei C, Palumbo I, Lupattelli M, Trastulli S, Cirocchi R, De Florio R, Valentini V. Preoperative radiotherapy and curative surgery for the management of localised rectal carcinoma. Cochrane Database Syst Rev. 2018;10:CD002102. [PMID: 30284239 DOI: 10.1002/14651858.cd002102.pub3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
321 Sebag-Montefiore D, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S, Quirke P, Couture J, de Metz C, Myint AS, Bessell E, Griffiths G, Thompson LC, Parmar M. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet. 2009;373:811-820. [PMID: 19269519 DOI: 10.1016/s0140-6736(09)60484-0] [Cited by in Crossref: 969] [Cited by in F6Publishing: 316] [Article Influence: 74.5] [Reference Citation Analysis]
322 Kong JC, Peacock O, Waters PS, Eglinton T, Warrier SK, Wakeman C, Frizelle FA, Heriot AG, McCormick JJ. Predictors of overall survival following extended radical resections for locally advanced and recurrent pelvic malignancies. Langenbecks Arch Surg 2020;405:491-502. [PMID: 32533361 DOI: 10.1007/s00423-020-01895-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
323 Wan JF, Zhu J, Li GC, Sun WJ, Zhang Z. YpT1-2N0 rectal cancer after neoadjuvant chemoradiation has lower survival compared with pT1-2N0 rectal cancer. Oncotarget 2015;6:41056-62. [PMID: 26517674 DOI: 10.18632/oncotarget.5379] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
324 Vacchelli E, Vitale I, Tartour E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Anticancer radioimmunotherapy. Oncoimmunology 2013;2:e25595. [PMID: 24319634 DOI: 10.4161/onci.25595] [Cited by in Crossref: 69] [Cited by in F6Publishing: 74] [Article Influence: 7.7] [Reference Citation Analysis]
325 Musio D, De Felice F, Bulzonetti N, Guarnaccia R, Caiazzo R, Bangrazi C, Raffetto N, Tombolini V. Neoadjuvant-intensified treatment for rectal cancer: Time to change? World J Gastroenterol 2013; 19(20): 3052-3061 [PMID: 23716984 DOI: 10.3748/wjg.v19.i20.3052] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
326 Seery TE, Ziogas A, Lin BS, Pan CJ, Stamos MJ, Zell JA. Mortality risk after preoperative versus postoperative chemotherapy and radiotherapy in lymph node-positive rectal cancer. J Gastrointest Surg. 2013;17:374-381. [PMID: 23242847 DOI: 10.1007/s11605-012-2116-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
327 Millard T, Kunk PR, Ramsdale E, Rahma OE. Current debate in the oncologic management of rectal cancer. World J Gastrointest Oncol 2016; 8(10): 715-724 [PMID: 27795811 DOI: 10.4251/wjgo.v8.i10.715] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
328 Nilsson PJ, van Etten B, Hospers GA, Påhlman L, van de Velde CJ, Beets-Tan RG, Blomqvist L, Beukema JC, Kapiteijn E, Marijnen CA, Nagtegaal ID, Wiggers T, Glimelius B. Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer--the RAPIDO trial. BMC Cancer 2013;13:279. [PMID: 23742033 DOI: 10.1186/1471-2407-13-279] [Cited by in Crossref: 198] [Cited by in F6Publishing: 160] [Article Influence: 22.0] [Reference Citation Analysis]
329 Lindsetmo RO, Joh YG, Delaney CP. Surgical treatment for rectal cancer: An international perspective on what the medical gastroenterologist needs to know. World J Gastroenterol 2008; 14(21): 3281-3289 [PMID: 18528924 DOI: 10.3748/wjg.14.3281] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
330 Suner A, Karakülah G, Dicle O, Sökmen S, Çelikoğlu CC. CorRECTreatment: a web-based decision support tool for rectal cancer treatment that uses the analytic hierarchy process and decision tree. Appl Clin Inform 2015;6:56-74. [PMID: 25848413 DOI: 10.4338/ACI-2014-10-RA-0087] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
331 Shin JK, Kim HC, Lee WY, Yun SH, Cho YB, Huh JW, Park YA. The Stage Migration Should be Reconsidered in Stage IIIA Rectal Cancer: Based on Propensity Score Analysis. Clin Colorectal Cancer 2021:S1533-0028(21)00093-1. [PMID: 34670724 DOI: 10.1016/j.clcc.2021.09.007] [Reference Citation Analysis]
332 Shen WC, Chen SW, Wu KC, Lee PY, Feng CL, Hsieh TC, Yen KY, Kao CH. Predicting pathological complete response in rectal cancer after chemoradiotherapy with a random forest using 18F-fluorodeoxyglucose positron emission tomography and computed tomography radiomics. Ann Transl Med. 2020;8:207. [PMID: 32309354 DOI: 10.21037/atm.2020.01.107] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
333 Lin JZ, Peng JH, Qdaisat A, Lu ZH, Wu XJ, Chen G, Ding PR, Li LR, Gao YH, Zeng ZF, Wan DS, Pan ZZ. Preoperative chemoradiotherapy creates an opportunity to perform sphincter preserving resection for low-lying locally advanced rectal cancer based on an oncologic outcome study. Oncotarget 2016;7:57317-26. [PMID: 27374175 DOI: 10.18632/oncotarget.10303] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
334 Kuo YH, Lai CH, Huang CY, Chen CJ, Huang YC, Huang WS, Chin CC. Monthly tegafur-uracil maintenance for increasing relapse-free survival in ypStage III rectal cancer patients after preoperative radiotherapy, radical resection, and 12 postoperative chemotherapy cycles: a retrospective study. BMC Cancer 2019;19:815. [PMID: 31419963 DOI: 10.1186/s12885-019-6019-0] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
335 Myerson RJ, Garofalo MC, El Naqa I, Abrams RA, Apte A, Bosch WR, Das P, Gunderson LL, Hong TS, Kim JJ, Willett CG, Kachnic LA. Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys 2009;74:824-30. [PMID: 19117696 DOI: 10.1016/j.ijrobp.2008.08.070] [Cited by in Crossref: 305] [Cited by in F6Publishing: 244] [Article Influence: 21.8] [Reference Citation Analysis]
336 Caramés C, Cristobal I, Moreno V, Marín JP, González-Alonso P, Torrejón B, Minguez P, Leon A, Martín JI, Hernández R, Pedregal M, Martín MJ, Cortés D, García-Olmo D, Fernández MJ, Rojo F, García-Foncillas J. MicroRNA-31 Emerges as a Predictive Biomarker of Pathological Response and Outcome in Locally Advanced Rectal Cancer. Int J Mol Sci 2016;17:E878. [PMID: 27271609 DOI: 10.3390/ijms17060878] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
337 Harada Y, Kazama S, Morikawa T, Sonoda H, Ishi H, Emoto S, Murono K, Kaneko M, Sasaki K, Shuno Y, Nishikawa T, Tanaka T, Kawai K, Hata K, Nozawa H, Ushiku T, Tahara H, Ishihara S. Clinical significance of CD8+ and FoxP3+ tumor-infiltrating lymphocytes and MFG-E8 expression in lower rectal cancer with preoperative chemoradiotherapy. Mol Clin Oncol 2021;14:87. [PMID: 33767856 DOI: 10.3892/mco.2021.2249] [Reference Citation Analysis]
338 Corner C, Khimji F, Tsang Y, Harrison M, Glynne-Jones R, Hughes R. Comparison of conventional and three-dimensional conformal CT planning techniques for preoperative chemoradiotherapy for locally advanced rectal cancer. Br J Radiol 2011;84:173-8. [PMID: 21257837 DOI: 10.1259/bjr/33089685] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
339 Bai X, Li S, Yu B, Su H, Jin W, Chen G, DU J, Zuo F. Sphincter-preserving surgery after preoperative radiochemotherapy for T3 low rectal cancers. Oncol Lett. 2012;3:1336-1340. [PMID: 22783445 DOI: 10.3892/ol.2012.656] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
340 Meyer J, Balch G, Willett C, Czito B. Update on treatment advances in combined-modality therapy for anal and rectal carcinomas. Curr Oncol Rep 2011;13:177-85. [PMID: 21465120 DOI: 10.1007/s11912-011-0166-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
341 Tomono A, Yamashita K, Kanemitsu K, Sumi Y, Yamamoto M, Kanaji S, Imanishi T, Nakamura T, Suzuki S, Tanaka K, Kakeji Y. Prognostic significance of pathological response to preoperative chemoradiotherapy in patients with locally advanced rectal cancer. Int J Clin Oncol 2016;21:344-9. [PMID: 26338272 DOI: 10.1007/s10147-015-0900-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
342 Vecchio R, Marchese S, Intagliata E. Laparoscopic Colorectal Surgery for Cancer: What Is the Role of Complete Mesocolic Excision and Splenic Flexure Mobilization? Indian J Surg 2017;79:338-43. [PMID: 28827909 DOI: 10.1007/s12262-017-1631-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
343 de Jongh SJ, Tjalma JJJ, Koller M, Linssen MD, Vonk J, Dobosz M, Jorritsma-Smit A, Kleibeuker JH, Hospers GAP, Havenga K, Hemmer PHJ, Karrenbeld A, van Dam GM, van Etten B, Nagengast WB. Back-Table Fluorescence-Guided Imaging for Circumferential Resection Margin Evaluation Using Bevacizumab-800CW in Patients with Locally Advanced Rectal Cancer.J Nucl Med. 2020;61:655-661. [PMID: 31628218 DOI: 10.2967/jnumed.119.232355] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
344 Slevin F, Hanna C, Appelt A, Muirhead R; UK Rectal IMRT Development Group. Launch of the National Rectal Cancer Intensity-Modulated Radiotherapy Guidance. Clin Oncol (R Coll Radiol) 2021;33:209-13. [PMID: 33341331 DOI: 10.1016/j.clon.2020.11.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
345 You KY, Huang R, Ding PR, Qiu B, Zhou GQ, Chang H, Xiao WW, Zeng ZF, Pan ZZ, Gao YH. Selective use of adjuvant chemotherapy for rectal cancer patients with ypN0. Int J Colorectal Dis. 2014;29:529-538. [PMID: 24474499 DOI: 10.1007/s00384-014-1831-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
346 Song JS, Park IJ, Kim JH, Lee HR, Kim JR, Lee JL, Yoon YS, Kim CW, Lim SB, Yu CS, Kim JC. Peri-treatment change of anorectal function in patients with rectal cancer after preoperative chemoradiotherapy. Oncotarget 2017;8:79982-90. [PMID: 29108380 DOI: 10.18632/oncotarget.20567] [Reference Citation Analysis]
347 Wu C, Williams TM, Robb R, Webb A, Wei L, Chen W, Mikhail S, Ciombor KK, Cardin DB, Timmers C, Krishna SG, Arnold M, Harzman A, Abdel-Misih S, Roychowdhury S, Bekaii-Saab T, Wuthrick E. Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer. Clin Cancer Res 2020;26:3117-25. [PMID: 32253228 DOI: 10.1158/1078-0432.CCR-19-4193] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
348 Jäger T, Neureiter D, Fallaha M, Schredl P, Kiesslich T, Urbas R, Klieser E, Holzinger J, Sedlmayer F, Emmanuel K, Dinnewitzer A. The potential predictive value of tumor budding for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer. Strahlenther Onkol 2018;194:991-1006. [PMID: 30069738 DOI: 10.1007/s00066-018-1340-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
349 Ohri N, Dicker AP, Lawrence YR. Can drugs enhance hypofractionated radiotherapy? A novel method of modeling radiosensitization using in vitro data. Int J Radiat Oncol Biol Phys 2012;83:385-93. [PMID: 22265460 DOI: 10.1016/j.ijrobp.2011.06.1990] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
350 Chionh F, Lau D, Yeung Y, Price T, Tebbutt N. Oral versus intravenous fluoropyrimidines for colorectal cancer. Cochrane Database Syst Rev 2017;7:CD008398. [PMID: 28752564 DOI: 10.1002/14651858.CD008398.pub2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
351 Jin F, Luo H, Zhou J, Wu Y, Sun H, Liu H, Zheng X, Wang Y. Dose-time fractionation schedules of preoperative radiotherapy and timing to surgery for rectal cancer. Ther Adv Med Oncol 2020;12:1758835920907537. [PMID: 32165928 DOI: 10.1177/1758835920907537] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
352 Xiao B, Peng J, Zhang R, Xu J, Wang Y, Fang Y, Lin J, Pan Z, Wu X. Density of CD8+ lymphocytes in biopsy samples combined with the circulating lymphocyte ratio predicts pathologic complete response to chemoradiotherapy for rectal cancer. Cancer Manag Res 2017;9:701-8. [PMID: 29225479 DOI: 10.2147/CMAR.S150622] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
353 Travaini LL, Zampino MG, Colandrea M, Ferrari ME, Gilardi L, Leonardi MC, Santoro L, Orecchia R, Grana CM. PET/CT with Fluorodeoxyglucose During Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. Ecancermedicalscience 2016;10:629. [PMID: 27110285 DOI: 10.3332/ecancer.2016.629] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
354 Chauvin A, Wang CS, Geha S, Garde-Granger P, Mathieu AA, Lacasse V, Boisvert FM. The response to neoadjuvant chemoradiotherapy with 5-fluorouracil in locally advanced rectal cancer patients: a predictive proteomic signature. Clin Proteomics 2018;15:16. [PMID: 29681787 DOI: 10.1186/s12014-018-9192-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
355 Lee JH, Kim SH, Jang HS, Chung HJ, Oh ST, Lee DS, Kim JG. Preoperative elevation of carcinoembryonic antigen predicts poor tumor response and frequent distant recurrence for patients with rectal cancer who receive preoperative chemoradiotherapy and total mesorectal excision: a multi-institutional analysis in an Asian population. Int J Colorectal Dis 2013;28:511-7. [PMID: 23208008 DOI: 10.1007/s00384-012-1584-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
356 Brunet J, Price J, Delluc C. An exercise trial for adults undergoing neoadjuvant chemoradiotherapy for rectal cancer proves not feasible: recommendations for future trials. Trials 2021;22:26. [PMID: 33407782 DOI: 10.1186/s13063-020-04958-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
357 Li Y, Wang J, Ma X, Tan L, Yan Y, Xue C, Hui B, Liu R, Ma H, Ren J. A Review of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer. Int J Biol Sci. 2016;12:1022-1031. [PMID: 27489505 DOI: 10.7150/ijbs.15438] [Cited by in Crossref: 68] [Cited by in F6Publishing: 59] [Article Influence: 11.3] [Reference Citation Analysis]
358 Maurel J, Grávalos C, Rivera F, Vera R, González Flores E; SEOM. SEOM clinical guidelines for the adjuvant treatment of colorectal cancer 2013. Clin Transl Oncol 2013;15:991-5. [PMID: 24026866 DOI: 10.1007/s12094-013-1083-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
359 Park JS, Sakai Y, Simon NSM, Law WL, Kim HR, Oh JH, Shan HCY, Kwak SG, Choi GS. Long-Term Survival and Local Relapse Following Surgery Without Radiotherapy for Locally Advanced Upper Rectal Cancer: An International Multi-Institutional Study. Medicine (Baltimore) 2016;95:e2990. [PMID: 27258487 DOI: 10.1097/MD.0000000000002990] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 3.2] [Reference Citation Analysis]
360 Ohue M, Hamaguchi T, Ito Y, Sakai D, Noura S, Kinugasa Y, Fujita S, Shimada Y, Saito N, Moriya Y. A phase I trial of preoperative S-1 in combination with oxaliplatin and pelvic radiation for lower rectal cancer with T4 and lateral pelvic lymph node metastasis. Int J Clin Oncol 2015;20:338-44. [PMID: 24839048 DOI: 10.1007/s10147-014-0705-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
361 Baik SH. Is Low-Dose-Rate Endorectal Brachytherapy a New Treatment Method for Locally Advanced Distal Rectal Cancer? Ann Coloproctol 2015;31:115-6. [PMID: 26361609 DOI: 10.3393/ac.2015.31.4.115] [Reference Citation Analysis]
362 Emile SH, de Lacy FB, Keller DS, Martin-Perez B, Alrawi S, Lacy AM, Chand M. Evolution of transanal total mesorectal excision for rectal cancer: From top to bottom. World J Gastrointest Surg 2018; 10(3): 28-39 [PMID: 29588809 DOI: 10.4240/wjgs.v10.i3.28] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
363 Mirjolet C, Charon-Barra C, Ladoire S, Arbez-Gindre F, Bertaut A, Ghiringhelli F, Leroux A, Peiffert D, Borg C, Bosset JF, Créhange G. Tumor lymphocyte immune response to preoperative radiotherapy in locally advanced rectal cancer: The LYMPHOREC study. Oncoimmunology 2018;7:e1396402. [PMID: 29399395 DOI: 10.1080/2162402X.2017.1396402] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
364 Keller DS, Berho M, Perez RO, Wexner SD, Chand M. The multidisciplinary management of rectal cancer.Nat Rev Gastroenterol Hepatol. 2020;17:414-429. [PMID: 32203400 DOI: 10.1038/s41575-020-0275-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 5.5] [Reference Citation Analysis]
365 Zhao J, Xu J, Zhang R. Clinical and Prognostic Significance of Pathological and Inflammatory Markers in Mucinous Rectal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy and Curative Surgery. Med Sci Monit 2017;23:4826-33. [PMID: 28988257 DOI: 10.12659/msm.904116] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
366 Milinis K, Thornton M, Montazeri A, Rooney PS. Adjuvant chemotherapy for rectal cancer: Is it needed? World J Clin Oncol 2015; 6(6): 225-236 [PMID: 26677436 DOI: 10.5306/wjco.v6.i6.225] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
367 Guerin O, Gal J, Francois E, Jacqueme B, Sciortino V, Gerard JP. Clinical outcome of rectal cancer in patients ≥ 80 years treated in southern France (PACA region) between 2002 and 2005. Strahlenther Onkol 2012;188:383-7. [PMID: 22410833 DOI: 10.1007/s00066-012-0076-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
368 Gash KJ, Chambers AC, Cotton DE, Williams AC, Thomas MG. Potentiating the effects of radiotherapy in rectal cancer: the role of aspirin, statins and metformin as adjuncts to therapy. Br J Cancer 2017;117:210-9. [PMID: 28641310 DOI: 10.1038/bjc.2017.175] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 5.6] [Reference Citation Analysis]
369 Kuo I, Wong JH, Roy-chowdhury S, Lum SS, Morgan JW, Kazanjian K. The Use of Pelvic Radiation in Stage II Rectal Cancer: A Population-Based Analysis. The American Surgeon 2010;76:1092-5. [DOI: 10.1177/000313481007601015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
370 Javle M, Hsueh CT. Recent advances in gastrointestinal oncology--updates and insights from the 2009 annual meeting of the American society of clinical oncology. J Hematol Oncol 2010;3:11. [PMID: 20331897 DOI: 10.1186/1756-8722-3-11] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
371 Lim YK, Law WL, Liu R, Poon JT, Fan JF, Lo OS. Impact of neoadjuvant treatment on total mesorectal excision for ultra-low rectal cancers. World J Surg Oncol. 2010;8:23. [PMID: 20346160 DOI: 10.1186/1477-7819-8-23] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
372 Lefevre JH, Rousseau A, Svrcek M, Parc Y, Simon T, Tiret E; French Research Group of Rectal Cancer Surgery (GRECCAR). A multicentric randomized controlled trial on the impact of lengthening the interval between neoadjuvant radiochemotherapy and surgery on complete pathological response in rectal cancer (GRECCAR-6 trial): rationale and design. BMC Cancer 2013;13:417. [PMID: 24028546 DOI: 10.1186/1471-2407-13-417] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
373 Midgley RS, Yanagisawa Y, Kerr DJ. Evolution of nonsurgical therapy for colorectal cancer. Nat Clin Pract Gastroenterol Hepatol 2009;6:108-20. [PMID: 19153564 DOI: 10.1038/ncpgasthep1337] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
374 Pisano M, Zorcolo L, Merli C, Cimbanassi S, Poiasina E, Ceresoli M, Agresta F, Allievi N, Bellanova G, Coccolini F, Coy C, Fugazzola P, Martinez CA, Montori G, Paolillo C, Penachim TJ, Pereira B, Reis T, Restivo A, Rezende-Neto J, Sartelli M, Valentino M, Abu-Zidan FM, Ashkenazi I, Bala M, Chiara O, De' Angelis N, Deidda S, De Simone B, Di Saverio S, Finotti E, Kenji I, Moore E, Wexner S, Biffl W, Coimbra R, Guttadauro A, Leppäniemi A, Maier R, Magnone S, Mefire AC, Peitzmann A, Sakakushev B, Sugrue M, Viale P, Weber D, Kashuk J, Fraga GP, Kluger I, Catena F, Ansaloni L. 2017 WSES guidelines on colon and rectal cancer emergencies: obstruction and perforation. World J Emerg Surg 2018;13:36. [PMID: 30123315 DOI: 10.1186/s13017-018-0192-3] [Cited by in Crossref: 85] [Cited by in F6Publishing: 54] [Article Influence: 21.3] [Reference Citation Analysis]
375 Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, Hamaguchi T, Hyodo I, Igarashi M, Ishida H, Ishihara S, Ishiguro M, Kanemitsu Y, Kokudo N, Muro K, Ochiai A, Oguchi M, Ohkura Y, Saito Y, Sakai Y, Ueno H, Yoshino T, Boku N, Fujimori T, Koinuma N, Morita T, Nishimura G, Sakata Y, Takahashi K, Tsuruta O, Yamaguchi T, Yoshida M, Yamaguchi N, Kotake K, Sugihara K; Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol. 2015;20:207-239. [PMID: 25782566 DOI: 10.1007/s10147-015-0801-z] [Cited by in Crossref: 379] [Cited by in F6Publishing: 363] [Article Influence: 54.1] [Reference Citation Analysis]
376 Yoo RN, Kim HJ. Total neoadjuvant therapy in locally advanced rectal cancer: Role of systemic chemotherapy. Ann Gastroenterol Surg. 2019;3:356-367. [PMID: 31346574 DOI: 10.1002/ags3.12253] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
377 Chen CF, Huang MY, Huang CJ, Wu CH, Yeh YS, Tsai HL, Ma CJ, Lu CY, Chang SJ, Chen MJ, Wang JY. A observational study of the efficacy and safety of capecitabine versus bolus infusional 5-fluorouracil in pre-operative chemoradiotherapy for locally advanced rectal cancer. Int J Colorectal Dis 2012;27:727-36. [PMID: 22258885 DOI: 10.1007/s00384-011-1377-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
378 Zhong X, Wu Z, Gao P, Shi J, Sun J, Guo Z, Wang Z, Song Y. The efficacy of adding targeted agents to neoadjuvant therapy for locally advanced rectal cancer patients: a meta-analysis. Cancer Med 2018;7:565-82. [PMID: 29464874 DOI: 10.1002/cam4.1298] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
379 Idasiak A, Galwas-Kliber K, Behrendt K, Wziętek I, Kryj M, Stobiecka E, Chmielik E, Suwiński R. Pre-operative hyperfractionated concurrent radiochemotherapy for locally advanced rectal cancers: a phase II clinical study. Br J Radiol 2017;90:20160731. [PMID: 28466686 DOI: 10.1259/bjr.20160731] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
380 Shen L, van Soest J, Wang J, Yu J, Hu W, Gong YU, Valentini V, Xiao Y, Dekker A, Zhang Z. Validation of a rectal cancer outcome prediction model with a cohort of Chinese patients. Oncotarget 2015;6:38327-35. [PMID: 26413811 DOI: 10.18632/oncotarget.5195] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
381 Vallböhmer D, Bollschweiler E, Brabender J, Wedemeyer I, Grimminger PP, Metzger R, Schröder W, Gutschow C, Hölscher AH, Drebber U. Evaluation of histological regression grading systems in the neoadjuvant therapy of rectal cancer: do they have prognostic impact? Int J Colorectal Dis. 2012;27:1295-1301. [PMID: 22614681 DOI: 10.1007/s00384-012-1487-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
382 Dong XH, Zhang XF, Yang Z, Liu GH. Efficacy and safety of preoperative radiochemotherapy combined with total mesorectal excision in treatment of stage Ⅱ/Ⅲ rectal cancer. Shijie Huaren Xiaohua Zazhi 2013; 21(29): 3163-3167 [DOI: 10.11569/wcjd.v21.i29.3163] [Reference Citation Analysis]
383 Peng Y, Wang L, Du C, Gu J. Expression of vascular endothelial growth factor can predict distant metastasis and disease-free survival for clinical stage III rectal cancer following 30-Gy/10-f preoperative radiotherapy. Int J Colorectal Dis. 2012;27:1555-1560. [PMID: 22645074 DOI: 10.1007/s00384-012-1485-8].] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
384 Schrag D. Evolving role of neoadjuvant therapy in rectal cancer. Curr Treat Options Oncol 2013;14:350-64. [PMID: 23828092 DOI: 10.1007/s11864-013-0242-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
385 Ciria JP, Eguiguren M, Cafiero S, Uranga I, Diaz de Cerio I, Querejeta A, Urraca JM, Minguez J, Guimon E, Puertolas JR. Could preoperative short-course radiotherapy be the treatment of choice for localized advanced rectal carcinoma? Rep Pract Oncol Radiother 2015;20:1-11. [PMID: 25535578 DOI: 10.1016/j.rpor.2014.06.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
386 De Felice F, Benevento I, Magnante AL, Musio D, Bulzonetti N, Caiazzo R, Tombolini V. Clinical benefit of adding oxaliplatin to standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a meta-analysis : Oxaliplatin in neoadjuvant treatment for rectal cancer. BMC Cancer 2017;17:325. [PMID: 28499428 DOI: 10.1186/s12885-017-3323-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
387 Tseng M, Soon YY, Vellayappan B, Ho F, Tey J. Radiation therapy for rectal cancer. J Gastrointest Oncol 2019;10:1238-50. [PMID: 31949945 DOI: 10.21037/jgo.2018.12.04] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
388 Suzuki T, Sadahiro S, Tanaka A, Okada K, Saito G, Miyakita H, Akiba T, Yamamuro H. A Modified Classification of Prognostic Factors Based on Pathological Stage and Tumor Regression Grade in Patients with Rectal Cancer Who Receive Preoperative Chemoradiotherapy. Oncology 2017;93:287-94. [PMID: 28728151 DOI: 10.1159/000478266] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
389 Mirnezami R, Chang GJ, Das P, Chandrakumaran K, Tekkis P, Darzi A, Mirnezami AH. Intraoperative radiotherapy in colorectal cancer: systematic review and meta-analysis of techniques, long-term outcomes, and complications. Surg Oncol. 2013;22:22-35. [PMID: 23270946 DOI: 10.1016/j.suronc.2012.11.001] [Cited by in Crossref: 64] [Cited by in F6Publishing: 50] [Article Influence: 6.4] [Reference Citation Analysis]
390 Cui CL, Luo WY, Cosman BC, Eisenstein S, Simpson D, Ramamoorthy S, Murphy J, Lopez N. Cost Effectiveness of Watch and Wait Versus Resection in Rectal Cancer Patients with Complete Clinical Response to Neoadjuvant Chemoradiation. Ann Surg Oncol 2021. [PMID: 34529175 DOI: 10.1245/s10434-021-10576-z] [Reference Citation Analysis]
391 Dewdney A, Cunningham D. Toward the non-surgical management of locally advanced rectal cancer. Curr Oncol Rep 2012;14:267-76. [PMID: 22460631 DOI: 10.1007/s11912-012-0234-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
392 Ikoma N, You YN, Bednarski BK, Rodriguez-Bigas MA, Eng C, Das P, Kopetz S, Messick C, Skibber JM, Chang GJ. Impact of Recurrence and Salvage Surgery on Survival After Multidisciplinary Treatment of Rectal Cancer. J Clin Oncol 2017;35:2631-8. [PMID: 28657814 DOI: 10.1200/JCO.2016.72.1464] [Cited by in Crossref: 29] [Cited by in F6Publishing: 13] [Article Influence: 5.8] [Reference Citation Analysis]
393 You KY, Huang R, Yu X, Liu YM, Gao YH. Is It Possible to Shorten the Duration of Adjuvant Chemotherapy for Locally Advanced Rectal Cancer? Medicine (Baltimore) 2016;95:e3427. [PMID: 27100436 DOI: 10.1097/MD.0000000000003427] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
394 Yamashita S, Brudvik KW, Kopetz SE, Maru D, Clarke CN, Passot G, Conrad C, Chun YS, Aloia TA, Vauthey JN. Embryonic Origin of Primary Colon Cancer Predicts Pathologic Response and Survival in Patients Undergoing Resection for Colon Cancer Liver Metastases. Ann Surg. 2018;267:514-520. [PMID: 28002060 DOI: 10.1097/sla.0000000000002087] [Cited by in Crossref: 36] [Cited by in F6Publishing: 17] [Article Influence: 12.0] [Reference Citation Analysis]
395 Berardi R, Maccaroni E, Onofri A, Morgese F, Torniai M, Tiberi M, Ferrini C, Cascinu S. Locally advanced rectal cancer: The importance of a multidisciplinary approach. World J Gastroenterol 2014; 20(46): 17279-17287 [PMID: 25516638 DOI: 10.3748/wjg.v20.i46.17279] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
396 Miyamoto R, Kikuchi K, Uchida A, Ozawa M, Sano N, Tadano S, Inagawa S, Oda T, Ohkohchi N. Pathological complete response after preoperative chemotherapy including FOLFOX plus bevacizumab for locally advanced rectal cancer: A case report and literature review. Int J Surg Case Rep 2019;62:85-8. [PMID: 31476559 DOI: 10.1016/j.ijscr.2019.08.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
397 Shadad AK, Sullivan FJ, Martin JD, Egan LJ. Gastrointestinal radiation injury: Symptoms, risk factors and mechanisms. World J Gastroenterol 2013; 19(2): 185-198 [PMID: 23345941 DOI: 10.3748/wjg.v19.i2.185] [Cited by in CrossRef: 122] [Cited by in F6Publishing: 100] [Article Influence: 13.6] [Reference Citation Analysis]
398 Kleiman LB, Krebs AM, Kim SY, Hong TS, Haigis KM. Comparative analysis of radiosensitizers for K-RAS mutant rectal cancers. PLoS One 2013;8:e82982. [PMID: 24349411 DOI: 10.1371/journal.pone.0082982] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
399 Biondo S, Fraccalvieri D, Golda T, Frago R, Trenti L, Kreisler E. Update on advances and controversy in rectal cancer treatment. Tech Coloproctol 2016;20:145-52. [PMID: 26754651 DOI: 10.1007/s10151-015-1418-y] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
400 Zhu HB, Wang L, Li ZY, Li XT, Zhang XY, Sun YS. Sphincter-preserving surgery for low-middle rectal cancer: Can we predict feasibility with high-resolution magnetic resonance imaging? Medicine (Baltimore) 2017;96:e7418. [PMID: 28723750 DOI: 10.1097/MD.0000000000007418] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
401 Erlenbach-Wünsch K, Semrau S, Fietkau R, Weber K, Hohenberger W, Rau T, Hartmann A, Merkel S, Agaimy A. ypN0 nodal status after neoadjuvant chemoradiotherapy for rectal carcinoma is not associated with adverse prognosis as compared with pN0 after primary surgery. Int J Colorectal Dis 2014;29:231-7. [PMID: 24221252 DOI: 10.1007/s00384-013-1790-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
402 Tanaka H, Yamaguchi T, Hachiya K, Okada S, Kitahara M, Matsuyama K, Matsuo M. Radiotherapy for locally recurrent rectal cancer treated with surgery alone as the initial treatment. Radiat Oncol J 2017;35:71-7. [PMID: 28395503 DOI: 10.3857/roj.2016.02005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
403 Marquardt F, Rödel F, Capalbo G, Weiss C, Rödel C. Molecular targeted treatment and radiation therapy for rectal cancer. Strahlenther Onkol. 2009;185:371-378. [PMID: 19506820 DOI: 10.1007/s00066-009-1936-5] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 3.5] [Reference Citation Analysis]
404 Ewart R, Lausen H, Millian N. Undisclosed changes in outcomes in randomized controlled trials: an observational study. Ann Fam Med 2009;7:542-6. [PMID: 19901314 DOI: 10.1370/afm.1017] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
405 Tripathi P, Li Z, Shen Y, Hu X, Hu D. Risk of nodal disease in patients with MRI-detected extramural vascular invasion in rectal cancer: a systematic review and meta-analysis. Tumori 2021;107:564-70. [PMID: 33243105 DOI: 10.1177/0300891620975867] [Reference Citation Analysis]
406 Yeoh Y, Low TY, Abu N, Lee PY. Regulation of signal transduction pathways in colorectal cancer: implications for therapeutic resistance. PeerJ 2021;9:e12338. [PMID: 34733591 DOI: 10.7717/peerj.12338] [Reference Citation Analysis]
407 Margalit O, Mamtani R, Lawrence YR, Yang YX, Baruch EN, Reiss KA, Golan T, Halpern N, Aderka D, Giantonio B, Shacham-Shmueli E, Boursi B. Locally advanced rectal adenocarcinoma: Are preoperative short and long course radiotherapy truly equivalent? Mol Clin Oncol 2019;10:555-9. [PMID: 30967950 DOI: 10.3892/mco.2019.1825] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
408 Ugidos L, Delgado S, Conill C, Ginés A, Gallego R, Ayuso JR, Miquel R, Tosca M, de Lacy A, Castells A. Phase I trial of neoadjuvant chemoradiotherapy (CRT) with capecitabine and weekly irinotecan followed by laparoscopic total mesorectal excision (LTME) in rectal cancer patients. Invest New Drugs. 2009;27:262-268. [PMID: 18923810 DOI: 10.1007/s10637-008-9192-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
409 Senetta R, Duregon E, Sonetto C, Spadi R, Mistrangelo M, Racca P, Chiusa L, Munoz FH, Ricardi U, Arezzo A, Cassenti A, Castellano I, Papotti M, Morino M, Risio M, Cassoni P. YKL-40/c-Met expression in rectal cancer biopsies predicts tumor regression following neoadjuvant chemoradiotherapy: a multi-institutional study. PLoS One 2015;10:e0123759. [PMID: 25875173 DOI: 10.1371/journal.pone.0123759] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
410 Derbel O, Wang Q, Desseigne F, Rivoire M, Meeus P, Peyrat P, Stella M, Martel-Lafay I, Lemaistre AI, de La Fouchardière C. Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery. BMC Cancer 2013;13:200. [PMID: 23617638 DOI: 10.1186/1471-2407-13-200] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
411 Tokuhara K, Ueyama Y, Nakatani K, Yoshioka K, Kon M. Outcomes of neoadjuvant chemoradiotherapy in Japanese locally advanced rectal carcinoma patients. World J Surg Oncol 2016;14:136. [PMID: 27129578 DOI: 10.1186/s12957-016-0898-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
412 Garajová I, Di Girolamo S, de Rosa F, Corbelli J, Agostini V, Biasco G, Brandi G. Neoadjuvant treatment in rectal cancer: actual status. Chemother Res Pract 2011;2011:839742. [PMID: 22295206 DOI: 10.1155/2011/839742] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
413 Glimelius B. Neo-adjuvant radiotherapy in rectal cancer. World J Gastroenterol 2013; 19(46): 8489-8501 [PMID: 24379566 DOI: 10.3748/wjg.v19.i46.8489] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 38] [Article Influence: 4.4] [Reference Citation Analysis]
414 Belluco C, Forlin M, Olivieri M, Cannizzaro R, Canzonieri V, Buonadonna A, Bidoli E, Matrone F, Bertola G, De Paoli A. Long-Term Outcome of Rectal Cancer With Clinically (EUS/MRI) Metastatic Mesorectal Lymph Nodes Treated by Neoadjuvant Chemoradiation: Role of Organ Preservation Strategies in Relation to Pathologic Response. Ann Surg Oncol 2016;23:4302-9. [PMID: 27489059 DOI: 10.1245/s10434-016-5451-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
415 Gao X, Wang C, Yu Y, Singh D, Yang L, Zhou Z. Lateral lymph node dissection reduces local recurrence of locally advanced lower rectal cancer in the absence of preoperative neoadjuvant chemoradiotherapy: a systematic review and meta-analysis. World J Surg Oncol 2020;18:304. [PMID: 33228677 DOI: 10.1186/s12957-020-02078-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
416 Del Puerto-Nevado L, Marin-Arango JP, Fernandez-Aceñero MJ, Arroyo-Manzano D, Martinez-Useros J, Borrero-Palacios A, Rodriguez-Remirez M, Cebrian A, Gomez Del Pulgar T, Cruz-Ramos M, Carames C, Lopez-Botet B, Garcia-Foncillas J. Predictive value of vrk 1 and 2 for rectal adenocarcinoma response to neoadjuvant chemoradiation therapy: a retrospective observational cohort study. BMC Cancer 2016;16:519. [PMID: 27456229 DOI: 10.1186/s12885-016-2574-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
417 Yu TK, Bhosale PR, Crane CH, Iyer RB, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Eng C, Wolff RA. Patterns of locoregional recurrence after surgery and radiotherapy or chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys. 2008;71:1175-1180. [PMID: 18207667 DOI: 10.1016/j.ijrobp.2007.11.018] [Cited by in Crossref: 45] [Cited by in F6Publishing: 33] [Article Influence: 3.2] [Reference Citation Analysis]
418 Smith CA, Kachnic LA. Evolving Role of Radiotherapy in the Management of Rectal Carcinoma. Surg Oncol Clin N Am 2017;26:455-66. [PMID: 28576182 DOI: 10.1016/j.soc.2017.01.011] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
419 Kowalski-Chauvel A, Gouaze-Andersson V, Vignolle-Vidoni A, Delmas C, Toulas C, Cohen-Jonathan-Moyal E, Seva C. Targeting progastrin enhances radiosensitization of colorectal cancer cells. Oncotarget 2017;8:58587-600. [PMID: 28938581 DOI: 10.18632/oncotarget.17274] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
420 Peng J, Lin J, Zeng Z, Wu X, Chen G, Li L, Lu Z, Ding P, Wan D, Pan Z. Addition of oxaliplatin to capecitabine-based preoperative chemoradiotherapy for locally advanced rectal cancer: Long-term outcome of a phase II study. Oncol Lett 2017;14:4543-50. [PMID: 29085451 DOI: 10.3892/ol.2017.6764] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
421 Lin YM, Chou CL, Kuo YH, Wu HC, Tsai CJ, Ho CH, Chen YC, Yang CC, Lin CW. Optimal Lymph Node Yield for Survival Prediction in Rectal Cancer Patients After Neoadjuvant Therapy. Cancer Manag Res 2021;13:8037-47. [PMID: 34729022 DOI: 10.2147/CMAR.S328666] [Reference Citation Analysis]
422 Baur M, Horvath M, Stättner S, Schratter-Sehn A, Horvath B, Sellner F, Hudec M, Klimpfinger M, Dittrich C, Karner J. Chemoradiotherapy with 5-fluorouracil/leucovorin, surgery and adjuvant chemotherapy for locally advanced rectal cancer. Oncol Lett 2010;1:189-94. [PMID: 22966281 DOI: 10.3892/ol_00000035] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
423 Petersen SH, Harling H, Kirkeby LT, Wille-Jørgensen P, Mocellin S. Postoperative adjuvant chemotherapy in rectal cancer operated for cure. Cochrane Database Syst Rev. 2012;3:CD004078. [PMID: 22419291 DOI: 10.1002/14651858.cd004078] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
424 Peng HH, You KY, Wang CT, Huang R, Shan HB, Zhou JH, Pei XQ, Gao YH, Wen BX, Liu MZ. Value of transrectal ultrasonography for tumor node metastasis restaging in patients with locally advanced rectal cancer after neoadjuvant chemoradiotherapy. Gastroenterol Rep (Oxf) 2013;1:186-92. [PMID: 24759964 DOI: 10.1093/gastro/got028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
425 Golo D, But-Hadzic J, Anderluh F, Brecelj E, Edhemovic I, Jeromen A, Omejc M, Oblak I, Secerov-Ermenc A, Velenik V. Induction chemotherapy, chemoradiotherapy and consolidation chemotherapy in preoperative treatment of rectal cancer - long-term results of phase II OIGIT-01 Trial. Radiol Oncol. 2018;52:267-274. [PMID: 30210040 DOI: 10.2478/raon-2018-0028] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
426 Engels B, Gevaert T, Sermeus A, De Ridder M. Current status of intensified neo-adjuvant systemic therapy in locally advanced rectal cancer. Front Oncol 2012;2:47. [PMID: 22655273 DOI: 10.3389/fonc.2012.00047] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
427 Zhou J, Qiu H, Lin G, Xiao Y, Wu B, Wu W, Sun X, Lu J, Zhang G, Xu L, Liu Y. Is adjuvant chemotherapy necessary for patients with pathological complete response after neoadjuvant chemoradiotherapy and radical surgery in locally advanced rectal cancer? Long-term analysis of 40 ypCR patients at a single center. Int J Colorectal Dis 2016;31:1163-8. [PMID: 27044403 DOI: 10.1007/s00384-016-2579-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
428 Cellier P, Leduc B, Martin L, Vié B, Chevelle C, Vendrely V, Salemkour A, Carrie C, Calais G, Burtin P, Campion L, Boisdron-Celle M, Morel A, Berger V, Gamelin E. Phase II study of preoperative radiation plus concurrent daily tegafur-uracil (UFT) with leucovorin for locally advanced rectal cancer. BMC Cancer 2011;11:98. [PMID: 21410976 DOI: 10.1186/1471-2407-11-98] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
429 Glynne-Jones R, Chau I. Neoadjuvant therapy before surgical treatment. EJC Suppl 2013;11:45-59. [PMID: 26217113 DOI: 10.1016/j.ejcsup.2013.07.032] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
430 Ogura A, Konishi T, Cunningham C, Garcia-Aguilar J, Iversen H, Toda S, Lee IK, Lee HX, Uehara K, Lee P, Putter H, van de Velde CJH, Beets GL, Rutten HJT, Kusters M; Lateral Node Study Consortium. Neoadjuvant (Chemo)radiotherapy With Total Mesorectal Excision Only Is Not Sufficient to Prevent Lateral Local Recurrence in Enlarged Nodes: Results of the Multicenter Lateral Node Study of Patients With Low cT3/4 Rectal Cancer. J Clin Oncol 2019;37:33-43. [PMID: 30403572 DOI: 10.1200/JCO.18.00032] [Cited by in Crossref: 110] [Cited by in F6Publishing: 51] [Article Influence: 27.5] [Reference Citation Analysis]
431 Saigusa S, Toiyama Y, Tanaka K, Inoue Y, Mori K, Ide S, Imaoka H, Kawamura M, Mohri Y, Kusunoki M. Prognostic relevance of stromal CD26 expression in rectal cancer after chemoradiotherapy. Int J Clin Oncol 2016;21:350-8. [PMID: 26370256 DOI: 10.1007/s10147-015-0902-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
432 Matsuda T, Sumi Y, Yamashita K, Hasegawa H, Yamamoto M, Matsuda Y, Kanaji S, Oshikiri T, Nakamura T, Suzuki S, Kakeji Y. Outcomes and prognostic factors of selective lateral pelvic lymph node dissection with preoperative chemoradiotherapy for locally advanced rectal cancer. Int J Colorectal Dis 2018;33:367-74. [PMID: 29442155 DOI: 10.1007/s00384-018-2974-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
433 Tang Z, Liu L, Liu D, Wu L, Lu K, Zhou N, Shen J, Chen G, Liu G. Clinical Outcomes and Safety of Different Treatment Modes for Local Recurrence of Rectal Cancer. Cancer Manag Res 2020;12:12277-86. [PMID: 33299348 DOI: 10.2147/CMAR.S278427] [Reference Citation Analysis]
434 Li ZY, Wang XD, Li M, Liu XJ, Ye Z, Song B, Yuan F, Yuan Y, Xia CC, Zhang X, Li Q. Multi-modal radiomics model to predict treatment response to neoadjuvant chemotherapy for locally advanced rectal cancer. World J Gastroenterol 2020; 26(19): 2388-2402 [PMID: 32476800 DOI: 10.3748/wjg.v26.i19.2388] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
435 Yao HW, Liu YH. Re-examination of the standardization of colon cancer surgery. Gastroenterol. 2013;Rep 1:113-118. [PMID: 24759816 DOI: 10.1093/gastro/got020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
436 Maas M, Nelemans PJ, Valentini V, Crane CH, Capirci C, Rödel C, Nash GM, Kuo LJ, Glynne-Jones R, García-Aguilar J, Suárez J, Calvo FA, Pucciarelli S, Biondo S, Theodoropoulos G, Lambregts DM, Beets-Tan RG, Beets GL. Adjuvant chemotherapy in rectal cancer: defining subgroups who may benefit after neoadjuvant chemoradiation and resection: a pooled analysis of 3,313 patients. Int J Cancer 2015;137:212-20. [PMID: 25418551 DOI: 10.1002/ijc.29355] [Cited by in Crossref: 66] [Cited by in F6Publishing: 62] [Article Influence: 8.3] [Reference Citation Analysis]
437 Šťastný M, Štengl V, Štenglová-Netíková I, Šrámová-Slušná M, Janoš P. Removal of anthracycline cytostatics from aquatic environment: Comparison of nanocrystalline titanium dioxide and decontamination agents. PLoS One 2019;14:e0223117. [PMID: 31603899 DOI: 10.1371/journal.pone.0223117] [Reference Citation Analysis]
438 Belluco C, Forlin M, Delrio P, Rega D, Degiuli M, Sofia S, Olivieri M, Pucciarelli S, Zuin M, De Manzoni G, Di Leo A, Scabini S, Zorcolo L, Restivo A. Elevated platelet count is a negative predictive and prognostic marker in locally advanced rectal cancer undergoing neoadjuvant chemoradiation: a retrospective multi-institutional study on 965 patients. BMC Cancer 2018;18:1094. [PMID: 30419864 DOI: 10.1186/s12885-018-5022-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
439 Levett DZ, Grocott MP. Cardiopulmonary exercise testing, prehabilitation, and Enhanced Recovery After Surgery (ERAS). Can J Anaesth 2015;62:131-42. [PMID: 25608638 DOI: 10.1007/s12630-014-0307-6] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 6.4] [Reference Citation Analysis]
440 Lopez-Lopez V, Abrisqueta J, Lujan J, Hernandez Q, Ono A, Parrilla P. Utility of rectoscopy in the assessment of response to neoadjuvant treatment for locally advanced rectal cancer. Saudi J Gastroenterol 2016;22:148-53. [PMID: 26997222 DOI: 10.4103/1319-3767.178526] [Reference Citation Analysis]
441 Chen YJ, Tsai TH, Wang LY, Hsieh CH. Local Radiotherapy Affects Drug Pharmacokinetics-Exploration of a Neglected but Significant Uncertainty of Cancer Therapy. Technol Cancer Res Treat 2017;16:705-16. [PMID: 29332468 DOI: 10.1177/1533034617737011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
442 Kim JG, Song KD, Cha DI, Kim HC, Yu JI. Indistinguishable T2/T3-N0 rectal cancer on rectal magnetic resonance imaging: comparison of surgery-first and neoadjuvant chemoradiation therapy-first strategies. Int J Colorectal Dis 2018;33:1359-66. [PMID: 30003363 DOI: 10.1007/s00384-018-3131-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
443 Cai X, Wu H, Peng J, Zhu J, Cai S, Cai G, Zhang Z. Tolerability and outcomes of radiotherapy or chemoradiotherapy for rectal cancer in elderly patients aged 70 years and older. Radiat Oncol 2013;8:86. [PMID: 23574985 DOI: 10.1186/1748-717X-8-86] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 3.1] [Reference Citation Analysis]
444 Sousa N, Sousa O, Santos LL, Henrique R, Teixeira MR, Dinis-Ribeiro M, Teixeira-Pinto A. Lapatinib-capecitabine versus capecitabine alone as radiosensitizers in RAS wild-type resectable rectal cancer, an adaptive randomized phase II trial (LaRRC trial): study protocol for a randomized controlled trial. Trials 2016;17:459. [PMID: 27655166 DOI: 10.1186/s13063-016-1583-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
445 Ju HE, Lee CS, Bae JH, Lee HJ, Yoon MR, Al-Sawat A, Lee DS, Lee IK, Lee YS, Song IH, Han SR. High incidence rate of late anastomosis leakage in patients for rectal cancer after neoadjuvant chemoradiotherapy: A comparative study. Asian J Surg 2021:S1015-9584(21)00702-8. [PMID: 34815142 DOI: 10.1016/j.asjsur.2021.10.039] [Reference Citation Analysis]
446 Dewdney A, Cunningham D, Chau I. Selecting patients with locally advanced rectal cancer for neoadjuvant treatment strategies. Oncologist. 2013;18:833-842. [PMID: 23821325 DOI: 10.1634/theoncologist.2013-0022] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
447 Letaief F, Nasri M, Ayadi M, Meddeb K, Mokrani A, Yahyaoui Y, Chraiet N, Raies H, Mezlini A. Potential predictive factors for pathologic complete response after the neoadjuvant treatment of rectal adenocarcinoma: a single center experience. Cancer Biol Med 2017;14:327-34. [PMID: 28884049 DOI: 10.20892/j.issn.2095-3941.2017.0037] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
448 Chitapanarux I, Chitapanarux T, Tharavichitkul E, Mayurasakorn S, Siriwittayakorn P, Yamada S, Lorvidhaya V. A phase II study of oxaliplatin with 5-FU/folinic acid and concomitant radiotherapy as a preoperative treatment in patients with locally advanced rectal cancer. Biomed Imaging Interv J 2011;7:e25. [PMID: 22279502 DOI: 10.2349/biij.7.4.e25] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
449 Watanabe T. Chemoradiotherapy and adjuvant chemotherapy for rectal cancer. Int J Clin Oncol. 2008;13:488-497. [PMID: 19093175 DOI: 10.1007/s10147-008-0849-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
450 Agarwal A, Chang GJ, Hu CY, Taggart M, Rashid A, Park IJ, You YN, Das P, Krishnan S, Crane CH, Rodriguez-Bigas M, Skibber J, Ellis L, Eng C, Kopetz S, Maru DM. Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy. Cancer 2013;119:4231-41. [PMID: 24089344 DOI: 10.1002/cncr.28331] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
451 Leroi N, Sounni NE, Van Overmeire E, Blacher S, Marée R, Van Ginderachter J, Lallemand F, Lenaerts E, Coucke P, Noel A, Martinive P. The timing of surgery after neoadjuvant radiotherapy influences tumor dissemination in a preclinical model. Oncotarget 2015;6:36825-37. [PMID: 26440148 DOI: 10.18632/oncotarget.5931] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
452 Fu XL, Fang Z, Shu LH, Tao GQ, Wang JQ, Rui ZL, Zhang YJ, Tian ZQ. Meta-analysis of oxaliplatin-based versus fluorouracil-based neoadjuvant chemoradiotherapy and adjuvant chemotherapy for locally advanced rectal cancer. Oncotarget 2017;8:34340-51. [PMID: 28423720 DOI: 10.18632/oncotarget.16127] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
453 Yu M, Jang HS, Jeon DM, Cheon GS, Lee HC, Chung MJ, Kim SH, Lee JH. Dosimetric evaluation of Tomotherapy and four-box field conformal radiotherapy in locally advanced rectal cancer. Radiat Oncol J 2013;31:252-9. [PMID: 24501715 DOI: 10.3857/roj.2013.31.4.252] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
454 Shen L, Sun Y, Zhang H, Zhang J, Deng W, Wang Y, Yao Y, Yang L, Zhu J, Tong T, Liang L, Zhang Z. T3 subclassification using the EMD/mesorectum ratio predicts neoadjuvant chemoradiation outcome in T3 rectal cancer patients. Br J Radiol 2018;91:20170617. [PMID: 29072488 DOI: 10.1259/bjr.20170617] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
455 Takemasa I, Hamabe A, Ishii M. Perspectives for circulating tumor DNA in clinical management of colorectal cancer. Int J Clin Oncol 2021;26:1420-30. [PMID: 34185174 DOI: 10.1007/s10147-021-01937-5] [Reference Citation Analysis]
456 Chadi SA, Berho M, Wexner SD. Surgeon perspectives on the use and effects of neoadjuvant chemoradiation in the treatment of rectal cancer: a comprehensive review of the literature. Langenbecks Arch Surg 2015;400:661-73. [PMID: 26250144 DOI: 10.1007/s00423-015-1328-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
457 Hacker U, Hallek M, Kubicka S. [Multimodality therapy of colorectal cancer]. Internist (Berl) 2010;51:1366-73. [PMID: 20967408 DOI: 10.1007/s00108-010-2671-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
458 Huang CM, Huang MY, Tsai HL, Huang CW, Ma CJ, Yeh YS, Juo SH, Huang CJ, Wang JY. An observational study of extending FOLFOX chemotherapy, lengthening the interval between radiotherapy and surgery, and enhancing pathological complete response rates in rectal cancer patients following preoperative chemoradiotherapy. Therap Adv Gastroenterol. 2016;9:702-712. [PMID: 27582883 DOI: 10.1177/1756283x16656690] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
459 Des Guetz G, Landre T, Bollet MA, Mathonnet M, Quéro L. Is There a Benefit of Oxaliplatin in Combination with Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer? An Updated Meta-Analysis. Cancers (Basel) 2021;13:6035. [PMID: 34885147 DOI: 10.3390/cancers13236035] [Reference Citation Analysis]
460 Hüttner FJ, Probst P, Kalkum E, Hackbusch M, Jensen K, Ulrich A, Büchler MW, Diener MK. Addition of platinum derivatives to neoadjuvant single-agent fluoropyrimidine chemoradiotherapy in patients with stage II/III rectal cancer: protocol for a systematic review and meta-analysis (PROSPERO CRD42017073064). Syst Rev 2018;7:11. [PMID: 29357929 DOI: 10.1186/s13643-018-0678-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
461 Kounalakis N, Gao D, Gonzalez R, Becker M, Lewis K, Poust J, Pearlman N, Robinson W, McCarter M. A neoadjuvant biochemotherapy approach to stage III melanoma: analysis of surgical outcomes. Immunotherapy 2012;4:679-86. [PMID: 22853754 DOI: 10.2217/imt.12.62] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
462 Roelands J, Kuppen PJK, Vermeulen L, Maccalli C, Decock J, Wang E, Marincola FM, Bedognetti D, Hendrickx W. Immunogenomic Classification of Colorectal Cancer and Therapeutic Implications. Int J Mol Sci 2017;18:E2229. [PMID: 29064420 DOI: 10.3390/ijms18102229] [Cited by in Crossref: 60] [Cited by in F6Publishing: 60] [Article Influence: 12.0] [Reference Citation Analysis]
463 Sutera P, Solomina J, Wegner RE, Abel S, Monga D, Finley G, McCormick J, Kirichenko AV. Post-Operative Morbidity and Mortality Following Total Neoadjuvant Therapy Versus Conventional Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. J Gastrointest Cancer 2021;52:976-82. [PMID: 32936391 DOI: 10.1007/s12029-020-00401-3] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
464 Gao P, Song YX, Sun JX, Chen XW, Xu YY, Zhao JH, Huang XZ, Xu HM, Wang ZN. Which is the best postoperative chemotherapy regimen in patients with rectal cancer after neoadjuvant therapy? BMC Cancer. 2014;14:888. [PMID: 25428401 DOI: 10.1186/1471-2407-14-888] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
465 Lee H, Kong JS, Lee SS, Kim A. Radiation-Induced Overexpression of TGFβ and PODXL Contributes to Colorectal Cancer Cell Radioresistance through Enhanced Motility. Cells 2021;10:2087. [PMID: 34440856 DOI: 10.3390/cells10082087] [Reference Citation Analysis]
466 Empuku S, Nakajima K, Akagi T, Kaneko K, Hijiya N, Etoh T, Shiraishi N, Moriyama M, Inomata M. An 80-gene set to predict response to preoperative chemoradiotherapy for rectal cancer by principle component analysis. Mol Clin Oncol 2016;4:733-9. [PMID: 27123272 DOI: 10.3892/mco.2016.806] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
467 Aghili M, Khalili N, Khalili N, Babaei M, Farhan F, Haddad P, Salarvand S, Keshvari A, Fazeli MS, Mohammadi N, Ghalehtaki R. Short-course versus long-course neoadjuvant chemoradiotherapy in patients with rectal cancer: preliminary results of a randomized controlled trial. Radiat Oncol J 2020;38:119-28. [PMID: 33012155 DOI: 10.3857/roj.2020.00115] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
468 Rivero M, Peinado-Serrano J, Muñoz-Galvan S, Espinosa-Sánchez A, Suarez-Martinez E, Felipe-Abrio B, Fernández-Fernández MC, Ortiz MJ, Carnero A. MAP17 (PDZK1IP1) and pH2AX are potential predictive biomarkers for rectal cancer treatment efficacy. Oncotarget 2018;9:32958-71. [PMID: 30250642 DOI: 10.18632/oncotarget.26010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
469 Pointreau Y, Hennequin C. [SFRO 2010: congress highlights]. Cancer Radiother 2011;15:1-6. [PMID: 21513891 DOI: 10.1016/S1278-3218(11)70001-4] [Reference Citation Analysis]
470 Sugano H, Shirai Y, Horiuchi T, Saito N, Shimada Y, Eto K, Uwagawa T, Ohashi T, Yanaga K. Nafamostat Mesilate Enhances the Radiosensitivity and Reduces the Radiation-Induced Invasive Ability of Colorectal Cancer Cells. Cancers (Basel) 2018;10:E386. [PMID: 30336548 DOI: 10.3390/cancers10100386] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
471 Ishikawa D, Nishi M, Takasu C, Kashihara H, Tokunaga T, Higashijima J, Yoshikawa K, Shimada M. The Role of Neutrophil-to-lymphocyte Ratio on the Effect of CRT for Patients With Rectal Cancer. In Vivo 2020;34:863-8. [PMID: 32111796 DOI: 10.21873/invivo.11850] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
472 Wolf M, Zehentmayr F, Belka C. [Radiotherapy of rectal cancer]. Radiologe 2012;52:545-9. [PMID: 22618627 DOI: 10.1007/s00117-011-2286-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
473 Yang YC, Chiang CS. Challenges of Using High-Dose Fractionation Radiotherapy in Combination Therapy. Front Oncol 2016;6:165. [PMID: 27446811 DOI: 10.3389/fonc.2016.00165] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
474 Xynos E, Tekkis P, Gouvas N, Vini L, Chrysou E, Tzardi M, Vassiliou V, Boukovinas I, Agalianos C, Androulakis N, Athanasiadis A, Christodoulou C, Dervenis C, Emmanouilidis C, Georgiou P, Katopodi O, Kountourakis P, Makatsoris T, Papakostas P, Papamichael D, Pechlivanides G, Pentheroudakis G, Pilpilidis I, Sgouros J, Triantopoulou C, Xynogalos S, Karachaliou N, Ziras N, Zoras O, Souglakos J; [the Executive Team on behalf of the Hellenic Society of Medical Oncologists (HeSMO)]. Clinical practice guidelines for the surgical treatment of rectal cancer: a consensus statement of the Hellenic Society of Medical Oncologists (HeSMO). Ann Gastroenterol 2016;29:103-26. [PMID: 27064746 DOI: 10.20524/aog.2016.0003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
475 Yeom SS, Park IJ, Yang DH, Lee JL, Yoon YS, Kim CW, Lim SB, Park SH, Kim HJ, Yu CS, Kim JC. Variation in the Height of Rectal Cancers According to the Diagnostic Modalities. Ann Coloproctol 2019;35:24-9. [PMID: 30879281 DOI: 10.3393/ac.2018.07.31] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
476 Hanna CR, Slevin F, Appelt A, Beavon M, Adams R, Arthur C, Beasley M, Duffton A, Gilbert A, Gollins S, Harrison M, Hawkins MA, Laws K, O'Cathail S, Porcu P, Robinson M, Sebag-Montefiore D, Teo M, Teoh S, Muirhead R. Intensity-modulated Radiotherapy for Rectal Cancer in the UK in 2020. Clin Oncol (R Coll Radiol) 2021;33:214-23. [PMID: 33423883 DOI: 10.1016/j.clon.2020.12.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
477 Calvo FA, Rivas F, Sole CV, Gómez-Espí M, Herranz R, Del Valle E, Rodríguez M, Alvarez E. Post-chemoradiation anastomotic recurrence in locally advanced rectal cancer: no increased risk associated with distal margin. Clin Transl Oncol 2014;16:573-80. [PMID: 24129427 DOI: 10.1007/s12094-013-1119-9] [Reference Citation Analysis]
478 Akgun E, Ozkok S, Tekin M, Yoldas T, Caliskan C, Kose T, Karabulut B, Sezak M, Elmas N, Ozutemiz O. The effects of chemoradiotherapy on recurrence and survival in locally advanced rectal cancers with curative total mesorectal excision: a prospective, nonrandomized study. World J Surg Oncol 2017;15:205. [PMID: 29166925 DOI: 10.1186/s12957-017-1275-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
479 Gunnlaugsson A, Nilsson P, Kjellén E, Johnsson A. The effect on the small bowel of 5-FU and oxaliplatin in combination with radiation using a microcolony survival assay. Radiat Oncol 2009;4:61. [PMID: 20003187 DOI: 10.1186/1748-717X-4-61] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
480 McCoy MJ, Hemmings C, Miller TJ, Austin SJ, Bulsara MK, Zeps N, Nowak AK, Lake RA, Platell CF. Low stromal Foxp3+ regulatory T-cell density is associated with complete response to neoadjuvant chemoradiotherapy in rectal cancer. Br J Cancer 2015;113:1677-86. [PMID: 26645238 DOI: 10.1038/bjc.2015.427] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 5.9] [Reference Citation Analysis]
481 Kawamoto A, Tanaka K, Saigusa S, Toiyama Y, Morimoto Y, Fujikawa H, Iwata T, Matsushita K, Yokoe T, Yasuda H. Clinical significance of radiation-induced CD133 expression in residual rectal cancer cells after chemoradiotherapy. Exp Ther Med. 2012;3:403-409. [PMID: 22969903 DOI: 10.3892/etm.2011.438] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
482 Punt CJ, Koopman M, Vermeulen L. From tumour heterogeneity to advances in precision treatment of colorectal cancer. Nat Rev Clin Oncol. 2017;14:235-246. [PMID: 27922044 DOI: 10.1038/nrclinonc.2016.171] [Cited by in Crossref: 239] [Cited by in F6Publishing: 236] [Article Influence: 39.8] [Reference Citation Analysis]
483 Guo S, Reddy CA, Kolar M, Woody N, Mahadevan A, Deibel FC, Dietz DW, Remzi FH, Suh JH. Intraoperative radiation therapy with the photon radiosurgery system in locally advanced and recurrent rectal cancer: retrospective review of the Cleveland clinic experience. Radiat Oncol. 2012;7:110. [PMID: 22817880 DOI: 10.1186/1748-717x-7-110] [Cited by in Crossref: 30] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
484 Avallone A, Piccirillo MC, Delrio P, Pecori B, Di Gennaro E, Aloj L, Tatangelo F, D'Angelo V, Granata C, Cavalcanti E, Maurea N, Maiolino P, Bianco F, Montano M, Silvestro L, Terranova Barberio M, Roca MS, Di Maio M, Marone P, Botti G, Petrillo A, Daniele G, Lastoria S, Iaffaioli VR, Romano G, Caracò C, Muto P, Gallo C, Perrone F, Budillon A. Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid--short Radiotherapy--rectum 3rd trial). BMC Cancer 2014;14:875. [PMID: 25421252 DOI: 10.1186/1471-2407-14-875] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
485 Roxburgh CS, Weiser MR. Selective use of radiation for locally advanced rectal cancer: one size does not fit all. Minerva Chir 2018;73:592-600. [PMID: 29806758 DOI: 10.23736/S0026-4733.18.07791-X] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
486 Qiu B, Ding PR, Cai L, Xiao WW, Zeng ZF, Chen G, Lu ZH, Li LR, Wu XJ, Mirimanoff RO, Pan ZZ, Xu RH, Gao YH. Outcomes of preoperative chemoradiotherapy followed by surgery in patients with unresectable locally advanced sigmoid colon cancer. Chin J Cancer. 2016;35:65. [PMID: 27389519 DOI: 10.1186/s40880-016-0126-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
487 Lin SC, Chen PC, Lee CT, Tsai HM, Lin PC, Chen HH, Wu YH, Lin BW, Su WP, Lee JC. Routine defunctioning stoma after chemoradiation and total mesorectal excision: A single-surgeon experience. World J Gastroenterol 2013; 19(11): 1797-1804 [PMID: 23555168 DOI: 10.3748/wjg.v19.i11.1797] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
488 de Leve S, Wirsdörfer F, Jendrossek V. Targeting the Immunomodulatory CD73/Adenosine System to Improve the Therapeutic Gain of Radiotherapy. Front Immunol 2019;10:698. [PMID: 31024543 DOI: 10.3389/fimmu.2019.00698] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
489 Hernandez JM, Clark W, Weber J, Fulp WJ, Lange L, Shibata D. The impact of pathologic nodal status on survival following neoadjuvant chemoradiation for locally advanced rectal cancer. Int J Colorectal Dis 2014;29:1061-8. [PMID: 24970021 DOI: 10.1007/s00384-014-1917-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
490 Appelt AL, Pløen J, Vogelius IR, Bentzen SM, Jakobsen A. Radiation dose-response model for locally advanced rectal cancer after preoperative chemoradiation therapy. Int J Radiat Oncol Biol Phys 2013;85:74-80. [PMID: 22763027 DOI: 10.1016/j.ijrobp.2012.05.017] [Cited by in Crossref: 141] [Cited by in F6Publishing: 118] [Article Influence: 14.1] [Reference Citation Analysis]
491 Williamson JS, Jones HG, Williams N, Griffiths AP, Jenkins G, Beynon J, Harris DA. Extramural vascular invasion and response to neoadjuvant chemoradiotherapy in rectal cancer: Influence of the CpG island methylator phenotype. World J Gastrointest Oncol 2017; 9(5): 209-217 [PMID: 28567185 DOI: 10.4251/wjgo.v9.i5.209] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
492 Schmidt B, Lee HJ, Ryeom S, Yoon SS. Combining Bevacizumab with Radiation or Chemoradiation for Solid Tumors: A Review of the Scientific Rationale, and Clinical Trials. Curr Angiogenes 2012;1:169-79. [PMID: 24977113 DOI: 10.2174/2211552811201030169] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
493 Krishnamurthi SS, Seo Y, Kinsella TJ. Adjuvant therapy for rectal cancer. Clin Colon Rectal Surg 2007;20:167-81. [PMID: 20011198 DOI: 10.1055/s-2007-984861] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
494 Fernández-Martos C, Nogué M, Cejas P, Moreno-García V, Machancoses AH, Feliu J. The role of capecitabine in locally advanced rectal cancer treatment: an update. Drugs. 2012;72:1057-1073. [PMID: 22621694 DOI: 10.2165/11633870-000000000-00000] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
495 Viganò L. Treatment strategy for colorectal cancer with resectable synchronous liver metastases: Is any evidence-based strategy possible? World J Hepatol 2012; 4(8): 237-241 [PMID: 22993665 DOI: 10.4254/wjh.v4.i8.237] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
496 Latkauskas T, Pauzas H, Kairevice L, Petrauskas A, Saladzinskas Z, Janciauskiene R, Gudaityte J, Lizdenis P, Svagzdys S, Tamelis A, Pavalkis D. Preoperative conventional chemoradiotherapy vs short-course radiotherapy with delayed surgery for rectal cancer: results of a randomized controlled trial. BMC Cancer. 2016;16:927. [PMID: 27903247 DOI: 10.1186/s12885-016-2959-9] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
497 Dong D, Zhang J, Zhang R, Li F, Li Y, Jia Y. Multiprobe Assay for Clinical SEPT9 Methylation Based on the Carbon Dot-Modified Liquid-Exfoliated Graphene Field Effect Transistor with a Potential to Present a Methylation Panorama. ACS Omega 2020;5:16228-37. [PMID: 32656445 DOI: 10.1021/acsomega.0c02022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
498 Contin P, Kulu Y, Bruckner T, Sturm M, Welsch T, Müller-stich BP, Huber J, Büchler MW, Ulrich A. Comparative analysis of late functional outcome following preoperative radiation therapy or chemoradiotherapy and surgery or surgery alone in rectal cancer. Int J Colorectal Dis 2014;29:165-75. [DOI: 10.1007/s00384-013-1780-z] [Cited by in Crossref: 56] [Cited by in F6Publishing: 41] [Article Influence: 6.2] [Reference Citation Analysis]
499 Ferrari L, Fichera A. Neoadjuvant chemoradiation therapy and pathological complete response in rectal cancer.Gastroenterol Rep (Oxf). 2015;3:277-288. [PMID: 26290512 DOI: 10.1093/gastro/gov039] [Cited by in Crossref: 7] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
500 Oki E, Murata A, Yoshida K, Maeda K, Ikejiri K, Munemoto Y, Sasaki K, Matsuda C, Kotake M, Suenaga T, Matsuda H, Emi Y, Kakeji Y, Baba H, Hamada C, Saji S, Maehara Y. A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC). Ann Oncol 2016;27:1266-72. [PMID: 27056996 DOI: 10.1093/annonc/mdw162] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
501 Hiraki M, Tanaka T, Hiraki Y, Watanabe T, Sato H, Aibe H, Kitahara K. Short-term outcomes of preoperative chemoradiotherapy with S-1 for locally advanced rectal cancer. Mol Clin Oncol 2021;14:4. [PMID: 33235732 DOI: 10.3892/mco.2020.2166] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
502 Glimelius B. Adjuvant chemotherapy. Eur J Cancer Suppl. 2013;11:72-79. [PMID: 26217115 DOI: 10.1016/j.ejcsup.2013.07.034] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
503 Miki Y, Maeda K, Hosono M, Nagahara H, Hirakawa K, Shimatani Y, Tsutsumi S, Miki Y. Neoadjuvant capecitabine, bevacizumab and radiotherapy for locally advanced rectal cancer: results of a single-institute Phase I study. J Radiat Res 2014;55:1171-7. [PMID: 25129557 DOI: 10.1093/jrr/rru063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
504 Ozgen Z, Ozden S, Atasoy BM, Ozyurt H, Gencosmanoglu R, Imeryuz N. Long-term effects of neoadjuvant chemoradiotherapy followed by sphincter-preserving resection on anal sphincter function in relation to quality of life among locally advanced rectal cancer patients: a cross-sectional analysis. Radiat Oncol 2015;10:168. [PMID: 26264590 DOI: 10.1186/s13014-015-0479-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
505 Li S, Gong Y, Yang Y, Guo Q, Qian J, Tian Y. Evaluation of small bowel motion and feasibility of using the peritoneal space to replace bowel loops for dose constraints during intensity-modulated radiotherapy for rectal cancer. Radiat Oncol 2020;15:211. [PMID: 32873308 DOI: 10.1186/s13014-020-01650-z] [Reference Citation Analysis]
506 Uehara K, Nagino M. Neoadjuvant treatment for locally advanced rectal cancer: a systematic review. Surg Today 2016;46:161-8. [PMID: 26170102 DOI: 10.1007/s00595-015-1218-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
507 O'Cathail SM, Davis S, Holmes J, Brown R, Fisher K, Seymour L, Adams R, Good J, Sebag-Montefiore D, Maughan T, Hawkins MA. A phase 1 trial of the safety, tolerability and biological effects of intravenous Enadenotucirev, a novel oncolytic virus, in combination with chemoradiotherapy in locally advanced rectal cancer (CEDAR). Radiat Oncol 2020;15:151. [PMID: 32532291 DOI: 10.1186/s13014-020-01593-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
508 Jankarashvili N, Kakhadze S, Topeshashvili M, Turkiasvili L, Tchiabrishvili M. Neoadjuvant volumetric modulated arc radiochemotherapy with a simultaneous integrated boost technique compared to standard chemoradiation for locally advanced rectal cancer. Turk J Med Sci 2019;49:1484-9. [PMID: 31651118 DOI: 10.3906/sag-1812-185] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
509 Kim DD, Eng C. The current state of targeted agents in rectal cancer. Int J Surg Oncol 2012;2012:406830. [PMID: 22675625 DOI: 10.1155/2012/406830] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
510 Kawai K, Kitayama J, Tsuno NH, Sunami E, Nagawa H. Hyperfibrinogenemia after preoperative chemoradiotherapy predicts poor response and poor prognosis in rectal cancer. Int J Colorectal Dis. 2011;26:45-51. [PMID: 20809424 DOI: 10.1007/s00384-010-1054-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
511 Wang S, Wen F, Zhang P, Wang X, Li Q. Cost-effectiveness analysis of long-course oxaliplatin and bolus of fluorouracil based preoperative chemoradiotherapy vs. 5x5Gy radiation plus FOLFOX4 for locally advanced resectable rectal cancer. Radiat Oncol 2019;14:113. [PMID: 31234886 DOI: 10.1186/s13014-019-1319-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
512 Conradi LC, Bleckmann A, Schirmer M, Sprenger T, Jo P, Homayounfar K, Wolff HA, Rothe H, Middel P, Becker H, Ghadimi MB, Beissbarth T, Liersch T. Thymidylate synthase as a prognostic biomarker for locally advanced rectal cancer after multimodal treatment. Ann Surg Oncol 2011;18:2442-52. [PMID: 21347782 DOI: 10.1245/s10434-011-1608-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
513 Glynne-Jones R, Kronfli M. Locally advanced rectal cancer: a comparison of management strategies. Drugs. 2011;71:1153-1177. [PMID: 21711061 DOI: 10.2165/11591330-000000000-00000] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
514 Xie L, Shen L, Zhu J. Short-course radiotherapy with delayed surgery for rectal cancer. Lancet Oncol 2017;18:e294. [PMID: 28593849 DOI: 10.1016/S1470-2045(17)30329-7] [Reference Citation Analysis]
515 Kim CW, Kang BM, Kim IY, Kim JY, Park SJ, Park WC, Bae KB, Bae BN, Baek SK, Baik SH, Son GM, Lee YS, Lee SH. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE). BMC Cancer 2018;18:538. [PMID: 29739356 DOI: 10.1186/s12885-018-4466-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
516 Bruera G, Di Staso M, Bonfili P, Galvano A, Manetta R, Coletti G, Vicentini R, Guadagni S, Ficorella C, Di Cesare E, Russo A, Ricevuto E. Dose-finding study of oxaliplatin associated to capecitabine-based preoperative chemoradiotherapy in locally advanced rectal cancer. Oncotarget 2018;9:17906-14. [PMID: 29707156 DOI: 10.18632/oncotarget.24665] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
517 Zlobec I, Baker K, Terracciano L, Peter S, Degen L, Beglinger C, Lugli A. Two-marker protein profile predicts poor prognosis in patients with early rectal cancer. Br J Cancer 2008;99:1712-7. [PMID: 18985041 DOI: 10.1038/sj.bjc.6604729] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
518 Li J, Liu Y, Wang JW, Gao Y, Hu YT, He JJ, Yu XY, Hu HG, Yuan Y, Zhang SZ, Ding KF. Oxaliplatin-based adjuvant chemotherapy without radiotherapy can improve the survival of locally-advanced rectal cancer. PLoS One 2014;9:e107872. [PMID: 25243406 DOI: 10.1371/journal.pone.0107872] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
519 Sato K, Morohashi H, Tsushima F, Sakamoto Y, Miura T, Fujita H, Umemura K, Suzuki T, Tsuruta S, Kura R, Ono S, Aoki M, Hakamada K. Dual energy CT is useful for the prediction of mesenteric and lateral pelvic lymph node metastasis in rectal cancer. Mol Clin Oncol 2019;10:625-30. [PMID: 31031979 DOI: 10.3892/mco.2019.1834] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
520 Langrand-Escure J, Diao P, Garcia MA, Wang G, Guy JB, Espenel S, Guillaume E, Rehailia-Blanchard A, Pigné G, de Laroche G, Kaczmarek D, Muron T, Porcheron J, Phelip JM, Vallard A, Magné N. Outcome and prognostic factors in 593 non-metastatic rectal cancer patients: a mono-institutional survey. Sci Rep 2018;8:10708. [PMID: 30013090 DOI: 10.1038/s41598-018-29040-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
521 Kawada K, Sakai Y. Preoperative, intraoperative and postoperative risk factors for anastomotic leakage after laparoscopic low anterior resection with double stapling technique anastomosis. World J Gastroenterol 2016; 22(25): 5718-5727 [PMID: 27433085 DOI: 10.3748/wjg.v22.i25.5718] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 34] [Article Influence: 7.3] [Reference Citation Analysis]
522 Mokarram P, Albokashy M, Zarghooni M, Moosavi MA, Sepehri Z, Chen QM, Hudecki A, Sargazi A, Alizadeh J, Moghadam AR, Hashemi M, Movassagh H, Klonisch T, Owji AA, Łos MJ, Ghavami S. New frontiers in the treatment of colorectal cancer: Autophagy and the unfolded protein response as promising targets. Autophagy 2017;13:781-819. [PMID: 28358273 DOI: 10.1080/15548627.2017.1290751] [Cited by in Crossref: 75] [Cited by in F6Publishing: 79] [Article Influence: 15.0] [Reference Citation Analysis]
523 Allemani C, Rachet B, Weir HK, Richardson LC, Lepage C, Faivre J, Gatta G, Capocaccia R, Sant M, Baili P. Colorectal cancer survival in the USA and Europe: a CONCORD high-resolution study. BMJ Open. 2013;3:e003055. [PMID: 24022388 DOI: 10.1136/bmjopen-2013-003055] [Cited by in Crossref: 54] [Cited by in F6Publishing: 45] [Article Influence: 6.0] [Reference Citation Analysis]
524 Spatola C, Privitera G, Milazzotto R, Tocco A, Acquaviva G, Marletta F, Marino L, Di Grazia A, Salvo R, Cartia G, Platania A, Molino L, Santacaterina A, Mattace Raso M, Frosina P, Ianni R, Bono M, Liardo L, Bonanno S, La Paglia L, Federico M, Fazio I, Mortellaro G, Ferrera G, Tripoli A, Evangelista G, Daidone A, Biti G, Badalamenti M, Ognibene L, Cacciola A, Parisi S, Pergolizzi S. Trends in combined radio-chemotherapy for locally advanced rectal cancer: a survey among radiation oncology centers of Sicily region on behalf of AIRO. Radiol Med 2019;124:671-81. [PMID: 30806918 DOI: 10.1007/s11547-019-01007-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
525 Boldrini L, Cusumano D, Chiloiro G, Casà C, Masciocchi C, Lenkowicz J, Cellini F, Dinapoli N, Azario L, Teodoli S, Gambacorta MA, De Spirito M, Valentini V. Delta radiomics for rectal cancer response prediction with hybrid 0.35 T magnetic resonance-guided radiotherapy (MRgRT): a hypothesis-generating study for an innovative personalized medicine approach. Radiol Med 2019;124:145-53. [PMID: 30374650 DOI: 10.1007/s11547-018-0951-y] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 10.5] [Reference Citation Analysis]
526 Sun PL, Li B, Ye QF. Effect of neoadjuvant cetuximab, capecitabine, and radiotherapy for locally advanced rectal cancer: results of a phase II study. Int J Colorectal Dis 2012;27:1325-32. [PMID: 22430888 DOI: 10.1007/s00384-012-1446-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
527 Farhat W, Azzaza M, Mizouni A, Ammar H, Ben Ltaifa M, Lagha S, Kahloul M, Gupta R, Mabrouk MB, Ali AB. Factors predicting recurrence after curative resection for rectal cancer: a 16-year study. World J Surg Oncol 2019;17:173. [PMID: 31660992 DOI: 10.1186/s12957-019-1718-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
528 Chen M, Chen LZ, Xu L, Zhang JS, Song X. Neoadjuvant chemoradiation for locally advanced rectal cancer: a systematic review of the literature with network meta-analysis. Cancer Manag Res 2019;11:741-58. [PMID: 30697067 DOI: 10.2147/CMAR.S189445] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
529 Finlay I. Preoperative staging for rectal cancer. BMJ 2006;333:766-7. [PMID: 17038713 DOI: 10.1136/bmj.38996.423102.BE] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
530 Bergquist JR, Thiels CA, Shubert CR, Habermann EB, Hayman AV, Zielinski MD, Mathis KL. Is Chemotherapy or Radiation Therapy in Addition to Surgery Beneficial for Locally Advanced Rectal Cancer in the Elderly? A National Cancer Data Base (NCDB) Study. World J Surg 2016;40:447-55. [PMID: 26566779 DOI: 10.1007/s00268-015-3319-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
531 Ahn DH, Wu C, Wei L, Williams TM, Wuthrick E, Abdel-Misih S, Harzman A, Husain S, Schmidt C, Goldberg RM, Bekaii-Saab T. The Efficacy of Adjuvant Chemotherapy in Patients With Stage II/III Resected Rectal Cancer Treated With Neoadjuvant Chemoradiation Therapy. Am J Clin Oncol 2017;40:531-4. [PMID: 25723741 DOI: 10.1097/COC.0000000000000185] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
532 Thomusch O, Ruf G. Manuscript 'close shave' margins do not increase rectal cancer recurrence after sphincter-saving surgery without neoadjuvant therapy by Lim et al. Int J Colorectal Dis 2012;27:1691-2. [PMID: 23011544 DOI: 10.1007/s00384-012-1529-0] [Reference Citation Analysis]
533 Petersen SH, Harling H, Kirkeby LT, Wille-Jørgensen P, Mocellin S. Postoperative adjuvant chemotherapy in rectal cancer operated for cure. Cochrane Database Syst Rev. 2012;CD004078. [PMID: 22419291 DOI: 10.1002/14651858.cd004078.pub2] [Cited by in Crossref: 48] [Cited by in F6Publishing: 71] [Article Influence: 4.8] [Reference Citation Analysis]
534 Ceelen WP. Progress in rectal cancer treatment. ISRN Gastroenterol 2012;2012:648183. [PMID: 22970381 DOI: 10.5402/2012/648183] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
535 Kim CH, Yeom SS, Lee SY, Kim HR, Kim YJ, Lee KH, Lee JH. Prognostic Impact of Perineural Invasion in Rectal Cancer After Neoadjuvant Chemoradiotherapy. World J Surg. 2019;43:260-272. [PMID: 30151676 DOI: 10.1007/s00268-018-4774-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
536 Okugawa Y, Toiyama Y, Fujikawa H, Ide S, Yamamoto A, Omura Y, Yin C, Kusunoki K, Kusunoki Y, Yasuda H, Yokoe T, Hiro J, Ohi M, Kusunoki M. Prognostic Potential of Lymphocyte-C-Reactive Protein Ratio in Patients with Rectal Cancer Receiving Preoperative Chemoradiotherapy. J Gastrointest Surg 2021;25:492-502. [PMID: 32040814 DOI: 10.1007/s11605-019-04495-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
537 Cuneo KC, Mehta RK, Kurapati H, Thomas DG, Lawrence TS, Nyati MK. Enhancing the Radiation Response in KRAS Mutant Colorectal Cancers Using the c-Met Inhibitor Crizotinib. Transl Oncol 2019;12:209-16. [PMID: 30412912 DOI: 10.1016/j.tranon.2018.10.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
538 Sato H, Shimada M, Kurita N, Iwata T, Yoshikawa K, Higashigima J, Chikakio M, Kashihara H, Takasu C, Matsumoto N, Eto S. Phase I trial of neoadjuvant preoperative chemotherapy with S-1, oxaliplatin, and bevacizumab plus radiation in patients with locally advanced rectal cancer. Int J Clin Oncol 2015;20:543-8. [PMID: 25080061 DOI: 10.1007/s10147-014-0733-z] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
539 Park IJ, Kim JY, Yu CS, Lee JS, Lim SB, Lee JL, Yoon YS, Kim CW, Kim JC. Preoperative chemoradiotherapy for clinically diagnosed T3N0 rectal cancer. Surg Today 2016;46:90-6. [PMID: 25712223 DOI: 10.1007/s00595-015-1136-0] [Cited by in Crossref: 4] [Article Influence: 0.6] [Reference Citation Analysis]
540 Xue Z, Yang S, Luo Y, Cai H, He M, Ding Y, Lei L, Peng W, Hong G, Guo Y. A 41-Gene Pair Signature for Predicting the Pathological Response of Locally Advanced Rectal Cancer to Neoadjuvant Chemoradiation. Front Med (Lausanne) 2021;8:744295. [PMID: 34595195 DOI: 10.3389/fmed.2021.744295] [Reference Citation Analysis]
541 Ikeda M, Sekimoto M, Fukunaga Y, Konishi K, Fujiwara Y, Mizushima T, Takemasa I, Yamamoto H, Doki Y, Mori M. A phase I study of oral UFT/leucovorin and irinotecan, plus radiation for locally recurrent rectal cancer. J Anus Rectum Colon 2017;1:50-5. [PMID: 31583301 DOI: 10.23922/jarc.2016-009] [Reference Citation Analysis]
542 Peca S, Sinha RS, Brown DW, Smith WL. In vivo Portal Imaging Dosimetry Identifies Delivery Errors in Rectal Cancer Radiotherapy on the Belly Board Device. Technol Cancer Res Treat 2017;16:956-63. [PMID: 28585490 DOI: 10.1177/1533034617711519] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
543 Deorukhkar A, Ahuja N, Mercado AL, Diagaradjane P, Raju U, Patel N, Mohindra P, Diep N, Guha S, Krishnan S. Zerumbone increases oxidative stress in a thiol-dependent ROS-independent manner to increase DNA damage and sensitize colorectal cancer cells to radiation. Cancer Med 2015;4:278-92. [PMID: 25450478 DOI: 10.1002/cam4.367] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
544 Sun W, Li G, Wan J, Zhu J, Shen W, Zhang Z. Circulating tumor cells: A promising marker of predicting tumor response in rectal cancer patients receiving neoadjuvant chemo-radiation therapy. Oncotarget 2016;7:69507-17. [PMID: 27486758 DOI: 10.18632/oncotarget.10875] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
545 Rosenberg R, Herrmann K, Gertler R, Künzli B, Essler M, Lordick F, Becker K, Schuster T, Geinitz H, Maak M. The predictive value of metabolic response to preoperative radiochemotherapy in locally advanced rectal cancer measured by PET/CT. Int J Colorectal Dis. 2009;24:191-200. [PMID: 19050900 DOI: 10.1007/s00384-008-0616-8] [Cited by in Crossref: 64] [Cited by in F6Publishing: 67] [Article Influence: 4.6] [Reference Citation Analysis]
546 Brown LC, Atherton PJ, Neben-Wittich MA, Wender DB, Behrens RJ, Kozelsky TF, Loprinzi CL, Haddock MG, Martenson JA. Assessment of long-term rectal function in patients who received pelvic radiotherapy: a pooled North Central Cancer Treatment Group trial analysis, N09C1. Support Care Cancer 2013;21:2869-77. [PMID: 23748483 DOI: 10.1007/s00520-013-1853-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
547 Trakarnsanga A, Ithimakin S, Weiser MR. Treatment of locally advanced rectal cancer: Controversies and questions. World J Gastroenterol 2012; 18(39): 5521-5532 [PMID: 23112544 DOI: 10.3748/wjg.v18.i39.5521] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
548 Bökkerink GMJ, van der Wilt GJ, de Jong D, van Krieken HHJM, Bleichrodt RP, de Wilt JHW, Bremers AJA. Value of macrobiopsies and transanal endoscopic microsurgery in the histological work-up of rectal neoplasms: A retrospective study. World J Gastrointest Oncol 2017; 9(6): 251-256 [PMID: 28656075 DOI: 10.4251/wjgo.v9.i6.251] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
549 Chablani P, Nguyen P, Pan X, Robinson A, Walston S, Wu C, Frankel WL, Chen W, Bekaii-Saab T, Chakravarti A, Wuthrick E, Williams TM. Perineural Invasion Predicts for Distant Metastasis in Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiation and Surgery. Am J Clin Oncol 2017;40:561-8. [PMID: 26703815 DOI: 10.1097/COC.0000000000000214] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
550 Sung S, Son SH, Kay CS, Lee YS. Prognosis Can Be Predicted More Accurately Using Pre- and Postchemoradiotherapy Carcinoembryonic Antigen Levels Compared to Only Prechemoradiotherapy Carcinoembryonic Antigen Level in Locally Advanced Rectal Cancer Patients Who Received Neoadjuvant Chemoradiotherapy. Medicine (Baltimore) 2016;95:e2965. [PMID: 26962798 DOI: 10.1097/MD.0000000000002965] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
551 Akiyoshi T, Kobunai T, Watanabe T. Predicting the response to preoperative radiation or chemoradiation by a microarray analysis of the gene expression profiles in rectal cancer. Surg Today. 2012;42:713-719. [PMID: 22706722 DOI: 10.1007/s00595-012-0223-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
552 Myint AS. Novel radiation techniques for rectal cancer. J Gastrointest Oncol. 2014;5:212-217. [PMID: 24982769 DOI: 10.3978/j.issn.2078-6891.2014.031] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
553 Salazar R, Capdevila J, Manzano JL, Pericay C, Martínez-Villacampa M, López C, Losa F, Safont MJ, Gómez-España A, Alonso-Orduña V, Escudero P, Gallego J, García-Paredes B, Palacios A, Biondo S, Grávalos C, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD). Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long term results. BMC Cancer 2020;20:1164. [PMID: 33246428 DOI: 10.1186/s12885-020-07661-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
554 Alsaad R, Fang SH. The Evolution of Multimodality Treatment of Rectal Cancer. JAMA Surg 2021. [PMID: 34586337 DOI: 10.1001/jamasurg.2021.4567] [Reference Citation Analysis]
555 Yan H, Yu J, Wang R, Jiang S, Zhu K, Mu D, Xu Z. Prognostic value of Smac expression in rectal cancer patients treated with neoadjuvant therapy. Med Oncol. 2012;29:168-173. [PMID: 21264534 DOI: 10.1007/s12032-011-9819-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
556 Bellows CF, Jaffe B, Bacigalupo L, Pucciarelli S, Gagliardi G. Clinical significance of magnetic resonance imaging findings in rectal cancer. World J Radiol 2011; 3(4): 92-104 [PMID: 21532870 DOI: 10.4329/wjr.v3.i4.92] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
557 But-Hadzic J, Boltezar AM, Skerl T, Zadnik V, Velenik V. Preoperative intensity-modulated chemoradiotherapy with simultaneous integrated boost in rectal cancer: five-year follow-up results of a phase II study. Radiol Oncol 2021;55:439-48. [PMID: 34821132 DOI: 10.2478/raon-2021-0028] [Reference Citation Analysis]
558 Maeda K, Shibutani M, Tachimori A, Nishii T, Aomatsu N, Fukuoka T, Nagahara H, Otani H, Inoue T, Ohira M. Prognostic Significance of Neoadjuvant Rectal Score and Indication for Postoperative Adjuvant Therapy in Rectal Cancer Patients After Neoadjuvant Chemoradiotherapy. In Vivo 2020;34:283-9. [PMID: 31882490 DOI: 10.21873/invivo.11772] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
559 Nguyen P, Wuthrick E, Chablani P, Robinson A, Simmons L, Wu C, Arnold M, Harzman AE, Husain S, Schmidt C, Abdel-Misih S, Bekaii-Saab T, Chakravarti A, Williams TM. Does Delaying Surgical Resection After Neoadjuvant Chemoradiation Impact Clinical Outcomes in Locally Advanced Rectal Adenocarcinoma?: A Single-Institution Experience. Am J Clin Oncol 2018;41:140-6. [PMID: 26535992 DOI: 10.1097/COC.0000000000000248] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
560 Ostwal V, Engineer R, Ramaswamy A, Sahu A, Zanwar S, Arya S, Chopra S, Bal M, Patil P, Desouza A, Saklani A. Surgical outcomes of post chemoradiotherapy unresectable locally advanced rectal cancers improve with interim chemotherapy, is FOLFIRINOX better than CAPOX? J Gastrointest Oncol 2016;7:958-67. [PMID: 28078119 DOI: 10.21037/jgo.2016.08.11] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
561 Fitzgerald TL, Biswas T, O’brien K, Zervos EE, Wong JH. Neoadjuvant Radiotherapy for Rectal Cancer: Adherence to Evidence-Based Guidelines in Clinical Practice. World J Surg 2013;37:639-45. [DOI: 10.1007/s00268-012-1862-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
562 Wang F, Fan W, Peng J, Lu Z, Pan Z, Li L, Gao Y, Li H, Chen G, Wu X, Ding P, Zeng Z, Wan D. Total mesorectal excision with or without preoperative chemoradiotherapy for resectable mid/low rectal cancer: a long-term analysis of a prospective, single-center, randomized trial. Cancer Commun (Lond) 2018;38:73. [PMID: 30572939 DOI: 10.1186/s40880-018-0342-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
563 Guckenberger M, Saur G, Wehner D, Sweeney RA, Thalheimer A, Germer CT, Flentje M. Comparison of preoperative short-course radiotherapy and long-course radiochemotherapy for locally advanced rectal cancer. Strahlenther Onkol 2012;188:551-7. [PMID: 22638934 DOI: 10.1007/s00066-012-0131-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
564 Quéro L, Guillerm S, Castelnau-Marchand P, Labidi M, Hennequin C. [Follow-up after rectal cancer treatment]. Cancer Radiother 2019;23:572-5. [PMID: 31422001 DOI: 10.1016/j.canrad.2019.07.123] [Reference Citation Analysis]
565 Park IJ, You YN, Agarwal A, Skibber JM, Rodriguez-Bigas MA, Eng C, Feig BW, Das P, Krishnan S, Crane CH, Hu CY, Chang GJ. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol. 2012;30:1770-1776. [PMID: 22493423 DOI: 10.1200/jco.2011.39.7901] [Cited by in Crossref: 269] [Cited by in F6Publishing: 154] [Article Influence: 26.9] [Reference Citation Analysis]
566 Puglisi C, Giuffrida R, Borzì G, Di Mattia P, Costa A, Colarossi C, Deiana E, Picardo MC, Colarossi L, Mare M, Marino L, Di Grazia A, Forte S. Radiosensitivity of Cancer Stem Cells Has Potential Predictive Value for Individual Responses to Radiotherapy in Locally Advanced Rectal Cancer. Cancers (Basel) 2020;12:E3672. [PMID: 33297488 DOI: 10.3390/cancers12123672] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
567 Tada N, Kawai K, Tsuno NH, Ishihara S, Yamaguchi H, Sunami E, Kitayama J, Oba K, Watanabe T. Prediction of the preoperative chemoradiotherapy response for rectal cancer by peripheral blood lymphocyte subsets. World J Surg Oncol. 2015;13:30. [PMID: 25890185 DOI: 10.1186/s12957-014-0418-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
568 Zijp JVDVV, Hoekstra HJ, Basson MD. Evolving management of colorectal cancer. World J Gastroenterol 2008; 14(25): 3956-3967 [PMID: 18609678 DOI: 10.3748/wjg.14.3956] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
569 Siegel R, Burock S, Wernecke KD, Kretzschmar A, Dietel M, Loy V, Koswig S, Budach V, Schlag PM. Preoperative short-course radiotherapy versus combined radiochemotherapy in locally advanced rectal cancer: a multi-centre prospectively randomised study of the Berlin Cancer Society. BMC Cancer. 2009;9:50. [PMID: 19200365 DOI: 10.1186/1471-2407-9-50] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 4.4] [Reference Citation Analysis]
570 Sadahiro S, Suzuki T, Tanaka A, Okada K, Saito G, Miyakita H, Ogimi T, Nagase H. Gene expression levels of gamma-glutamyl hydrolase in tumor tissues may be a useful biomarker for the proper use of S-1 and tegafur-uracil/leucovorin in preoperative chemoradiotherapy for patients with rectal cancer. Cancer Chemother Pharmacol 2017;79:1077-85. [PMID: 28417167 DOI: 10.1007/s00280-017-3295-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
571 Delitto D, George TJ Jr, Loftus TJ, Qiu P, Chang GJ, Allegra CJ, Hall WA, Hughes SJ, Tan SA, Shaw CM, Iqbal A. Prognostic Value of Clinical vs Pathologic Stage in Rectal Cancer Patients Receiving Neoadjuvant Therapy. J Natl Cancer Inst 2018;110:460-6. [PMID: 29165692 DOI: 10.1093/jnci/djx228] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
572 Nakamura T, Watanabe M. Lateral lymph node dissection for lower rectal cancer. World J Surg. 2013;37:1808-1813. [PMID: 23703637 DOI: 10.1007/s00268-013-2072-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
573 Zhou Y, Guo Z, Wu Z, Shi J, Zhou C, Sun J, Hidasa I, Lu X, Lu C. The efficacy and safety of adding bevacizumab in neoadjuvant therapy for locally advanced rectal cancer patients: A systematic review and meta-analysis. Transl Oncol 2021;14:100964. [PMID: 33248411 DOI: 10.1016/j.tranon.2020.100964] [Reference Citation Analysis]
574 Tomono A, Yamashita K, Kanemitsu K, Sumi Y, Yamamoto M, Kanaji S, Imanishi T, Nakamura T, Suzuki S, Tanaka K. Prognostic significance of pathological response to preoperative chemoradiotherapy in patients with locally advanced rectal cancer. Int J Clin Oncol. 2016;21:344-349. [PMID: 26338272 DOI: 10.1007/sl0147-015-0900-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
575 Oh SG, Park IJ, Seo JH, Kim YI, Lim SB, Kim CW, Yoon YS, Lee JL, Yu CS, Kim JC. Beware of Early Relapse in Rectal Cancer Patients Treated With Preoperative Chemoradiotherapy. Ann Coloproctol 2020;36:382-9. [PMID: 32674549 DOI: 10.3393/ac.2020.06.11] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
576 Audisio RA, Papamichael D. Treatment of colorectal cancer in older patients. Nat Rev Gastroenterol Hepatol. 2012;9:716-725. [PMID: 23045000 DOI: 10.1038/nrgastro.2012.196] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
577 Aizer AA, Chen MH, McCarthy EP, Mendu ML, Koo S, Wilhite TJ, Graham PL, Choueiri TK, Hoffman KE, Martin NE, Hu JC, Nguyen PL. Marital status and survival in patients with cancer. J Clin Oncol. 2013;31:3869-3876. [PMID: 24062405 DOI: 10.1200/jco.2013.49.6489] [Cited by in Crossref: 480] [Cited by in F6Publishing: 295] [Article Influence: 53.3] [Reference Citation Analysis]
578 Uda S, Mukai M, Kishima K, Yokoyama D, Hasegawa S, Koike T, Tajima T, Nomura E, Tomita K, Matsumoto T, Hasebe T, Makuuchi H. Pelvic local recurrence as first relapse predicts prognosis for clinical stage II/III lower rectal cancer: A clinicopathological investigation. Mol Clin Oncol 2021;14:33. [PMID: 33414914 DOI: 10.3892/mco.2020.2195] [Reference Citation Analysis]
579 Krishnamurty DM, Hawkins AT, Wells KO, Mutch MG, Silviera ML, Glasgow SC, Hunt SR, Dharmarajan S. Neoadjuvant Radiation Therapy in Locally Advanced Colon Cancer: a Cohort Analysis. J Gastrointest Surg 2018;22:906-12. [PMID: 29427227 DOI: 10.1007/s11605-018-3676-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
580 Li J, Shang W, Li Y, Fu S, Tian J, Lu L. Advanced nanomaterials targeting hypoxia to enhance radiotherapy. Int J Nanomedicine 2018;13:5925-36. [PMID: 30319257 DOI: 10.2147/IJN.S173914] [Cited by in Crossref: 23] [Cited by in F6Publishing: 4] [Article Influence: 5.8] [Reference Citation Analysis]
581 Min BS, Kim NK, Pyo JY, Kim H, Seong J, Keum KC, Sohn SK, Cho CH. Clinical impact of tumor regression grade after preoperative chemoradiation for locally advanced rectal cancer: subset analyses in lymph node negative patients. J Korean Soc Coloproctol. 2011;27:31-40. [PMID: 21431095 DOI: 10.3393/jksc.2011.27.1.31] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
582 Kitayama J, Yasuda K, Kawai K, Sunami E, Nagawa H. Circulating lymphocyte is an important determinant of the effectiveness of preoperative radiotherapy in advanced rectal cancer. BMC Cancer. 2011;11:64. [PMID: 21306650 DOI: 10.1186/1471-2407-11-64] [Cited by in Crossref: 60] [Cited by in F6Publishing: 65] [Article Influence: 5.5] [Reference Citation Analysis]
583 Peng J, Li X, Ding Y, Shi D, Wu H, Cai S. Is adjuvant radiotherapy warranted in resected pT1-2 node-positive rectal cancer? Radiat Oncol 2013;8:290. [PMID: 24350579 DOI: 10.1186/1748-717X-8-290] [Reference Citation Analysis]
584 Riesco-Martinez MC, Fernandez-Martos C, Gravalos-Castro C, Espinosa-Olarte P, La Salvia A, Robles-Diaz L, Modrego-Sanchez A, Garcia-Carbonero R. Impact of Total Neoadjuvant Therapy vs. Standard Chemoradiotherapy in Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis of Randomized Trials. Cancers (Basel) 2020;12:E3655. [PMID: 33291454 DOI: 10.3390/cancers12123655] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
585 Wang Y, Zhang J, Zhou M, Yang L, Wan J, Shen L, Liang L, Yao Y, Zhang H, Zhang Z. Poor prognostic and staging value of tumor deposit in locally advanced rectal cancer with neoadjuvant chemoradiotherapy. Cancer Med 2019;8:1508-20. [PMID: 30790459 DOI: 10.1002/cam4.2034] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
586 Kim HJ, Choi GS, Park JS, Park SY, Cho SH, Lee SJ, Kang BW, Kim JG. Optimal treatment strategies for clinically suspicious lateral pelvic lymph node metastasis in rectal cancer. Oncotarget. 2017;8:100724-100733. [PMID: 29246016 DOI: 10.18632/oncotarget.20121] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 5.6] [Reference Citation Analysis]
587 Chiloiro G, Boldrini L, Meldolesi E, Re A, Cellini F, Cusumano D, Corvari B, Mantini G, Balducci M, Valentini V, Gambacorta MA. MR-guided radiotherapy in rectal cancer: First clinical experience of an innovative technology. Clin Transl Radiat Oncol 2019;18:80-6. [PMID: 31341981 DOI: 10.1016/j.ctro.2019.04.006] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 9.0] [Reference Citation Analysis]
588 Staal DP, Vlooswijk C, Mols F, Lidington E, van der Graaf WTA, Bijlsma RM, Husson O. Diagnosed with a common cancer at an unusual age: causal attributions of survivors of adolescent and young adult colorectal cancer. Support Care Cancer 2021;29:409-16. [PMID: 32377841 DOI: 10.1007/s00520-020-05502-0] [Reference Citation Analysis]
589 Huang CM, Huang CW, Huang MY, Lin CH, Chen CF, Yeh YS, Ma CJ, Huang CJ, Wang JY. Coexistence of perineural invasion and lymph node metastases is a poor prognostic factor in patients with locally advanced rectal cancer after preoperative chemoradiotherapy followed by radical resection and adjuvant chemotherapy.Med Princ Pract. 2014;23:465-470. [PMID: 25012611 DOI: 10.1159/000363604] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
590 Cheong C, Oh SY, Kim YB, Suh KW. Differences in biological behaviors between young and elderly patients with colorectal cancer. PLoS One. 2019;14:e0218604. [PMID: 31211804 DOI: 10.1371/journal.pone.0218604] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
591 Saglam S, Bugra D, Saglam EK, Asoglu O, Balik E, Yamaner S, Basaran M, Oral EN, Kizir A, Kapran Y. Fourth versus eighth week surgery after neoadjuvant radiochemotherapy in T3-4/N0+ rectal cancer: Istanbul R-01 study. J Gastrointest Oncol. 2014;5:9-17. [PMID: 24490038 DOI: 10.3978/j.issn.2078-6891.2013.025] [Cited by in F6Publishing: 14] [Reference Citation Analysis]
592 Jalilian M, Davis S, Mohebbi M, Sugamaran B, Porter IW, Bell S, Warrier SK, Wale R. Pathologic response to neoadjuvant treatment in locally advanced rectal cancer and impact on outcome. J Gastrointest Oncol. 2016;7:603-608. [PMID: 27563451 DOI: 10.21037/jgo.2016.05.03] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
593 Kim JY, Park SG, Kim KS, Choi YH, Kim NK. The Krüppel-like factor (KLF5) as a predictive biomarker in preoperative chemoradiation therapy for rectal cancer. Ann Surg Treat Res 2019;97:83-92. [PMID: 31388510 DOI: 10.4174/astr.2019.97.2.83] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
594 Imano N, Murakami Y, Kubo K, Kawahara D, Takeuchi Y, Nishibuchi I, Kimura T, Kochi M, Takakura Y, Shimizu W, Egi H, Uegami S, Ohge H, Takahashi S, Ohdan H, Nagata Y. Efficacy and tolerability of preoperative chemoradiotherapy with S-1 alone for locally advanced rectal cancer. J Radiat Res 2021;62:300-8. [PMID: 33341902 DOI: 10.1093/jrr/rraa117] [Reference Citation Analysis]
595 Yu M, Lee JH, Jang HS, Jeon DM, Cheon JS, Lee HC, Lee JH. A comparison of dosimetric parameters between tomotherapy and three-dimensional conformal radiotherapy in rectal cancer. Radiat Oncol 2013;8:181. [PMID: 23866263 DOI: 10.1186/1748-717X-8-181] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
596 Randall JK, Gilbert JM. Innovations and developments in surgical coloproctology. J R Soc Med 2013;106:178-83. [PMID: 23761526 DOI: 10.1177/0141076813479190] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
597 Li N, Jin J, Yu J, Li S, Tang Y, Ren H, Liu W, Wang S, Liu Y, Song Y, Fang H, Yu Z, Li Y. Down-staging depth score to predict outcomes in locally advanced rectal cancer achieving ypI stage after neoadjuvant chemo-radiotherapy versus de novo stage pI cohort: A propensity score-matched analysis. Chin J Cancer Res 2018;30:373-81. [PMID: 30046231 DOI: 10.21147/j.issn.1000-9604.2018.03.09] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
598 Ahmed S, Eng C. Role of Chemotherapy in the Neoadjuvant/Adjuvant Setting for Patients With Rectal Adenocarcinoma Undergoing Chemoradiotherapy and Surgery or Radiotherapy and Surgery. Curr Oncol Rep 2018;20:3. [PMID: 29362905 DOI: 10.1007/s11912-018-0652-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
599 Avallone A, Aloj L, Caracò C, Delrio P, Pecori B, Tatangelo F, Scott N, Casaretti R, Di Gennaro F, Montano M, Silvestro L, Budillon A, Lastoria S. Early FDG PET response assessment of preoperative radiochemotherapy in locally advanced rectal cancer: correlation with long-term outcome. Eur J Nucl Med Mol Imaging 2012;39:1848-57. [PMID: 23053320 DOI: 10.1007/s00259-012-2229-2] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 4.5] [Reference Citation Analysis]
600 O'Neil BH, Tepper JE. Current options for the management of rectal cancer. Curr Treat Options Oncol 2007;8:331-8. [PMID: 18181024 DOI: 10.1007/s11864-007-0048-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
601 Yoo RN, Kim HJ. Organ Preservation Strategies After Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer.Ann Coloproctol. 2019;35:53-64. [PMID: 31113170 DOI: 10.3393/ac.2019.04.15.1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
602 Marks J, Mizrahi B, Dalane S, Nweze I, Marks G. Laparoscopic transanal abdominal transanal resection with sphincter preservation for rectal cancer in the distal 3 cm of the rectum after neoadjuvant therapy. Surg Endosc. 2010;24:2700-2707. [PMID: 20414681 DOI: 10.1007/s00464-010-1028-8] [Cited by in Crossref: 73] [Cited by in F6Publishing: 54] [Article Influence: 6.1] [Reference Citation Analysis]
603 Ide S, Okugawa Y, Omura Y, Yamamoto A, Ichikawa T, Kitajima T, Shimura T, Imaoka H, Fujikawa H, Yasuda H, Yokoe T, Okita Y, Ohi M, Toiyama Y. Geriatric nutritional risk index predicts cancer prognosis in patients with local advanced rectal cancer undergoing chemoradiotherapy followed by curative surgery. World J Surg Oncol 2021;19:34. [PMID: 33516219 DOI: 10.1186/s12957-021-02139-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
604 Lee JB, Kim HS, Jung I, Shin SJ, Beom SH, Chang JS, Koom WS, Kim TI, Hur H, Min BS, Kim NK, Park S, Jeong SY, Baek JH, Kim SH, Lim JS, Lee KY, Ahn JB. Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial. Trials 2020;21:320. [PMID: 32264919 DOI: 10.1186/s13063-020-04266-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
605 Leccisotti L, Gambacorta MA, de Waure C, Stefanelli A, Barbaro B, Vecchio FM, Coco C, Persiani R, Crucitti A, Tortorelli AP, Giordano A, Valentini V. The predictive value of 18F-FDG PET/CT for assessing pathological response and survival in locally advanced rectal cancer after neoadjuvant radiochemotherapy. Eur J Nucl Med Mol Imaging 2015;42:657-66. [PMID: 25687534 DOI: 10.1007/s00259-014-2820-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
606 Erlandsson J, Fuentes S, Radu C, Frödin JE, Johansson H, Brandberg Y, Holm T, Glimelius B, Martling A. Radiotherapy regimens for rectal cancer: long-term outcomes and health-related quality of life in the Stockholm III trial. BJS Open 2021;5:zrab137. [PMID: 35040942 DOI: 10.1093/bjsopen/zrab137] [Reference Citation Analysis]
607 Zhai Z, Zhang K, Wang C, Zhang T, Wang L, Yao J, Wang Z. Adding Three Cycles of CAPOX after Neoadjuvant Chemoradiotherapy Increases the Rates of Complete Response for Locally Advanced Rectal Cancer. Curr Oncol 2021;28:283-93. [PMID: 33419188 DOI: 10.3390/curroncol28010033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
608 Toiyama Y, Inoue Y, Kawamura M, Kawamoto A, Okugawa Y, Hiro J, Saigusa S, Tanaka K, Mohri Y, Kusunoki M. Elevated platelet count as predictor of recurrence in rectal cancer patients undergoing preoperative chemoradiotherapy followed by surgery. Int Surg 2015;100:199-207. [PMID: 25692418 DOI: 10.9738/INTSURG-D-13-00178.1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 4.2] [Reference Citation Analysis]
609 Glynne-Jones R, Hadaki M, Harrison M. The status of targeted agents in the setting of neoadjuvant radiation therapy in locally advanced rectal cancers. J Gastrointest Oncol 2013;4:264-84. [PMID: 23997939 DOI: 10.3978/j.issn.2078-6891.2013.037] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
610 Wen B, Zhang L, Wang C, Huang R, Peng H, Zhang T, Dong J, Xiao W, Zeng Z, Liu M, Gao Y. Prognostic significance of clinical and pathological stages on locally advanced rectal carcinoma after neoadjuvant chemoradiotherapy. Radiat Oncol 2015;10:124. [PMID: 26040453 DOI: 10.1186/s13014-015-0425-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
611 Yan H, Wang R, Yu J, Jiang S, Zhu K, Mu D, Xu Z. Predictive value of Smac, VEGF and Ki-67 in rectal cancer treated with neoadjuvant therapy. Oncol Lett 2010;1:641-7. [PMID: 22966357 DOI: 10.3892/ol_00000113] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
612 Allegra CJ, Yothers G, O'Connell MJ, Beart RW, Wozniak TF, Pitot HC, Shields AF, Landry JC, Ryan DP, Arora A, Evans LS, Bahary N, Soori G, Eakle JF, Robertson JM, Moore DF Jr, Mullane MR, Marchello BT, Ward PJ, Sharif S, Roh MS, Wolmark N. Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial. J Natl Cancer Inst 2015;107:djv248. [PMID: 26374429 DOI: 10.1093/jnci/djv248] [Cited by in Crossref: 140] [Cited by in F6Publishing: 135] [Article Influence: 20.0] [Reference Citation Analysis]
613 Glynne-Jones R, Harrison M, Hughes R. Is the NSABP R-03 study in line with other chemoradiation studies? J Clin Oncol 2010;28:e305-6; author reply e307. [PMID: 20479393 DOI: 10.1200/JCO.2010.28.4356] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
614 Yu X, Wang QX, Xiao WW, Chang H, Zeng ZF, Lu ZH, Wu XJ, Chen G, Pan ZZ, Wan DS, Ding PR, Gao YH. Neoadjuvant oxaliplatin and capecitabine combined with bevacizumab plus radiotherapy for locally advanced rectal cancer: results of a single-institute phase II study. Cancer Commun (Lond) 2018;38:24. [PMID: 29784042 DOI: 10.1186/s40880-018-0294-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
615 Yoo BC, Yeo SG. Clinical utility of pretreatment prediction of chemoradiotherapy response in rectal cancer: a review. EPMA J 2017;8:61-7. [PMID: 28620444 DOI: 10.1007/s13167-017-0082-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
616 Park YY, Lee KY, Kim NK, Lee SB, Kim GR, Min BS, Oh ST. Impact of Adjuvant Chemotherapy Completion on Oncologic Outcomes in ypTNMstage 2 Rectal Cancer Patients. Ann Coloproctol 2019;35:335-41. [PMID: 31937073 DOI: 10.3393/ac.2019.03.10] [Reference Citation Analysis]
617 Sun Z, Adam MA, Kim J, Czito B, Mantyh C, Migaly J. Intensity-Modulated Radiation Therapy Is Not Associated with Perioperative or Survival Benefit over 3D-Conformal Radiotherapy for Rectal Cancer. J Gastrointest Surg 2017;21:106-11. [PMID: 27510332 DOI: 10.1007/s11605-016-3242-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
618 Roos M, Wong JH, Roy-chowdhury S, Lum SS, Morgan JW, Kazanjian K. The Impact of Multidisciplinary Therapy in Node-Positive Rectal Cancer. The American Surgeon 2010;76:1163-6. [DOI: 10.1177/000313481007601033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
619 Vanneste BGL, Van Limbergen EJ, Dubois L, Samarska IV, Wieten L, Aarts MJB, Marcelissen T, De Ruysscher D. Immunotherapy as sensitizer for local radiotherapy. Oncoimmunology 2020;9:1832760. [PMID: 33194319 DOI: 10.1080/2162402X.2020.1832760] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
620 Snipstad K, Fenton CG, Kjaeve J, Cui G, Anderssen E, Paulssen RH. New specific molecular targets for radio-chemotherapy of rectal cancer. Mol Oncol 2010;4:52-64. [PMID: 19969511 DOI: 10.1016/j.molonc.2009.11.002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
621 Ferrero VT, Oset MM, Masferrer JP, Pardo EH, Sorolla EJ, Largo SC; PrevaDIOR Study Group. Prevalence and characterization of breakthrough pain in cancer patients with proctalgia treated with 3D pelvic radiotherapy. Clin Transl Oncol 2019;21:1707-11. [PMID: 30949931 DOI: 10.1007/s12094-019-02102-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
622 Boland PM, Fakih M. The emerging role of neoadjuvant chemotherapy for rectal cancer. J Gastrointest Oncol. 2014;5:362-373. [PMID: 25276409 DOI: 10.3978/j.issn.2078-6891.2014.060] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
623 Agostini M, Zangrando A, Pastrello C, D'Angelo E, Romano G, Giovannoni R, Giordan M, Maretto I, Bedin C, Zanon C, Digito M, Esposito G, Mescoli C, Lavitrano M, Rizzolio F, Jurisica I, Giordano A, Pucciarelli S, Nitti D. A functional biological network centered on XRCC3: a new possible marker of chemoradiotherapy resistance in rectal cancer patients. Cancer Biol Ther 2015;16:1160-71. [PMID: 26023803 DOI: 10.1080/15384047.2015.1046652] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
624 Parnaby CN, Jenkins JT, Weston V, Wright DM, Sunderland GT. Defunctioning stomas in patients with locally advanced rectal cancer prior to preoperative chemoradiotherapy. Colorectal Dis 2009;11:26-31. [PMID: 18462220 DOI: 10.1111/j.1463-1318.2008.01540.x] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
625 Peng HH, Liao ZW, Lin XD, Qiu XS, You KY. Definitive radiotherapy or chemoradiotherapy for distal rectal cancer with early stage of cT1-2N0. Cancer Manag Res 2019;11:5221-9. [PMID: 31354342 DOI: 10.2147/CMAR.S198113] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
626 Tural D, Selcukbiricik F, Yıldız Ö, Elcin O, Erdamar S, Güney S, Demireli F, Büyükünal E, Serdengeçti S. Preoperative versus postoperative chemoradiotherapy in stage T3, N0 rectal cancer. Int J Clin Oncol 2014;19:889-96. [PMID: 24218281 DOI: 10.1007/s10147-013-0636-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
627 Lee EM, Hong YS, Kim KP, Lee JL, Kim SY, Park YS, Choi DH, Kim JH, Lim SB, Yu CS, Kim JC, Lee JH, Kim AY, Kim TW. Phase II study of preoperative chemoradiation with S-1 plus oxaliplatin in patients with locally advanced rectal cancer. Cancer Sci 2013;104:111-5. [PMID: 23057495 DOI: 10.1111/cas.12041] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
628 Lin J, Peng J, Qdaisat A, Li L, Chen G, Lu Z, Wu X, Gao Y, Zeng Z, Ding P, Pan Z. Severe weight loss during preoperative chemoradiotherapy compromises survival outcome for patients with locally advanced rectal cancer. J Cancer Res Clin Oncol 2016;142:2551-60. [PMID: 27613188 DOI: 10.1007/s00432-016-2225-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
629 McDermott DM, Singh SA, Renz PB, Hasan S, Weir J. Predictors of Pathologic Response After Total Neoadjuvant Therapy in Patients With Rectal Adenocarcinoma: A National Cancer Database Analysis. Cureus 2021;13:e17233. [PMID: 34540460 DOI: 10.7759/cureus.17233] [Reference Citation Analysis]
630 Velenik V, Oblak I, Anderluh F. Long-term results from a randomized phase II trial of neoadjuvant combined-modality therapy for locally advanced rectal cancer. Radiat Oncol 2010;5:88. [PMID: 20920276 DOI: 10.1186/1748-717X-5-88] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
631 Babar L, Bakalov V, Abel S, Ashraf O, Finley GG, Raj MS, Lundeen K, Monga DK, Kirichenko AV, Wegner RE. Retrospective review of total neoadjuvant therapy. World J Gastrointest Oncol 2019; 11(10): 857-865 [PMID: 31662824 DOI: 10.4251/wjgo.v11.i10.857] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
632 Peng JH, Lin JZ, Rong YM, Zhu Y, Deng YX, Zhao YJ, Lu ZH, Wu XJ, Pan ZZ. Oxaliplatin-containing adjuvant chemotherapy improves the survival of locally advanced rectal cancer patients with pathological complete response after pre-operative chemoradiotherapy. Gastroenterol Rep (Oxf) 2018;6:195-201. [PMID: 30151204 DOI: 10.1093/gastro/goy009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
633 Glimelius B. On a prolonged interval between rectal cancer (chemo)radiotherapy and surgery. Ups J Med Sci 2017;122:1-10. [PMID: 28256956 DOI: 10.1080/03009734.2016.1274806] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
634 Doussot A, Vernerey D, Rullier E, Lefevre JH, Meillat H, Cotte E, Piessen G, Tuech JJ, Panis Y, Mege D, Meurisse A, De Bari B, Heyd B, Lakkis Z; French Research Group of Rectal Cancer Surgery (GRECCAR). Surgical Management and Outcomes of Rectal Cancer with Synchronous Prostate Cancer: A Multicenter Experience from the GRECCAR Group. Ann Surg Oncol 2020;27:4286-93. [PMID: 32500342 DOI: 10.1245/s10434-020-08683-4] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
635 Shim BY, Jung JH, Lee KM, Kim HJ, Hong SH, Kim SH, Sun DS, Cho HM. Glucose transporter 1 (GLUT1) of anaerobic glycolysis as predictive and prognostic values in neoadjuvant chemoradiotherapy and laparoscopic surgery for locally advanced rectal cancer. Int J Colorectal Dis. 2013;28:375-383. [PMID: 22847606 DOI: 10.1007/s00384-012-1542-3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
636 Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, Barni S. Pathologic complete response and disease-free survival are not surrogate endpoints for 5-year survival in rectal cancer: an analysis of 22 randomized trials. J Gastrointest Oncol 2017;8:39-48. [PMID: 28280607 DOI: 10.21037/jgo.2016.11.03] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
637 Aklilu M, Eng C. The current landscape of locally advanced rectal cancer. Nat Rev Clin Oncol. 2011;8:649-659. [PMID: 21826084 DOI: 10.1038/nrclinonc.2011.118] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 4.9] [Reference Citation Analysis]
638 Shi C, Zhou H, Li X, Cai Y. A Retrospective Analysis on Two-week Short-course Pre-operative Radiotherapy in Elderly Patients with Resectable Locally Advanced Rectal Cancer. Sci Rep 2016;6:37866. [PMID: 27886277 DOI: 10.1038/srep37866] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
639 Bujko K, Glynne-Jones R, Papamichael D, Rutten HJT. Optimal management of localized rectal cancer in older patients. J Geriatr Oncol 2018;9:696-704. [PMID: 30150020 DOI: 10.1016/j.jgo.2018.08.001] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
640 Hernandez PT, Paspulati RM, Shanmugan S. Diagnosis of Anastomotic Leak. Clin Colon Rectal Surg 2021;34:391-9. [PMID: 34853560 DOI: 10.1055/s-0041-1735270] [Reference Citation Analysis]
641 Jung SM, Yu CS, Park IJ, Kim TW, Kim JH, Yoon YS, Lim SB, Kim JC. Oncologic Safety of Local Excision Compared With Total Mesorectal Excision for ypT0-T1 Rectal Cancer: A Propensity Score Analysis. Medicine (Baltimore) 2016;95:e3718. [PMID: 27196490 DOI: 10.1097/MD.0000000000003718] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
642 Germani P, Di Candido F, Léonard D, Cuicchi D, Elmore U, Allaix ME, Barbieri VP, D'Allens L, Faes S, Milani M, Caputo D, Martinez C, Grosek J, Caracino V, Christou N, Roodbeen SX, Bracale U, Wildeboer A, Usai A, Benedetti M, Balani A, Piccinni G, Catarci M, Millo P, Bouvy N, Corcione F, Hompes R, Ris F, Basti M, Tomazic A, Targarona E, Coppola A, Pietrabissa A, Hahnloser D, Adamina M, Viola M, Morino M, Rosati R, Poggioli G, Kartheuser A, Spinelli A, de Manzini N; TRG Snapshot Study Group. Contemporary snapshot of tumor regression grade (TRG) distribution in locally advanced rectal cancer: a cross sectional multicentric experience. Updates Surg 2021. [PMID: 33818750 DOI: 10.1007/s13304-021-01044-0] [Reference Citation Analysis]
643 DI Tommaso M, Rosa C, Caravatta L, Augurio A, Borzillo V, DI Santo S, Perrotti F, Taraborrelli M, Cianci R, Innocenti P, DI Sebastiano P, Colasante A, Angelucci D, Basti M, Sindici G, Mazzola L, Pizzicannella G, DI Bartolomeo N, Marchioni M, DI Nicola M, Genovesi D. Treatment Intensification for Locally Advanced Rectal Cancer: Impact on Pathological Complete Response and Outcomes. In Vivo 2020;34:1223-33. [PMID: 32354913 DOI: 10.21873/invivo.11896] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
644 Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart A. Revised tumor and node categorization for rectal cancer based on surveillance, epidemiology, and end results and rectal pooled analysis outcomes. J Clin Oncol. 2010;28:256-263. [PMID: 19949015 DOI: 10.1200/jco.2009.23.9194] [Cited by in Crossref: 156] [Cited by in F6Publishing: 75] [Article Influence: 12.0] [Reference Citation Analysis]
645 Pruitt R, Sasi N, Freeman ML, Sekhar KR. Radiosensitization of cancer cells by hydroxychalcones. Bioorg Med Chem Lett 2010;20:5997-6000. [PMID: 20826087 DOI: 10.1016/j.bmcl.2010.08.081] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
646 Tanaka A, Sadahiro S, Suzuki T, Okada K, Saito G. A comparison of the localization of rectal carcinomas according to the general rules of the Japanese classification of colorectal carcinoma (JCCRC) and Western guidelines. Surg Today 2017;47:1086-93. [PMID: 28271342 DOI: 10.1007/s00595-017-1487-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
647 Schiffmann L, Wedermann N, Gock M, Prall F, Klautke G, Fietkau R, Rau B, Klar E. Intensified neoadjuvant radiochemotherapy for rectal cancer enhances surgical complications. BMC Surg 2013;13:43. [PMID: 24073705 DOI: 10.1186/1471-2482-13-43] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
648 Xin KY, Ng DW, Tan GH, Teo MC. Role of pelvic exenteration in the management of locally advanced primary and recurrent rectal cancer. J Gastrointest Cancer 2014;45:291-7. [PMID: 24563189 DOI: 10.1007/s12029-014-9586-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
649 Nakanishi R, Akiyoshi T, Toda S, Murakami Y, Taguchi S, Oba K, Hanaoka Y, Nagasaki T, Yamaguchi T, Konishi T, Matoba S, Ueno M, Fukunaga Y, Kuroyanagi H. Radiomics Approach Outperforms Diameter Criteria for Predicting Pathological Lateral Lymph Node Metastasis After Neoadjuvant (Chemo)Radiotherapy in Advanced Low Rectal Cancer. Ann Surg Oncol 2020;27:4273-83. [PMID: 32767224 DOI: 10.1245/s10434-020-08974-w] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
650 Wahba HA, El-Hadaad HA, Roshdy S. Combination of irinotecan and 5-fluorouracil with radiation in locally advanced rectal adenocarcinoma. J Gastrointest Cancer 2012;43:467-71. [PMID: 22147447 DOI: 10.1007/s12029-011-9350-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
651 Morris EJ, Finan PJ, Spencer K, Geh I, Crellin A, Quirke P, Thomas JD, Lawton S, Adams R, Sebag-Montefiore D. Wide Variation in the Use of Radiotherapy in the Management of Surgically Treated Rectal Cancer Across the English National Health Service. Clin Oncol (R Coll Radiol) 2016;28:522-31. [PMID: 26936609 DOI: 10.1016/j.clon.2016.02.002] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 5.8] [Reference Citation Analysis]
652 Huang MY, Chen CF, Huang CM, Tsai HL, Yeh YS, Ma CJ, Wu CH, Lu CY, Chai CY, Huang CJ, Wang JY. Helical tomotherapy combined with capecitabine in the preoperative treatment of locally advanced rectal cancer. Biomed Res Int 2014;2014:352083. [PMID: 24949438 DOI: 10.1155/2014/352083] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
653 Saigusa S, Toiyama Y, Tanaka K, Okugawa Y, Fujikawa H, Matsushita K, Uchida K, Inoue Y, Kusunoki M. Prognostic significance of glucose transporter-1 (GLUT1) gene expression in rectal cancer after preoperative chemoradiotherapy. Surg Today 2012;42:460-9. [PMID: 22072148 DOI: 10.1007/s00595-011-0027-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
654 Cheong CK, Nistala KRY, Ng CH, Syn N, Chang HSY, Sundar R, Yang SY, Chong CS. Neoadjuvant therapy in locally advanced colon cancer: a meta-analysis and systematic review. J Gastrointest Oncol 2020;11:847-57. [PMID: 33209481 DOI: 10.21037/jgo-20-220] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
655 Gaertner WB, Kwaan MR, Madoff RD, Melton GB. Rectal cancer: An evidence-based update for primary care providers. World J Gastroenterol 2015; 21(25): 7659-7671 [PMID: 26167068 DOI: 10.3748/wjg.v21.i25.7659] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
656 Belluco C, De Paoli A, Canzonieri V, Sigon R, Fornasarig M, Buonadonna A, Boz G, Innocente R, Perin T, Cossaro M, Polesel J, De Marchi F. Long-term outcome of patients with complete pathologic response after neoadjuvant chemoradiation for cT3 rectal cancer: implications for local excision surgical strategies. Ann Surg Oncol 2011;18:3686-93. [PMID: 21691880 DOI: 10.1245/s10434-011-1822-0] [Cited by in Crossref: 60] [Cited by in F6Publishing: 57] [Article Influence: 5.5] [Reference Citation Analysis]
657 Debucquoy A, Libbrecht L, Roobrouck V, Goethals L, McBride W, Haustermans K. Morphological features and molecular markers in rectal cancer from 95 patients included in the European Organisation for Research and Treatment of Cancer 22921 trial: prognostic value and effects of preoperative radio (chemo) therapy. Eur J Cancer 2008;44:791-7. [PMID: 18353631 DOI: 10.1016/j.ejca.2008.02.023] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
658 Crotti S, Fraccaro A, Bedin C, Bertazzo A, Di Marco V, Pucciarelli S, Agostini M. Tryptophan Catabolism and Response to Therapy in Locally Advanced Rectal Cancer (LARC) Patients. Front Oncol 2020;10:583228. [PMID: 33178611 DOI: 10.3389/fonc.2020.583228] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
659 Yang R, Younis M, Joseph K, Ghosh S, Nijjar T, Severin D, Tankel K, Tamhane Y, Fairchild A, Spratlin J, Mulder K, Usmani N. Impact of dose-capping chemotherapy in concurrent chemoradiotherapy in rectal cancer patients. J Oncol Pharm Pract 2021;27:1596-603. [PMID: 33023385 DOI: 10.1177/1078155220962192] [Reference Citation Analysis]
660 Charlton ME, Mattingly-Wells LR, Marcet JE, McMahon Waldschmidt BC, Cromwell JW. Association between surgeon characteristics and their preferences for guideline-concordant staging and treatment for rectal cancer. Am J Surg. 2014;208:817-823. [PMID: 24997492 DOI: 10.1016/j.amjsurg.2014.03.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
661 Begum SS, Das D, Gour NK, Deka RC. Computational modelling of nanotube delivery of anti-cancer drug into glutathione reductase enzyme. Sci Rep 2021;11:4950. [PMID: 33654109 DOI: 10.1038/s41598-021-84006-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
662 Ha GW, Lee MR. Oncologic effects of adjuvant chemotherapy in patients with ypT0-2N0 rectal cancer after neoadjuvant chemoradiotherapy and curative surgery: a meta-analysis. Ann Surg Treat Res 2020;99:97-109. [PMID: 32802815 DOI: 10.4174/astr.2020.99.2.97] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
663 Koukourakis GV. Role of radiation therapy in neoadjuvant era in patients with locally advanced rectal cancer. World J Gastrointest Oncol 2012; 4(12): 230-237 [PMID: 23443049 DOI: 10.4251/wjgo.v4.i12.230] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
664 Issa N, Murninkas A, Powsner E, Dreznick Z. Long-term outcome of local excision after complete pathological response to neoadjuvant chemoradiation therapy for rectal cancer. World J Surg. 2012;36:2481-2487. [PMID: 22736345 DOI: 10.1007/s00268-012-1697-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
665 Hu YH, Wei JW, Chang H, Xiao WW, Lin JZ, Cai MY, Cai PQ, Kong LH, Chen G, Pan ZZ, Zeng ZF, Ding PR, Gao YH. The high pCR rate of sandwich neoadjuvant treatment in locally advanced rectal cancer may translate into a better long-term survival benefit: 5-year outcome of a Phase II clinical trial. Cancer Manag Res 2018;10:4363-9. [PMID: 30349369 DOI: 10.2147/CMAR.S168573] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
666 Deng H, Zhang J, Shi J, Guo Z, He C, Ding L, Tang JH, Hou Y. Role of long non-coding RNA in tumor drug resistance. Tumour Biol 2016;37:11623-31. [PMID: 27380056 DOI: 10.1007/s13277-016-5125-8] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 8.7] [Reference Citation Analysis]
667 Hsieh CH, Hou ML, Chiang MH, Tai HC, Tien HJ, Wang LY, Tsai TH, Chen YJ. Head and neck irradiation modulates pharmacokinetics of 5-fluorouracil and cisplatin. J Transl Med 2013;11:231. [PMID: 24066670 DOI: 10.1186/1479-5876-11-231] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
668 Osada S, Imai H, Sasaki Y, Tanaka Y, Matsuhashi N, Okumura N, Nagase M, Nonaka K, Yoshida K. Therapeutic strategies for synchronous and multiple liver metastases from colorectal cancer. Oncol Rev 2012;6:e9. [PMID: 25992211 DOI: 10.4081/oncol.2012.e9] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
669 Boustani J, Derangère V, Bertaut A, Adotevi O, Morgand V, Charon-Barra C, Ghiringhelli F, Mirjolet C. Radiotherapy Scheme Effect on PD-L1 Expression for Locally Advanced Rectal Cancer. Cells 2020;9:E2071. [PMID: 32927784 DOI: 10.3390/cells9092071] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
670 Zhan T, Wang L, Li M, Li Z, Cai Y, Shen L, Gu J. A multidisciplinary clinical treatment of locally advanced rectal cancer complicated with rectovesical fistula: a case report. J Med Case Rep 2012;6:369. [PMID: 23107561 DOI: 10.1186/1752-1947-6-369] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
671 Wang Y, Feng M, Lin B, Peng X, Wang Z, Lv R. MET-targeted NIR II luminescence diagnosis and up-conversion guided photodynamic therapy for triple-negative breast cancer based on a lanthanide nanoprobe. Nanoscale 2021;13:18125-33. [PMID: 34605506 DOI: 10.1039/d1nr05847a] [Reference Citation Analysis]
672 Fahy MR, Hayes C, Kelly ME, Winter DC. Updated systematic review of the approach to pelvic exenteration for locally advanced primary rectal cancer. Eur J Surg Oncol 2022:S0748-7983(21)01444-X. [PMID: 35031157 DOI: 10.1016/j.ejso.2021.12.471] [Reference Citation Analysis]
673 Liu WY, Dinapoli N, Wang X, Meldolesi E, Gambacorta MA, Chiloiro G, Ren H, Fang H, Lu NN, Tang Y, Deng L, Wang JY, Jing H, Xiao Q, Feng YR, Li YX, Wang SL, Song YW, Liu YP, Wang WH, Valentini V, Jin J. Possible contribution of IMRT in postoperative radiochemotherapy for rectal cancer: analysis on 1798 patients by prediction model. Oncotarget 2016;7:46536-44. [PMID: 27340785 DOI: 10.18632/oncotarget.10228] [Reference Citation Analysis]
674 Wang Y, Zhou M, Yang J, Sun X, Zou W, Zhang Z, Zhang J, Shen L, Yang L, Zhang Z. Increased lymph node yield indicates improved survival in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Cancer Med. 2019;8:4615-4625. [PMID: 31250569 DOI: 10.1002/cam4.2372] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
675 Doubeni CA, Fedewa SA, Levin TR, Jensen CD, Saia C, Zebrowski AM, Quinn VP, Rendle KA, Zauber AG, Becerra-Culqui TA, Mehta SJ, Fletcher RH, Schottinger J, Corley DA. Modifiable Failures in the Colorectal Cancer Screening Process and Their Association With Risk of Death. Gastroenterology 2019;156:63-74.e6. [PMID: 30268788 DOI: 10.1053/j.gastro.2018.09.040] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 8.8] [Reference Citation Analysis]
676 Mainenti PP, Iodice D, Segreto S, Storto G, Magliulo M, Palma GDD, Salvatore M, Pace L. Colorectal cancer and 18FDG-PET/CT: What about adding the T to the N parameter in loco-regional staging? World J Gastroenterol 2011; 17(11): 1427-1433 [PMID: 21472100 DOI: 10.3748/wjg.v17.i11.1427] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
677 Huang MY, Lin CH, Huang CM, Tsai HL, Huang CW, Yeh YS, Chai CY, Wang JY. Relationships between SMAD3 expression and preoperative fluoropyrimidine-based chemoradiotherapy response in locally advanced rectal cancer patients.